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Diabetes mellitus is one of the most common endocrine disorders and its 
global prevalence is increasing at an alarming rate. Cardiovascular disease is the 
major cause of morbidity and mortality among diabetic patients. In addition to 
defects in contraction, the diabetic heart also frequently suffers from disturbances to 
the electrical conduction system. This study investigates the effects of diabetes on the 
sinoatrial node (SAN) of the rat heart. Previous in vivo and in vitro experiments have 
demonstrated reduced heart rate, longer SAN action potential duration, prolonged 
pacemaker cycle length and sino-atrial conduction time in streptozotocin (STZ)-
induced diabetic rat heart. Thus it is of paramount importance to identify the 
molecular basis of electrical disturbances in SAN of diabetic heart. The hypothesis is 
that alterations in mRNA encoding various proteins associated with the generation 
and transmission of electrical signals in the heart may be responsible for the 
functional disturbances in the SAN of diabetic heart. Experiments were performed in 
male Wistar rats 10-12 weeks of age after STZ treatment with a single intraperitoneal 
injection (60 mg/kg body weight). Heart rate was measured in isolated perfused heart 
with an extracellular suction electrode. Expression of mRNA encoding a variety of 
cardiac proteins, involved in electrical transmission, were measured in SAN and right 
atrial biopsies using real time reverse transcription polymerase reaction technique. 
Expression of proteins in SAN biopsies was measured using sodium dodecyl 
sulphate polyacramide gel electrophoresis and Western blotting technique. 
Ultrastructure of the STZ-SAN was studied using transmission electron microscopy. 
The heart rate was significantly lower in STZ compared to controls. Of the 85 genes 
viii 
studied, there were some changes of particular interest. These include an increase in 
the expression of Gja7 (connexin), Cacna1g, Cacna1h, Cacnb3 (calcium channel), 
Nppa, Nppb (natriuretic peptide) Kcnj5 and Kcnk3 (potassium channel), in STZ-
SAN. There was also decrease in the expression of Scn7a (sodium channel), Kcna2 
(potassium channel), a 6-fold decrease in Kcnd2 and a 7-fold decrease in Cacng4. 
Some of the proteins encoded by these genes showed similar changes in expression 
including Ryr3, Cav3.1 and Kv4.2 while others like Pro-ANP and BNP did not. The 
ultrastructure of STZ-SAN had reduced mitochondria. These changes in gene and 
protein expression may contribute to the electrophysiological disturbances seen in 
the diabetic SAN. Further studies will be required to investigate whether these 
changes in mRNA and protein translate into changes in electrophysiological 
function. 
Keywords: Sinoatrial node, Diabetes mellitus, Streptozotocin, mRNA. 
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Title and Abstract (in Arabic) 
العقدة الجٍناث و البروتٍناث فً تعبٍر على  -المسبب عه طرٌق ستربتوزوتوسٍه –آثار مرض السكري 
 الجٍبٍت األذٌنٍت فً قلب الجرذان
 ملخصال
ٍشض اىسنشي ٕ٘ ٗاحذ ٍِ أمثش اظطشاثبد اىغذد اىصَبء شٍ٘عب ٌٗزضاٌذ اّزشبسٓ عبىٍَب ثَعذه ٌْزس إُ 
شظى أٍشاض اىقيت ٗاألٗعٍخ اىذٌٍ٘خ ًٕ اىسجت اىشئٍسً ىَعذالد االعزاله ٗاى٘فٍبد ثٍِ ٍإُ ثبىخطش. 
، فقيت ٍشٌط اىسنشي أٌعب فً مثٍش ٍِ األحٍبُ ٌعبًّ ٍِ ّقجبضاىسنشي. ثبإلظبفخ إىى عٍ٘ة فً اال
 اظطشاثبد فً ّظبً اىز٘صٍو اىنٖشثبئً. رحقق ٕزٓ اىذساسخ فً آثبس ٍشض اىسنشي عيى اىعقذح اىجٍجٍخ األرٌٍْخ
 (SAN)  ٗفً اىَخزجش خفط ٍعذه  ٘سػ اىحٍ٘يسبثقخ فً اىجشٌخ اىاىَخثجزذ اىزجبسة أ. جشراُ اىزجبسةىقيت
، ٗاصدٌبد ٍذح دٗسح رْظٌٍ ظشثبد  SAN يَذح اىَحزَيخ ىـ اىعقذح اىجٍجٍخ األرٌٍْخىظشثبد اىقيت، ٗعَو أغ٘ه 
ٗاىزً رٌ رحفٍض اصبثزٖب  جشراُ اىزجبسةٗقذ اىز٘صٍو اىجٍجً األرًٌْ فً قيت ٗاىقيت ىفزشاد غٌ٘يخ، 
. ٗثبىزبىً فئّٔ ٍِ األٍَٕخ اىفبئقخ رحذٌذ األسبط اىجضٌئً  (STZ)ثبىسنشي عِ غشٌق عقبسسزشرج٘صٗرسٍِ
 أُ اىزغٍشاد فً  عيىاىفشظٍخ  رْص ىقيت ٍشٌط اىسنشي. ىالظطشاثبد اىنٖشثبئٍخ فً اىعقذح اىجٍجٍخ األرٌٍْخ
mRNA , ًرنُ٘ قذ  ، قو اإلشبساد اىنٖشثبئٍخ فً اىقيتٍخزيف اىجشٗرٍْبد اىَشرجطخ ثز٘ىٍذ ّٗرقً٘ ثزشفٍش اىز
ٍشٌط اىسنشي. ٗقذ أجشٌذ  فً قيت  SANٍسؤٗىخ عِ االظطشاثبد اى٘ظٍفٍخ فً اىعقذح اىجٍجٍخ األرٌٍْخ 
ثعذ عالج اىعقذح اىجٍجٍخ األرٌٍْخ  ،أسج٘عب 12-10 رزشاٗح أعَبسٕب ثٍِاىزً  ،ٌخرجبسة جشداُ ٌٗسزبس اىزمش
ِ ٗصُ اىجسٌ(. ٗقذ رٌ قٍبط ٍعذه ٍيغٌ / مغٌ ٍ 00ٗاحذ فً اىزجٌ٘ف اىجشٌزًّ٘ ) خٍع حقْ STZ ثعقبس
 قيت ٍعضٗه ٍع قطت شفػ خبسجً. إسٗاءظشثبد اىقيت فً 
  فً ّقو اىطبقخ اىنٖشثبئٍخ شبسكرز اىزً ىَجَ٘عخ ٍزْ٘عخ ٍِ ثشٗرٍْبد اىقيت،  mRNAرعجٍش  رٌ قٍبطقذ ٗ 
بعو اىجيَشح ثبىْسخ اسزخذاً رقٍْخ رفعِ غشٌق  ،ٗثخضعبد األرًٌْ األٌَِ SANفً اىعقذح اىجٍجٍخ األرٌٍْخ 
 اىعنسً ىي٘قذ اىحقٍقً.
فً رقٍْخ  SDS ثبسزخذاً ٕالً SANاىجشٗرٍْبد فً اىخضعبد اىعقذح اىجٍجٍخ األرٌٍْخ  اّزبجٗقذ رٌ قٍبط 
Western blottingرَذ دساسخ اىزشمٍت اىذقٍق ىو . STZ-SAN  ُثبسزخذاً اىَجٖش اإلىنزشًّٗ اىْبفز. ٗمب
x 
. ٍِٗ STZاىغٍش ٍحقّ٘خ ة ٍقبسّخ ثبىَجَ٘عخ  STZ اىجشراُ اىَحقّ٘خ ة فً ٍعذه ظشثبد اىقيت أقو ثنثٍش
ٗرشَو اىضٌبدح فً اىزعجٍش  ،جٍْبً اىزً رَذ دساسزٖب، مبّذ ْٕبك ثعط اىزغٍٍشاد راد األٍَٕخ اىخبصخ 58اىـ 
 قْبح اىنبىسًٍ٘(،)  Cacnb3، ٗاىجٍِ Cacna1hٗاىجٍِ  ؛Cacna1gاىجٍِ )االرصبه(،  Gja7عِ اىجٍِ 
 . STZ-SANفً   Kcnk3ٗاىجٍِ  Kcnj5)ىججزٍذ اىْبرشٌ٘رشٌل( ٗاىجٍِ  Nppb، ٗاىجٍِ Nppaٗاىجٍِ 
 0)قْبح اىج٘ربسًٍ٘(، ثبّخفبض  Kcna2)قْبح اىص٘دًٌ٘(،   Scn7aمبُ ْٕبك اّخفبض أٌعب فً اىزعجٍش اىجًٍْ
ث٘اسطخ ٕزٓ  . ٗأظٖشد ثعط اىجشٗرٍْبد اىَشفشحCacng4أظعبف فً  7ٗاّخفبض  Kcnd2أظعبف فً 
 Pro-ANP   ٗ BNPفً حٍِ أُ Ryr3 ،Cav3.1 ٗKv4.2اىجٍْبد رغٍٍشاد ٍَبثيخ فً اىزعجٍش ثَب فً رىل 
اىٍَز٘مّ٘ذسٌب. قذ رسبٌٕ ٕزٓ اىزغٍشاد  حجٌ قذ خفعذ STZ-SAN.  اُ اىزشمٍت اىذقٍق ه ىٌ ٌظٖشٗا رغٍشاد
ىَشض اىسنشي. س٘ف  عقذح اىجٍجٍخ األرٌٍْخاىفً اىجٍْبد ٗاىجشٗرٍِ فً االظطشاثبد اىنٖشثٍخ اىَشبٕذح فً 
ٗاىجشٗرٍِ رزشجٌ  mRNAرنُ٘ ْٕبك حبجخ إىى ٍضٌذ ٍِ اىذساسبد ىيزحقٍق فٍَب إرا مبّذ ٕزٓ اىزغٍشاد فً 
 إىى رغٍشاد فً اى٘ظٍفخ اىنٖشثبئٍخ.
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Chapter 1: Introduction 
1.1 Diabetes Mellitus 
Diabetes mellitus (DM) is a chronic disease of metabolic dysregulation, 
characterized by persistent hyperglycemia either due to the pancreatic cells not 
producing enough insulin or body tissues becoming insensitive to insulin [1]. 
Functioning as an endocrine gland, the pancreas secretes the hormone insulin, which 
is responsible for regulation of the level of blood glucose in the body [2]. Glucose 
derived externally from the food consumed, and internally synthesized in liver and 
muscle, provides the main fuel for energy in our body. Any impairment in uptake of 
glucose from blood by the cells will result in elevated blood glucose.  
The severity of DM depends on its type and molecular mechanism. Some 
diabetic patients can be completely asymptomatic, while others with marked 
hyperglycemia, may present with polyuria, polydipsia, polyphagia and weight loss 
[3]. Untreated or uncontrolled DM may lead to life threatening complications 
affecting mainly the heart, kidney, vascular system, brain and eyes. Coma and death 
may result in these patients due to ketoacidosis or non-ketotic hyperosmolar 
syndrome [3, 4] 
Epidemiological evidence suggests that DM is increasing alarmingly 
throughout the world. Individuals with DM are at high risk of developing 
microvascular and macrovascular complications [3]. Among the microvascular 
complications cardiovascular complications are the leading cause of DM related 
morbidity and mortality [5]. Improved health care in susceptible patients has 
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certainly increased the life of diabetic patients but along with it has also increased the 
risk of cardiovascular complications. In addition to the DM, risk factors such as 
obesity, physical inactivity and increased consumption of fast food fuel the 
development  of cardiovascular complications [5]. 
1.1.1 Epidemiology 
Diabetes Mellitus is described as a pandemic disease (Fig. 1-1), and due to its 
widespread prevalence imposes a serious global health burden with a predicted rise 
from 415 million diabetic people in 2014 to 642 million in 2040 [6]. Opposing an 
earlier misconception of DM being a disease of the wealthy, estimates provided by 
the International Diabetes Federation (IDF) clearly suggest regional differences in 
prevalence of DM across the seven IDF regions and income groups with developing 
countries worst affected [6] . The seven IDF regions include: Africa, MENA regions 
(Middle East and North Africa), Europe, NAC regions (North America and 
Caribbean islands), South and Central America, South – East Asia and Western 
Pacific.  According to the regional distribution, prevalence of DM is highest in the 
MENA region (10.9%), followed by NAC regions (9.6) while the Africa region has 
the lowest prevalence of DM (5.7%) [6] There is also considerable variation in age 
distribution across the regions, where diabetic people in high income countries are 
largely over the age of 50 while those in low income countries are mostly under the 
age of 50 [6]. In urban and rural areas, although urban areas contain more people 
with diabetes, the increase in prevalence of diabetes is more in rural areas [6]. In 
2014, the IDF estimated that diabetes resulted in 4.9 million deaths and more than 




Figure 1-1: Global prevelance of diabetes across the seven International Diabetes 
Federation regions [7]. 
1.1.2 Diabetes in the Gulf and UAE 
Studies of non-communicable diseases conducted in the Arab world show a 
large increase in the prevalence of DM (36.8 million) with related risk factors which 
include mainly obesity and physical inactivity [8]. Among the world‘s top 10 
countries with highest prevalence of DM, three of them are in the MENA region: 
Saudi Arabia, Kuwait, and Qatar [6]. Recent data suggests, 1 in 10 adults have 
diabetes in the Middle East and North Africa [6]. Rapid economic transformation, 
sedentary lifestyle, physical inactivity, smoking and unhealthy eating habits have 
been identified as the main underlying causes for the increasing prevalence of DM in 





worldwide, with 19% of its population living with diabetes. A study conducted 
among Emarati citizens living in Al-Ain, in 2007, reported a prevalence of 10.5% 
people with DM, while those of undiagnosed cases were 6.6% [9]. There were 
803,900 cases of DM in UAE in the year 2014 [6]. 
1.1.3 Types of Diabetes Mellitus  
Several classification criteria have been developed for DM since its 
identification. Age was the initial criterion which was soon replaced by insulin 
dependency, that categorized diabetes broadly into 2 major groups: Insulin dependent 
DM (IDDM) and non-insulin dependent DM (NIDDM) [10]. Another broad 
classification adapted for its convenience by clinical practitioners mostly is Type 1 
diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). However, in 
subsequent years, with better understanding of the pathology involved in the 
development of DM, many diabetic individuals did not fit in these criteria[1, 11]. 
Hence, in addition to insulin dependency, several other criteria have been introduced 
based on pathogenesis, etiology and circumstances present at the time of diagnosis 




Figure 1-2: Classification of diabetes mellitus [11].  
Diabetes is also often conveniently classified according to the state of 
glycaemia (Fig. 1-3) [11]. For a particular disease process the degree of severity 
might change over time ranging from normoglycaemia, to impaired glucose tolerance 
to full blown DM. This approach imparts diversity in clinical presentation and mode 
of control for the same type of disease in different individuals. For instance for a 
specific type of disease process, adequate glycemic control in some individuals can 
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be achieved by diet and exercise alone, some may require oral hypoglycemic agents, 
and some are solely dependent on regular insulin therapy [11]. 
 
Figure 1-3: Disorders of glycemia: etiologic types and stages.  
*Honeymoon remission: patients in this category sometimes return to 
normoglycaemia after presenting with ketoacidosis; **in rare instances, patients in 
these categories may require insulin for survival (e.g., Vacor toxicity, Type 1 
diabetes presenting in pregnancy) [11]. 
1.1.3.1 Type 1 Diabetes Mellitus 
Although T1DM represents only 10% of all cases of DM, its incidence is 
increasing worldwide.  It is found in almost all age groups, however, the majority of 
individuals diagnosed are aged 4 to 5 years, especially those of Caucasian 
background [3, 13], and this is why it is also referred to as juvenile onset DM [11]. 
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1.1.3.1.1 Immune mediated Type 1 Diabetes Mellitus  
This form of diabetes results from cellular mediated autoimmune destruction of 
the β cells of the pancreas leading to absolute insulin deficiency [12]. The rate of β 
cell destruction is variable: being more rapid in infants and children and slower in 
adults [11]. About 80-90% of individuals with T1DM have marker proteins in the 
body which are useful for clinical diagnosis. This includes islet cells autoantibodies,  
autoantibodies to insulin, autoantibodies to glutamic acid decarboxylase (GAD65 
and GAD67) and autoantibodies to secretory granule protein islet cell antigen which 
contains tyrosine phosphatase like domain (IA-2 and IA2β) [11]. 
1.1.3.1.2 Idiopathic Type 1 Diabetes Mellitus 
This form of DM has no known aetiologies for β cell destruction [11, 12]. 
Around 1% of patients with T1DM fall in to this category, mostly African and Asian, 
and may present with episodic ketoacidosis due to varying degrees of insulin 
deficiency within the same individual [11]. This form is strongly inherited and 
characterized by absence of any autoimmune markers and is not HLA associated 
[14]. 
1.1.3.1.3 Fulminant Type 1 Diabetes Mellitus 
This form of diabetes described mainly in Japan and other East Asian countries, 
is characterized by acute onset with rapid progression to ketoacidocis [15]. Though 
both genders are equally affected, females tend to develop fulminant T1DM at a 
younger age (35.1 ± 15.8 years) than male patients (42.8 ± 14.8 years) [16]. Unlike 
other forms of DM, the period of fulminant DM from normal β cell to absolute 
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deficiency rarely exceeds 1 week (Fig. 1-4) [16]. Its aggressive nature provides one 
of the distinctive features of fulminant DM compared to other T1DM. Prior to 
diabetic ketoacidosis (DKA), patients may have hyperglycemia associated 
symptoms: like polyuria, polydipsia, polyphagia and weight loss [16]. Patients 
usually present with elevated plasma glucose (≥228 mg/dl), hemoglobin A1c < 8.5% 
with undetectable levels of serum C peptide [16]. Although the  pathogenesis is still 
not clear, it is associated with viral infections like the common cold and 
gastrointestinal infections (diseases mostly associated with enterovirus and herpes 
virus) [15]. Cases have also been reported among pregnant women in their third 
trimester or soon after delivery[17]. The development usually proves lethal to the 
fetus [16]. Evidence also suggests its strong genetic association with HLA (class II 
especially) [16]. Some of the distinctive pathological features include excessive 
reduction in both α and β cells of the pancreas, lymphocytic infiltration in the 
exocrine pancreas tissues with presence or absence of insulitis [18]. Owing to its 
aggressive nature, patients with suspected fulminant T1DM must be treated 




Figure 1-4: Schematic diagram showing destruction of β cells in idiopathic DM and 
fulminant DM [16] 
1.1.3.2 Latent autoimmune diabetes in adults  
The first incidence of Latent autoimmune diabetes in adults (LADA) was 
described 27 years ago when a patient diagnosed and managed as T2DM, later 
required insulin[19]. Several studies were performed subsequently with regard to its 
clinical, metabolic, immunological and genetic characteristics, yet an accurate 
definition could not be formulated. Owing to the presence of immune markers these 
patients can be classified as T1DM, but due to slow progression of β cell destruction, 
they do not require insulin [10]. Thus it has also been referred to as slow onset 
autoimmune diabetes, as the disease process is different from T1DM, in spite of 
possessing immunological and genetic features typical of T1DM [20]. Obesity may 
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coexist in this group of patients. Among the immune markers, the presence of islet 
cell antibodies (ICA) and GAD at the time of diagnosis has been described while the 
genetic markers included association with HLA class II [21]. 
1.1.3.3 Double diabetes  
The term double diabetes (DD), also referred to as hybrid diabetes, was first 
introduced by Libman and Becker in order to define certain groups of patients 
exhibiting mixed pictures of both T1DM and T2DM [22]. Even though its prevalence 
has increased since then, diagnosis of DD has been a challenge. Patients, both 
children and adults, usually present with clinical features of T2DM which includes 
hypertension, dyslipidemia, increased body mass index (BMI) with no or reduced 
features of T1DM such as weight loss and ketoacidosis. The main features of DD 
that differentiate it from LADA which is found in approximately 10% of all cases of 
T2DM includes insulin resistance and obesity [23]. The other parameter that assists 
with the diagnosis of DD, in patients with established hyperglycemic state, is the 
presence of autoimmune markers that include GAD, tyrosine phosphate antibodies 
(IA-2), and insulin autoantibodies (IAA), but reduced number and titre compared to 
T1DM [24]. Studies have also identified involvement of environmental factors and 
genes in the development of DD (Fig. 1-5) [25]. Dietary exposure to infants, vitamin 
D deficiency and enterovirus infections are recognized as potential risk factors [25]. 
Some of the genes that influence the molecular mechanism of both T1DM and 
T2DM include insulin receptor substrate-1 (IRS-1) variants and peroxisome 
proliferator activated receptor γ (PPARγ) [25]. In addition to a positive family 
history of diabetes, increased risk of cardiovascular disease, decrease in hepatic fat 
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stores and increase in epicardial fat stores have been documented in patients with DD 
[23] 
 
Figure 1-5: Mechanism of insulin resistance in patients with DD [23] 
1.1.3.4 Type 2 Diabetes Mellitus  
According to IDF 2013, the global prevalence of T2DM is 8.3% in adults (20-
79 yrs old) and is expected to rise above 10.1% by 2035. This alarming trend 
imposes an enormous public health concern [6]. The increase in incidence of T2DM 
among youth is mainly attributed to sedentary lifestyle and less healthy food [6, 26]. 
T2DM results from insulin resistance that leads to increased demand for insulin. 
Although specific etiologies have not been identified the pathophysiology ranges 
from insulin resistance, with relative insulin deficiency, to an insulin secretory defect 
with insulin resistance [11]. Obesity is linked to T2DM in most patients and this has 
been shown to contribute significantly to insulin resistance. The molecular 
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mechanism in obesity involves increased production of adipokines, ectopic fat 
deposition and mitochondrial dysfunction [27]. Increased adipokines cause activation 
of macrophages that in turn release inflammatory factors (LTB4). This process 
initiates a positive feedback loop causing more and more macrophage recruitment, an 
increase in inflammatory factors that bind to cells having LTB4 receptors and 
ultimately rendering these cells insulin resistant [27]. Other metabolic abnormalities 
associated with insulin resistance include dyslipidemia, hypertension, fatty liver, 
ovarian hyperandrogenism and premature adrenarche [26, 28]. The differences 
between T1DM and T2DM are not always straightforward and in many cases a 
common pathogenic process may operate. However, features that differentiate T2DM 
from T1DM are lack of insulin dependency, absence of ketoacidosis and absence of 
evidence indicating autoimmune destruction of β cells [28]. T2DM has stronger 
genetic predisposition than T1DM, but is complex and poorly understood [26]. 
Patients may remain asymptomatic for years due to a gradual rise of glucose, 
resulting in delayed diagnosis and increasing incidence of long term macrovascular 
and microvascular complications [4]. 
1.1.3.5 Diabetes due to genetic defects 
Defects or mutations in genes could affect β cell function or insulin action. A 
single gene defect in a pancreatic β cell, leading to loss of β cell function is referred 
to as monogenetic diabetes [3]. Depending on the age of onset, it is further classified 
as neonatal diabetes, which occurs before the age of 6 months and maturity onset 
diabetes of young (MODY), which occurs before the age of 25 years. Around 1-4% 
of diabetic children fall into this category globally [29]. Based on the pattern of 
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genomic loci several forms of monogenetic diabetes have been identified which 
include common subtypes of MODY: mutations in glucokinase gene (GCK), hepatic 
nuclear factor (HNF α1) on chromosome 12, HNF-4α and some less common forms 
like HNF-1β, insulin promoter factor (IPF-1), and NeuroD1 [29] . Likewise a defect 
on ZAC/HYMYI gene causes transient neonatal diabetes whereas a defect in the 
gene encoding the subunit of the β cell potassium ATPase channel results in 
permanent neonatal DM [11]. Another group of DM associated with point mutation 
in mitochondrial DNA, is referred to as mitochondrial DM and usually presents with 
deafness [3]. Subjects with mild glucose intolerance have also been identified where 
a point mutation resulted in inability to convert proinsulin to insulin [11]. 
Mutations of genes can also result in reduced insulin action. The 
pathophysiological effects involved in the mutations of the insulin receptor gene may 
range from hyperinsulinamia and mild hyperglycemia to severe DM. It may also be 
associated with syndromes like Leprechaunism and the Rabson-Mendenhall 
syndrome and signs like acanthosis nigricans and cystic ovaries in women. 
1.1.3.6 Gestational diabetes 
Gestational diabetes mellitus (GDM) is classically defined as glucose 
intolerance developed during pregnancy, usually around the 24
th
 week. Insulin 
resistance exists before pregnancy in women with a history of GDM but worsens 
during gestation [30]. Patients, as they remain asymptomatic, are generally diagnosed 
by screening for plasma glucose during pregnancy. According to Carpentar/Coustan 
criteria the presence of at least two of four plasma glucose measurements need to be 
positive before a diagnosis of GDM. The four plasma glucose levels are:  FPG ≥ 95 
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mg/dL (5.3 mmol/L); 1-h ≥ 180 mg/dL (10.0 mmol/L); 2-h ≥ 155 mg/dL (8.6 
mmol/L); and 3-h ≥ 140 mg/dL (7.8 mmol/L) [11]. There are two approaches to 
diagnose GDM in women not previously diagnosed as diabetic. The first approach 
adopted by World Health Orgaization (WHO) is based on the ―one-step‖ 
International Association of Diabetes and Pregnancy Study Groups (IADPSG) 
consensus, that incorporates diagnostic oral glucose tolerance test (OGTT) without 
prior plasma or serum glucose screening while the second approach is based on the 
―two-step‖ National Institute of Health (NIH) consensus, used in the United States 
and involves an initial screening by measuring the plasma or serum glucose 
concentration 1 h after a 50-g oral glucose load (glucose challenge test [GCT]) and a 
diagnostic OGTT on the subset of women exceeding the glucose threshold value in 
the GCT  [31-33]. Development of GDM poses risks for both mother and baby if not 
adequately managed. Patients with GDM have been reported to have increased 
incidence of pre-elampsia and C-section and babies of these mothers are at increased 
risk of developing complications like, macrosomia, hypoglycemia, jaundice and 
seizures [33]. Evidence of GDM being lethal to the fetus has also been reported in 
untreated cases [33]. Mothers are also at increased risk to develop T2DM after 
pregnancy [33]. Common risk factors for the development of GDM are: a positive 
family history of T2DM in first degree relatives, a maternal age of more than 35 
years at the time of pregnancy, members of an ethnic group with high prevalence of 
DM (e.g., Hispanic, Pacific Islander, African-Americans, Afro-Carribeans and 
Native Americans), obesity and a previous history of abnormal glucose metabolism 




Action of insulin is altered by several hormones including glucagon, growth 
hormone, cortisol and epinephrine. Excessive amounts of these hormones are 
associated with endocrinopathies like Cushing‘s syndrome, acromegaly, 
glucagonoma and pheochromocytoma. Symptoms of the respective diseases are 
present along with evidence of hyperglycemia and DM which are usually resolved on 
treatment of the specific endocrine disorder. However, insulin secretion is also 
disturbed by certain drugs which could also be hormones. Diabetes has been reported 
in patients receiving α interferon, glucocorticoids and nicotinic acid [11]. 
Exocrine pancreatic disorders may also lead to altered glucose state. Conditions 
causing trauma to the pancreas which include pancreatitis, pancreatic carcinoma, 
pancreatic steatosis cause progressive damage to  the pancreatic β cells [34]. 
Diabetes has also been associated with certain viruses (coxsackievirus B, 
cytomegalovirus, adenovirus, and mumps virus) which cause β cell destruction [35].  
1.1.4 Pathobiology 
1.1.4.1 Insulin secretion 
The human insulin coding gene, located on the short arm of chromosome 11, is 
initially synthesized as preproinsulin and processed to proinsulin by β cells of the 
pancreas [36]. The 86 amino acid polypeptide single chain is then subsequently 
cleaved removing a C-peptide strand, leaving a double chain insulin molecule with 
51 amino acid residues [36]. Insulin together with C peptide is then bound and stored 
within secretory vesicles and discharged to the circulation upon stimulation [36]. A 
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greater proportion of insulin is bound to its receptor and undergoes hepatic 
metabolism whereas C peptide escapes this phase and hence, the peripheral C peptide 
level provides a better marker for endogenous insulin secretion [36]. Insulin 
synthesis is regulated, at transcriptional level by cis acting sequences and trans-
activators: paired box gene 6 (PAX6)P, pancreatic and deuodenal homebox-1 
(PDX1) and NeuroD1[37]. While at translational level it is regulated by stability of 
preproinsulin mRNA [37]. A sequence of events is involved in secretion of the 
vesicles containing insulin as shown in Fig. 1-6.  Briefly among the various 
secretagouges, glucose is the primary stimuli for insulin secretion [38, 39]. It enters 
the cell via the glucose transporter protein 2 (GLUT 2) transporter, the only glucose 
transporter expressed in β cells. Following its metabolism via the tricarboxylic acid 
(TCA) cycle, adenosine triphosphate (ATP) is generated which causes closure of the 
ATP-sensitive K
+
 channel, and depolarization of the membrane [38]. This in turn 
opens the Ca
2+
 channel, allowing Ca
2+ 
to enter the cell [38]. Increased intracellular 
Ca
2+
 eventually leads to exocytosis of insulin granules in a process that involves 




Figure 1-6: Schematic diagram showing mechanism of insulin secretion [37] 
1.1.4.2 Insulin action 
Insulin binds to the α subunit (insulin binding site) chain of the insulin receptor 
and this causes phosphorylation of the β subunit on serine, threonine and tyrosine 
residues on the cytoplasmic side of the membrane [36]. Activation of tyrosine kinase 
and autophosphoryalation of insulin receptor substrates (IRS-1 and IRS-2) are the 
crucial initial steps for insulin action followed by a series of phosphorylation and 
dephosphorylation reactions, leading to insulin‘s cellular effects in target tissues 
(primarily liver, fat and muscle) [36]. Along the signal transduction pathway, 
activation of phosphotidylinositol 3 kinase is also critical in translocation of GLUT 4 




Figure 1-7: Diagram showing mechanism of insulin action and glucose uptake in a 
cell. [40] 
1.1.4.3 Metabolic effects of insulin 
1.1.4.3.1 Fasting state 
In the fasted state most of the glucose uptake occurs in insulin insensitive 
tissues like brain. In order to maintain the homeostasis of blood glucose, endogenous 
production of glucose (glycogenolysis and gluconeogenesis) takes place in the liver 
(7 – 10 gms/hr) which provides sufficient glucose for insulin insensitive tissues.  [36] 
1.1.4.3.2 Fed state  
In the state of high glucose uptake, multiple homeostatic mechanisms are 
activated in order to maintain normal blood glucose levels. This includes a decrease 
in endogenous glucose production, an increase in uptake of glucose by peripheral 
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insulin sensitive tissues like muscle and stimulation of hepatic uptake of glucose 
(Fig. 1-8). 
 
Figure 1-8: Glucose homeostasis in fasting (blue arrow) and fed state (red arrow). 
https://www.atrainceu.com/images/img_90_Diabetes/insulin_and_glucagon.png 
1.1.4.4 Glucose and other secretagouges 
Glucose is the main regulator of insulin secretion. The mechanism involves 
activation of signal transduction pathways and mitochondrial signals, upon entry of 
glucose into the β cell via the GLUT 2 transporter protein [2, 38]. This subsequently 
causes ATP-sensitive potassium channel closure along with calcium entry into the 
cytoplasm of β cells [38, 41]. Following a small rise in glucose above the fasting 
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level, insulin is secreted initially from stored secretory vesicles and later from de 
novo synthesis[36, 38]. In addition to concentration the mode of entry of glucose also 
determines the amount of insulin secretion; compared to intravenous administration, 
higher levels of insulin is released when glucose is administered orally [38]. Other 
secretagouges which regulate and amplify insulin secretion include vagal 
stimulation, sulfonylurea drugs, amino acids like leucine and incretins (e.g. glucagon 
like peptide – GLP-1) [36].  
1.1.4.5 Role of incretins 
The incretin hormones: GLP-1 and glucose-dependent insulinotropic 
polypeptide (GIP), are released during meals from gut endocrine cells and are 
responsible for 70% of postparandial insulin secretion [42]. Compared to equivalent 
carbohydrate administered intravenously, oral administration generates a more 
vigorous insulin response [36]. The mechanism of their action involves proliferation 
of β cells and prevention of apoptosis, thus maintaining glucose homeostasis [42]. 
The other beneficial effects of these hormones include attenuation of glucagon 
secretion, slowing of gastric emptying, and a central nervous system effect to 
enhance satiety [36] . 
1.1.5 Pathogenesis of Type 1 diabetes mellitus 
T1DM is due to autoimmune destruction of β cells and patients in this category 
are diagnosed during the end stage of β cell destruction, along with the following 
characteristics: presence of islet cell autoantibodies, immunocompetent cells and 
alterations of T cell mediated immunoregulation [43]. The autoimmune mechanism 
is chronic in nature, recruiting a mixture of cells along its pathway which include, 
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pseudoatrophic islets producing glycogen, somatostatin, pancreatic polypetide and 
infiltrating lyphocytes and monocytes. This in turn reflects heterogenicity of the islet 
lesions, explaining the difficulty in clearly defining the pathogenesis. Al Homsi et al 
(1992), suggested that  the chronic time course in the natural process of the disease is 
a consequence of down regulation of the immune system in T1DM. The development 
of T1DM shows genetic suceptibility predominantly to HLA genotypes DR and DQ. 
In addition environmental triggers and epigenetic changes also interfere with the 
immune system thereby causing β cell destruction [44]. The autoimmune destruction 
of β cells follows 2 pathways (Fig. 1-9). The first pathway involves T cell mediated 
activation of CD4+ which in turn induces insulitis. The findings from Yagi et al 
(1992) and Wang et al (1991) confirmed that CD4+ T cells are the major 
immunocompetent cells required in the disease process [45, 46]. The second pathway 
involves activating macrophages that release large amounts of cytokines and 
interferons which enhance the disease process. Several in vitro studies demonstrated 
that IL-1 and TNF α decrease insulin releasing capacity by causing structural 
changes of the β cell while Interferon γ is involved in activating the macrophages to 
synthesize nitric oxide which has been recently identified as a potent pathogenic 




Figure 1-9: Pathogenesis of Type 1 DM [41].  
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1.1.6 Pathophysiology of type 1 diabetes mellitus 
The autoimmune destruction of β cells leads to absolute deficiency of insulin 
that subsequently causes a variety of metabolic disturbances affecting all the major 
nutritional pathways. In addition to insulin deficiency, there is also an increase in 
glucagon due to abnormal α cell function, which in turn further accelerates the 
metabolic derangements. The major metabolic derangements resulting from insulin 
deficiency are discussed as shown in Fig. 1-10 [47]. 
1.1.6.1 Effect on glucose metabolism 
In the absence of insulin, the liver glycogen stores are mobilized through the 
process of glycogenolysis. This is followed by hepatic gluconeogenesis which further 
increases hepatic glucose output. Additionally insulin deficiency impairs non hepatic 
utilization of glucose especially in the adipose tissues and skeletal muscles which 
depend on insulin to mediate the movement of glucose transporters to the plasma 
membrane.  This in turn causes reduction in glucose metabolism by the peripheral 
tissues. Insulin also regulates the level of hepatic glucokinase which reduces the rate 
of glucose phosphorylation in hepatocytes. As a consequence of increased hepatic 
glucose production combined with decreased peripheral uptake of glucose, the 
plasma glucose is elevated. This elevated glucose leads to glucosuria, and glucose 
being an osmotic diuretic, increases renal loss of glucose which is accompanied by 
loss of water and electrolytes leading to activation of the thirst mechanism. The 
calorie imbalance caused by tissue catabolism and glucosuria leads to an increase in 
appetite and food intake. 
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1.1.6.2 Effect on lipid metabolism 
Insulin is required for synthesis and storage of triglyceride in hepatocytes. In its 
absence free fatty acid (FFA) is mobilized from hepatocytes leading to increased 
FFA and subsequently hypertriglyceridemia. Metabolism of the FFA provides a 
source of nutrition for all the body tissues except brain. Oxidation of FFA in 
mitochondria generates acetyl co-A that is unable to enter the tricarboxylic (TCA) 
cycle and is instead metabolized to ketone bodies (acetoacetate and β 
hydroxybutrate), that can be used by the brain, heart and skeletal muscles as a source 
of energy. Excess of ketone production, in uncontrolled IDDM, results in 
ketoacidosis. Increase in FFA and ketone bodies further exacerbates hyperglycemia 
impeding glucose utilization. 
1.1.6.3 Effect on protein metabolism 
Insulin‘s role on protein metabolism is anabolic causing protein synthesis and 
reducing rate of protein degradation. In the absence of insulin, protein is degraded 
rapidly and the resulting increased amino acid pool serves as a gluconeogenic 









Figure 1-10: Pathophysiology of Type 1 DM [41] 
1.1.7 Diagnostic criteria of diabetes mellitus 
With sudden onset, symptoms usually include polyuria, polydipsia, polyphagia, 
weight loss despite normal or increased eating, blurred vision, frequent or continuous 
infections and tingling or pain in the hands, feet or both [12]. Diagnosis is based on 
measurement of blood glucose and HbA1C level and the corresponding range of 
measurement differs among children and adults. The American Diabetic Association 
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(ADA) diagnostic criteria for diabetes are shown in Tab. 1-1 and diagnosis is 
confirmed by repeated testing. Introduced by an International Expert Committee in 
2009, HbA1c has been shown to be more reliable than fasting plasma glucose (FPG) 
with respect to convenience and preanalytical stability[48, 49]. HbA1c also has a 
lower coefficient of variation compared to FPG and 2 hours oral glucose tolerance 
test (2h OGTT) and a stronger correlation with microvascular complications and is 
therefore, a better marker of glycemic control [49]. 
Test Threshold State 
Random plasma glucose 
(RPG) 







Fasting plasma glucose 
(FPG) 
≥7 mmol/L (≥126 mg/dL) 
2 hours Oral glucose 
tolerance test (2h OGTT) 
≥11.1 mmol/L (≥200 
mg/dL) 
Hemoglobin A1c (HbA1c) ≥6.5% (48 mmol/mol) 
Impaired fasting plasma 
glucose (IGF) 





Impaired plasma glucose 
with 2 hours OGTT (IGT) 
7.8-11 mmol/L (140-199 
mg/dL) 
Table 1-1: Diagnostic criteria for diabetes and prediabetes [11]. 
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Some individuals are at high risk of developing DM but their plasma glucose 
does not define them as diabetic. Instead such people are diagnosed to be in a state of 
prediabetes, with plasma glucose above the normal range but below that of clinical 
DM. Its prevalence is rapidly increasing worldwide with a projected rise of 155 
million in the year 2030 from the year 2013 [6]. Prediabetes is associated with other 
features of metabolic syndrome that include elevated blood pressure, elevated 
tryglyceride, reduced high density lipoprotein (HDL) and obesity [50]. Huang Y et al 
(2014) established a correlation between prediabetes and increased cardiovascular 
mortality and cancer [51].  
1.1.8 Complications of diabetes mellitus 
Untreated DM causes both acute and chronic complications. The major acute 
complication due to metabolic derangements is DKA. In addition hyperosmolar non 
ketotic coma and hypoglycemia are also seen in patients who are not adequately 
treated. However, the chronic complications are more a consequence of prolonged 
exposure of tissues to hyperglycemia and can be further divided into microvascular 
complications (due to damage of small blood vessels) and macrovascular 
complications (due to damage of arteries). Microvascular complications mainly 
affect the eyes, kidney and nerves whereas macrovascular complications affect the 





Figure 1-11:  Complications of DM [7]. 
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1.1.8.1 Microvascular complications 
Prolonged elevated glucose level may cause thickening and weakening of the 
walls of small blood vessels. This damage to small blood vessels leads to 
microangiopathy which is associated with one or more of the following: diabetic 
neuropathy, diabetic nephropathy and diabetic retinopathy [52]. The development of 
most microvascular complications is dependent on the magnitude and duration of 
hyperglycemia. There are other pathological mechanisms by which DM leads to the 
development of microvascular complications as shown in Fig. 1-12. One of them is 
the intracellular polyol pathway which involves conversion of glucose to sorbitol by 
the enzyme aldose reductase. Elevated glucose results in accumulation of sorbitol in 
cells that in turn exerts osmotic stress. Glycation, defined as a reaction between any 
reducing sugar and protein, also induces cellular damage by enhancing the formation 
of advanced glycation end products (AGEs). Hyperglycemia also stimulates free 
radical production and reactive oxygen species (ROS) formation. This in turn 




Figure 1-12:  Mechanism of development of microvascular complications [53]. 
1.1.8.1.1 Diabetic nephropathy 
Diabetes is one of the leading causes of chronic kidney disease and a leading 
cause of renal failure in the United States. It occurs in both type 1 and type 2 DM in 
the absence of adequate treatment. Diabetic nephropathy is characterized by massive 
proteinuria (>500mg in 24 hours in the setting of DM) preceded by 
microalbuminuria (albumin excretion of 30-299 mg/24hrs). The mechanism causing 
damage to small blood vessels includes thickening of glomerular basement 
membrane, microaneurysm development, mesangial nodule formation known as 
Kimmelsteil-Wilson bodies and other changes that subsequently result in pathology 
of the kidney [52]. 
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1.1.8.1.2 Diabetic neuropathy 
Elevated blood glucose damages nerves throughout the body causing diabetic 
neuropathy. The ADA defines neuropathy as ―the presence of symptoms and/or signs 
of peripheral nerve dysfunction in people with DM after the exclusion of other 
causes‖ [54]. Neuropathy affects 50% of both type 1 and type 2 diabetic patients. 
The mechanisms that underlie nerve injury by hyperglycemia is poorly understood. 
However, as described by Fowler (2008), oxidative stress, polyol accumulation and 
injury from AGEs may be responsible for peripheral nerve damage [52]. Somatic 
diabetic neuropathy manifests as  polyneuropathy and mononeuropathy or visceral 
that includes cardiovascular, gastrointestinal, genitourinary, sudomotor, vasomotor 
and pupillary neuropathy [53]. A diabetic patient with peripheral neuropathy may 
present with one or all of the following: sensory, focal/multifocal and autonomic 
neuropathies. The most common form of neuropathy in DM is chronic sensorimotor 
distal symmetric polyneuropathy; rarer is pure sensory neuropathy. Diabetic 
mononeuropathies are sudden in onset, acute in nature and primarily involve median, 
ulnar and radial nerves. However, diabetic autonomic neuropathy occurs in most 
organ systems, interfering with their normal function. Patients may present with a 
range of symptoms including constipation, diarrhea, resting tachycardia, silent 
ischemia and sudden cardiac death.  
1.1.8.1.3 Diabetic retinopathy 
The most common microvascular complication is diabetic retinopathy resulting 
from damage to the small blood vessels supplying the retina due to chronic 
hyperglycemia. It is the most common cause of vision loss among people with DM 
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and the leading cause of vision impairment and blindness among working age adults. 
Injury to blood vessels causes a leak of fluid in the retina with subsequent 
deprivation of oxygen and distortion of vision. In the long term the ischemic retina 
releases a variety of growth factors like vasoendothelial growth factor (VEGF) that 
simultaneously stimulates formation of new blood vessels (angiogenesis) which 
eventually proliferates on the surface of the retina leading to scarring and retinal cell 
loss. In brief diabetic retinopathy progresses through the following stages: mild non-
proliferative retinopathy, moderate non-proliferative retinopathy, severe non-
proliferative retinopathy and proliferative diabetic retinopathy. 
1.1.8.2 Macrovascular complications 
The major pathology involved in the development of macrovascular 
complications is atherosclerosis: narrowing of arterial walls throughout the body. In 
people with DM, hyperglycemia leads to chronic inflammation and injury to the 
arterial walls in the periphery or coronary vascular system. This endothelial injury in 
turn causes accumulation of oxidized lipid from low density lipoprotein (LDL) 
particles in the endothelial wall of arteries. This is then followed by infiltration of 
monocytes which are subsequently differentiated into macrophages, which again 
accumulate oxidized lipids to form foam cells. Also called fatty streaks these foam 
cells stimulate macrophage proliferation and recruit T lymphocytes which in turn 
cause smooth muscle proliferation and collagen accumulation in the arterial walls. 
Finally, a lipid rich atherosclerotic lesion with fibrous cap (atheromatous plaque) is 
formed, which when ruptured results in thrombosis and acute vascular infarction. As  
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shown in Fig. 1-13, the pathophysiology of atherosclerosis results from a sequence of 
events in the arterial wall [55].  
 





Another mechanism involved in development of macrovascular complication is 
increased platelet aggregation and hypercoagulability induced by reduced nitric 
oxide production, increased free radical formation in platelets and altered calcium 
regulation. In addition impaired fibrinolysis due to elevated plasminogen activator 
inhibitor in T1DM may also contribute to the development of macrovascular 
diseases. Risk factors for macrovascular disease in diabetic patients includes 
dyslipidemia, hypertension, obesity, reduced physical activity and smoking. 
1.1.8.2.1 Stroke 
A stroke occurs when the blood supply to the brain ceases suddenly due to a 
blockage of cerebral blood vessels. Brain cells become deficient in oxygen and die. 
People with diabetes are two to four times more likely to have a stroke than people 
without diabetes. People with diabetes also tend to have strokes at an earlier age than 
other people. Stroke in DM is mainly due to blockage of brain vessels by blood clots. 
Patients with stroke may present with problems of movement, pain, numbness, 
problems with speech and memory.  
1.1.8.2.2 Peripheral arterial disease 
Another vascular complication related to heart disease is peripheral arterial 
disease (PAD), which is common among diabetic patients. The narrowing of the 
peripheral arteries due to athereslerosis decreases the blood flow to the legs and feet. 
PAD in turn is a major risk factor for lower extremity amputation and increases the 
chances of heart attack and stroke. Its diagnosis serves as a marker for 
atherothrombotic disease in vascular beds which includes myocardial infarction, 
stroke and death. 
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The most common symptom of PAD is intermittent claudication in the calves 
and thighs, exacerbated by walking and relieved by rest. Other presentations include 
rest pain, ischemic ulcers, tissue loss and gangrene. However, studies have reported 
that one half of patients with PAD are asymptomatic and among the remaining 
symptomatic patients with PAD, 20% have DM [56]. The development of PAD in 
people with DM is proportional to age, duration of DM and presence of peripheral 
neuropathy. It causes long term disability and severe functional impairment, thus 
impeding quality of life. 
1.1.8.2.3 Cardiovascular disease 
Cardiovascular disease is the leading cause of death and a common cause of 
disability among people with DM [7]. Adults with DM are at five times more risk to 
develop cardiovascular diseases that include angina, myocardial infarction and 
congestive heart failure than adults without diabetes. Angina and MI are grouped 
under ischemic heart diseases (IHD). The result of several studies labeled DM as an 
independent risk factor for the development of IHDs [5]. The underlying mechanism 
of DM causing cardiovascular dysfunction is complex and predisposing factors 
include prothrombotic state atherosclerosis, dyslipidemia, and hypertension.   
Angina 
Patients with coronary artery disease (CAD) and DM have a greater risk of 
angina than patients without DM [57].  Angina is characterized by chest pain or 
discomfort that usually occurs with activity or stress resulting from poor blood flow 
through the vessels of the heart. This poor blood flow is a result of atherosclerosis of 
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coronary arteries. The symptoms are usually relieved by rest or nitroglycerine within 
10 – 15 minutes [53].  
Myocardial infarction 
Rupture of arethomatous plaques in diabetic patients is the major cause of 
occlusion of coronary arteries leading to MI. Hence, unlike angina, MI occurs due to 
a complete blockage of blood supply to a region of the heart and is characterized by 
sudden onset of severe retrosternal chest pain that is steady and crushing in nature 
and radiates to the left side of the neck. Studies have shown the risk of MI in people 
with DM is equivalent to the risk in non-diabetic patients who already had MI. With 
regard to this, ADA and AHA recommended DM to be considered a CAD risk 
equivalent rather than a risk factor and that people with DM should be treated as if 
they already have vascular disease [58]. The symptoms of MI are not relieved with 
rest or nitroglycerine differentiating it markedly from angina. 
Diabetic cardiomyopathy 
Diabetic cardiomyopathy is described as left ventricular function impairment in 
a diabetic patient in the absence of coronary disease or hypertension and is initially 
identified by diastolic dysfunction which is often followed by development of 
systolic dysfunction. Though a direct pathophysiological link between DM and heart 
disease is debatable in humans, studies in rodents have demonstrated development of 
diabetic cardiomyopathy without any confounding factors like atherosclerosis, 
elevated triglyceride or hypertension [59].  
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The mechanisms involved in development of diabetic cardiomyopathy are as 
follows: 
i) Impaired calcium signaling causing alteration in the time course of 
relaxation. 
ii) Increased oxidative stress due to elevated glucose causing damage to 
structural components of the heart and activation of inflammatory signaling 
pathways such as NF-κB and protein kinase C that induce multiple 
deleterious effects which include capillary occlusion and pro-inflammatory 
gene expression. 
iii) Toxicity exerted by endoplasmic reticulum stress and accumulated 
glycation products leading to cardiomyocyte apoptosis. 
iv) Depressed cardiac function due to low grade inflammation and 
interference in cytokine signaling. 
The inability of the heart to circulate blood to the body leads to a condition 
called congestive heart failure (CHF) with accumulation of fluids in lung 
and lower limbs. 
Cardiac autonomic neuropathy 
A subcommittee of the Toronto Consensus Panel on Diabetic Neuropathy, 
defined cardiac autonomic neuropathy (CAN) as an impairment of autonomic control 
of the cardiovascular system in patients with established DM, excluding all other 
causes  [60] . These cardiac complications of DM are often underdiagnosed as they 
remain subclinical in the early stages, and become evident as they progress to the 
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clinical stage with its symptoms ranging from resting tachycardia to cardiomyopathy 
[61]. With its prevalence range from 1% - 90% in patient with T1DM and 20% - 
73% in patients with T2DM, it accounts for a large proportion of mortality and 
morbidity in patients with DM. The large variation in its prevalence is due to 
inconsistency of diagnostic criteria used to diagnose CAN [61]. One of the major risk 
factors for progression of CAN in diabetic patients is poor glycemic control [62]. 
However, its association with other CVD risk factors such as smoking, hypertension, 
hyperlipidemia and obesity has also been reported. Abbott et al (2010) established 
ethnicity as a risk factor for CAN as Europeans have a higher prevalence than South 
Asians [63]. A correlation with age and microvascular complications of DM have 
also been identified [64]. While its exact pathogenenesis is complex and poorly 
understood, CAN is diagnosed by five simple non-invasive tests. These are known as 
CARTs (cardiovascular autonomic reflex tests), proposed by Ewing et al, that 
measures the cardiac autonomic function, based on heart rate and blood pressure 
responses to certain physiological manoeuvres like Valsalva and deep breathing [65]. 
1.2 Cardiac anatomy and function 
The heart receives deoxygenated blood from the entire body, pumping blood 
through the lungs where it is oxygenated and is then pumped around the whole body 
[53]. Since the topic of my thesis deals with DM and its effect on the sinoatrial node 





The heart consists of four chambers divided into two pumping zones (Fig. 1-
14). The right zone pumps blood to the lungs and the left zone pumps blood to the 
rest of body. The deoxygenated blood from the body drains into the right atrium 
(RA) through the superior and inferior vena cava (SVC and IVC, respectively) and 
flows to the right ventricle (RV) via the tricuspid valve [53]. The blood is then 
pumped to the right and left lung via the pulmonary artery. Oxygenated blood from 
the lungs then enters the left atrium (LA), and then to the left ventricle (LV) to be 
pumped to the whole body via the aorta [53]. The circulation of blood in the heart is 
controlled by four valves: bicuspid/mitral (MV) and tricuspid valve (TV), that open 
during diastole and close during systole and pulmonary valve (PV) and aortic valve 
(AV), that open during systole and close during diastole [53]. The opening and 
closure of the atrioventricular (MV and TV) valves are supported by a group of 
muscles and muscle fibres attached to the myocardium and known as the papillary 
muscles and chordae tendineae, respectively [66]. The wall of tissue separating the 
atria and ventricles is called the interatrial septum and interventricular septum, 
respectively and this wall prevents the mixing of oxygenated and deoxygenated 




Figure.1-14: Gross internal structure of the heart (Anterior view). 
http://cnx.org/contents/FPtK1zmh@6.13:Y5T_wVSC@3/Heart-
Anatomyhttp://cnx.org/contents/FPtK1zmh@6.13:Y5T_wVSC@3/Heart-Anatomy 
1.2.2 Coronary circulation and nerve supply of the heart 
The heart is supplied by right and left coronary arteries that arise from the right 
and left coronary sinuses and divide into several branches supplying different areas 
of heart [66]. The right coronary artery and its branches supply the RA, RV, 
inferoposterior aspect of LV, inferior part of interventricular septum, SAN in about 
60% and atrioventricular node (AVN) in about 90% of individuals [66]. The left 
coronary artery and its branches supply the anterior interventricular groove, posterior 
AV groove, LV and apex [66]. The venous system runs along the coronary arteries 
and drains into the right atrium via the coronary sinus in the atrioventricular groove 
[66]. 
The heart is innervated by both sympathetic and parasympathetic nerve fibres. The 
adrenergic nerve fibres are present throughout the atria, ventricles and conduction 
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system and release norepinephrine and produce positive ionotropic (increase 
contraction) and positive chronotropic (increase heart rate) effects mediated by β1 
adrenoceptors [53]. The parasympathetic supply predominates in the resting state. 
Innervated by vagus and mediated by muscarinic receptors it exerts an inhibitory 
effect and slows the heart rate [53].  
1.2.3 Conduction system of the heart 
The major function of the heart is to pump oxygenated blood to the entire body. 
This coordinated and regulated activity is controlled both by the autonomic nervous 
system and the intrinsic cardiac conduction system (CCS). The CCS of the heart 
generates and propagates action potentials (APs) that are required for cardiac 
contraction [67]. The CCS consists of the SAN, AVN, bundle of His, right and left 
bundle branches and the Purkinje fibers (Fig. 1-15) [67]. The SAN initiates the 
impulse causing the atria to contract. From there electrical activity is propagated to 
the AVN, where the conduction is delayed, through the internodal tract, through the 
Bundle of His, down the bundle branches and Purkinje fibers causing the ventricles 
to contract [67]. The electrophysiological mechanism by which an AP is set up in 




Figure 1-15: Cardiac conduction system 
Schematic diagram showing different components of the cardiac conduction system 
and typical action potential morphologies in different regions of heart [68]. 
1.3 Sinoatrial node 
The SAN is the primary pacemaker of the heart, and is responsible for initiation 
of the heartbeat. It spontaneously produces rhythmic electrical impulses which 
propagate through the conduction system of the heart and initiate and regulate the 
process of contraction.  
1.3.1 Discovery of the sinoatrial node and arrangement of the electrical 
conduction system 
The existence of the primary pacemaker was established almost 100 years ago. 
Following the discovery of a network of gelatinous fibers in the subendocardium by 
 Jan Evangelista Purkinje in 1839, Walter Gaskell discovered that the sinus venosus 
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was the site of impulse generation in 1880 [69]. Although Purkinje was the first to 
define the Bundle, its functional importance was brought to light by Sunao Tawara in 
1906 [69]. Tawara confirmed the presence of the specialized Bundle of His and 
described the concept of the electrical conduction system [69, 70]. Working for his 
doctorate in Aschoff‘s lab,  he succeeded in mapping the cardiac conduction system  
which continued from AVN, through the Bundle of His and terminated in the 
Purkinje fibers [69, 70]. Finally in 1907, the collaborative work of Keith and Flack 
led to the discovery of the sinus node completing the electrical system of the heart 
[70].  
The SAN generates and propagates electrical impulses in the heart [71]. The 
SAN is located in the junction between the SVC and RA as shown in Fig 1-16. This 
part which is classically termed the ‗ultimum moriens‘ has been found to be the last 
part of the heart to stop beating[70]. Travelling though the internodal tract which are 
specialized atrial myocytes the impulse reaches the AVN which is located in the 
lower part of the RA from which the conduction system extends as the Bundle of 
His, and then divides into right and left bundle branches penetrating the right and left 
ventricles, respectively [68]. The descending Purkinje fibers are enveloped in a 
connective tissue sheath which separates the specialized myocardium from the 
surrounding working myocardium [68, 70]. Towards the end, the connective tissue 
disappears and the ramifications become continuous with the ventricular 




Figure 1-16: Anatomical location of the sinoatrial node [66]. 
1.3.2 Structure of the sinoatrial node 
The SAN being the primary pacemaker is responsible for the initiation of the 
heartbeat. The human SAN has previously been described as a small highly localized 
and microscopically distinct tissue area at the junction of the SVC and RA [72]. 
Adding to its unique embryonic development, the histological features stand out 
from the rest of the myocardium. The wedge shaped node is now better appreciated 
as a more diffuse and complex structure. Its extensive distribution has been described 
in several studies based on histology, gene expression and physiological function. 
The expression of the gene, T-box transcription factor (Tbx3), is found only in the 
cardiac conduction system, throughout the path continuing from the SVC down to 
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the crista terminalis to the IVC and finally to the AVN [68]. Tbx3 regulates the 
embryonic development of the SAN while inhibiting expression of atrial genes in the 
same site. In addition, detection of the novel paranodal area using molecular markers 
has shown that the SAN is not a discrete structure as previously thought. The 
paranodal area has the characteristic feature intermediate between the node and 
surrounding atrial muscle. This feature includes a mixture of loosely packed nodal 
and atrial myocytes located within the crista terminalis close to the SAN. Three 
distinct forms of cells have been identified in the SAN which are supported by a 
dense connective tissue matrix that is found to increase with age compared to the 
nodal cells [73, 74]. This supporting tissue comprises a collagenous network of 
fibers; the cells being attached to the collagen by its basement membrane. It also 
contains capillaries, fibrocytes and nerves within the intracellular space [75]. The 
distribution of cells not only varies within different areas of sinus node but also 
among nodes from different hearts.  
1.3.3 Function of the sinoatrial node 
The heart pumps blood in a regular, coordinated, rhythmic pattern which is 
controlled by activity of the excitatory and contractile system of the heart. The 
characteristic function of the SAN (component of excitatory system) is to initiate 
APs that are distinct from those in atrial or ventricular myocytes (components of 
contractile system). In SAN cells, the AP is the result of various inward and outward 
currents and is best described in 3 phases (Fig. 1-17). 
i) Phase 0: opening of long lasting (L-type) calcium channels causing 
inward calcium currents (ICa L) depolarization of the cell membrane. 
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ii) Phase 3: repolarization phase due to closure of calcium channels 
decreasing calcium conductance and opening of potassium channels 
increasing potassium conductance. 
iii) Phase 4: sets up the diastolic depolarization that is known to be the 
hallmark of spontaneously active cardiac tissues. Also known as the 
pacemaker potential, it is driven by inward funny Na current (If) and 
triggers the action potential when a threshold potential is reached (around -
40mV). 
 
Figure 1-17: Action potential of SAN [76]. 
The AP of working myocytes is generated by a different mechanism (Fig. 1-
18). Unlike the unstable membrane potential of SAN, the working cardiomyocytes 
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have a true resting membrane potential (phase 4) which remains near the equilibrium 
potential for K
+
 (EK). The EK is defined as the negative charge required across the 
membrane to oppose the movement of K
+
 down its concentration gradient. The 
resting membrane potential (RMP) during phase 4 is very negative, around -90mV, 
as K
+ 





; hence RMP is closer to EK than ENa. As the cell membrane depolarizes and the 
membrane potential reaches the threshold voltage of -70mV, fast Na
+
 channels open 
and cause a transient increase in fast Na
+
 channel conductance (phase 0). At this 
stage the increase in inward Na
+ 
 current, and fall in outward K
+
 current causes a shift 
of membrane potential  from EK, which is negative, towards the equilibrium potential 
for Na
+
, which is positive. The initial repolarization (phase 1) is caused by opening 
of transient outward K
+
 channel (IKto). The plateau phase (phase 2) is due to IKto in 
addition to slow inward Ca
2+
 through the long lasting (L-type) Ca
2+
 channels that 
opens when the membrane potential depolarizes to -40mV. It is the plateau phase 
that prolongs the AP duration and differentiates it from APs found in other 
contracting cells. The phase of rapid repolarization (phase 3) is caused by closure of 
L-type Ca
2+
 channels that decreases Ca
2+ 





Figure 1-18: Action potential of cardiac muscle. 
http://www.pathophys.org/physiology-of-cardiac-conduction-and-contractility/ 
1.3.4 Leading pacemaking site 
In comparison to histological studies of smaller mammals, where the location 
of the sinus node is more diffuse extending from SVC to IVC, in the human, the 
node is identified to be more restricted with a minor extension towards the terminal 




Figure 1-19: Location of SAN. 
A) Ventral view of right human heart showing the extent and location of sinus node 
B) Schematic diagram of rabbit heart showing: central leading pacemaker site in red 
and peripheral paranodal area in green. Ao indicates Aorta, PA, pulmonary artery; 
PV, pulmonary vein; RA and RV, right atrium and right ventricle; RAA, right atrial 
appendage; SCV and ICV, superior vena cava and inferior vena cava; CS, coronary 
sinus [77]. 
However, functional studies have established that the SAN in human heart is as 
extensive as in smaller mammals. The pacemaking in an intact SAN is not limited to 
a single anatomical area and the position of the leading pacemaker site is highly 
variable both in animals and humans as demonstrated in Fig. 1-20: A, B and C.  This 
phenomenon of shifting pacemaker site under different physiological stimuli or 
conditions is known as pacemaker shift or wandering pacemaker. Experiments in 
dogs by Schuessler et al (1996), concluded that sympathetic nerve stimulation causes 
a superior shift whereas vagal stimulation causes an inferior shift of the leading 
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pacemaker site thus contributing to acceleration and deceleration of the heart rate 
[78]. This has helped to establish the concept of hierarchy of pacemakers within the 
SAN, where the slowest is located inferiorly and the fastest superiorly. 
 
Figure 1-20: Schematic diagram showing pacemaker site. 
A) Pacemaker shift in rabbit SAN: the black star indicates the leading pacemaker site 
under basal conditions and circles represent the pacemaker sites under indicated 
conditions [79]. B) and C) schematic diagrams showing positions of the leading 
pacemaker site (highlighted in red) in two patients during cardiac surgery. In the first 
patient the leading pacemaker site was near the superior vena cava and in the second 
patient it was near the inferior vena cava [68] . 
1.3.5 Ultrastructure of the sinoatrial node 
The SAN in human heart is a fusiform structure that lies at the posterolateral 
aspect of the superior cavo-atrial junction [80]. It is a heterogeneous structure as the 
components of SAN, that is the cells and connective tissues, are not distributed 
uniformly. However, studies on the ultrastructure of sinus node in human heart 
remains limited to postmortem samples due to the likelihood of significant damage to 
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critical centers involved in the sampling technique in vivo in humans [75]. Therefore, 
the ultrastructure has been mostly described in subhuman species: dog, rabbit, frog, 
sheep, rat and steer [68, 71, 75, 81]. 
The SAN is comprised of cells distributed in a collagenous framework; the 
cells are attached to the collagen by the basement membrane. It also contains 
capillaries, fibrocytes and nerves within the intracellular space [75]. The major form 
of nodal cell recognized is termed the P cell. However, a study by Verheijck et al 
(1998), demonstrated 4 types of cell within rabbit SAN. These included 3 types of 
nodal cell classified according to their shape and size and a 4
th
 type, the atrial cells 
which most likely correspond to transitional nodal cells described by other authors 
(Fig. 1-21) [81, 82] . Although the nodal cells obtained after enzymatic dispersion 
are morphologically different they do not exhibit any functional difference [82]. 
Elongated spindle cells and spindle cells were similar in shape except for the length 
whereas the spider cells were distinguished by the presence of a number of 
irregularly shaped branches. All the nodal cells reacted with antineurofilament 
monoclonal antibodies whereas the atrial cells remained quiescent. However, these 




Figure 1-21: Photomicrograph showing different cell types in SAN. 
 a) elongated spindle cell, b) spindle cell, c) spider cell and d) atrial cell [82] 
1.3.5.1 The P cell 
The main cell of the sinus node is the P cell which is situated mostly in the 
central portion of the SAN in clusters and decreases in number while moving 
towards the periphery, thus exhibiting variation in different areas of the SAN [75]. It 
is considered to be the actual site of pacemaking. Under the light microscope, 
clusters of P cells appear elongated with no spatial order. A single polyhedral P cell 
averaging 5-10 µm, stands out from the other myocardial cells due to its distinctive 
features of being extremely small and pale with poorly developed myofiblrils, 
sarcomere and sarcoplasmic reticulum (SR) (Fig. 1-22) [74, 75]. Its sarcolemma is 
composed of an external basement membrane that covers clusters of P cells and an 
internal plasma membrane that permits intercellular contact [75]. Although the 
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thickness of the plasma membrane remains almost constant (40 to 70 Angstrom), the 
thickness of the basement membrane varies widely (40 to 120 Angstrom). However, 
the distance between the two membranes remains relatively constant (70 to 180 
Angstrom units). Devoid of intercalated discs, the P cells are in contact with each 
other in all directions, the apparent contact being the desmosomes [75].  
 
Figure 1-22: Photomicrograph of the sinus node from the adult human heart.  
The cells of the sinus node are histologically distinct and set in a firm fibrous matrix, 
but they are not insulated from the adjacent working atrial myocardium. P indicates 
location of P cells [84].  
P cells also contain relatively few sarcosomes (mitochondria) in comparison to 
the working myocardium, varying widely in size and shape and distributed randomly 
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within a cell (Fig.1-23). The sarcosomes are surrounded by a double layered 
membrane, each exhibiting a consistent thickens of 30 Angstrom and the distance 
between the 2 layers is also about 30 Angstrom. The simple internal structure 
contains very few cristae that exhibit various distributions like rosette arrangements 
with peripheral cristae and a central clear space. In parallel to the distribution of 
sarcosomes, myofibrils containing few myofilaments are also scanty in these cells. 
The presence and physiological role of the SR is also poorly understood. The double 
membrane bound nucleus is relatively large occupying around one third of the 
interior of some P cells. 
 
Figure 1-23: Histological image of the sinoatrial node  
A indicates the sinoatrial nodal artery and N indicates the sinoatrial nodal cells [74].  
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As P cells were concentrated in the center of the SAN, it was hypothesized that 
these cells were the actual pacemaking cells within the sinus node [85]. Identification 
of similar cells in rabbit SAN by their electrophysiological properties and confirming 
them under the electron microscope strongly supported the hypothesis [86]. 
1.3.5.2 The Transitional cell 
Transitional cells refer to those nodal cells that exhibit mixed phenotypes of 
both P cell and atrial cell.  Generally located towards the periphery of the SAN, the 
cells have increasing numbers of myofibrils, sarcosomes and SR and the cytoplasm 
becomes progressively electron dense unlike the P cells. Variations in transition are 
identified among these cells. Some cells are more similar to P cells, some are nearly 
identical to working myocardial cells and some present features of both the P cell 
and working myocyte. Intercellular contacts between P and transitional cell occurs 
via a few scattered desmosomes, whereas that between transitional and working 
myocardial cells occurs through numerous desmosomes or intercalated discs [75] 
1.3.6 Development of the sinoatrial node  
The heart is developed as a single tube formed by the fusion of 2 lateral plates 
of mesoderm during the gastrulation stage in mammalian embryos [87]. As the cells 
of the mesoderm differentiate at different rates, the multi chambered heart attains a 
basic configuration that is found in embryos and adults of all vertebrates including 
human. Although the initial embryonic heart tube possesses nodal characteristics 
(like automacity and poor contraction), a major portion differentiates into the 
working myocardium containing the fast conducting myocardial component (atria 
and ventricle). Only a minor portion of embryonic myocytes will form the slow 
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conducting and poorly contracting pacemaker components (SAN, AVN and the 
bundle) [87]. Concomitant with the first observed heart beat the SAN develops from 
the sinus venosus myocardium at embryonic day (E) 9.5 (E9.5). The sinus venosus is 
composed of the sinus primordium,  venous side of bilayered venous valves and the 
right and left sinus horns [88]. As shown in Fig. 1-24.A. , the development of SAN is 
principally regulated by three genes Tbx5, Shox2 and Nkx2.5 [89].  
The SAN cells develop from the messenchymal cells at E11.5 [90]. These cells 
express the T-Box transcription factor Tbx 18 but not the Nkx2.5 (homebox 
transcription factor) which is apparently expressed in all myocardium derived from 
the first and second heart field [91]. The first heart field, also known as the primary 
heart field, refers to the first wave of mesodermal cells that differentiate to form the 
initial heart tube and express cardiac specific proteins [92]. The second heart field 
refers to the progenitors that are added to the formed tube at the arterial or venous 
pole and contribute to the progressive development of the myocardium, smooth 
muscle and endothelial cells [92]. The point of myocardial differentiation of the sinus 





). After this period the SAN increases in size by 
proliferation [93].  
Differing form the atrial working myocardium, the mature SAN resembles 
embryonic myocytes, where Tbx3 (transcriptional repressor) acts as a key regulator 
of the SAN phenotype [94]. Though Tbx3 is selectively expressed at E9 to E9.5 in 
mouse, its expression is conserved in human [95]. It has been established that loss of 
Tbx3 would result in expression of the atrial gene  in the SAN area while expression 
57 
 
of Tbx3 in atrial region results in development of functional pacemaker cells instead 
of atrial myocytes [94].  
1.3.7 Transcriptional hierarchy of the sinoatrial node 
As shown in Fig. 1-24, the T-box transcription factor Tbx5, takes up the top 
position in the transcriptional hierarchy and is controlled by retinoic acid signaling 
[96]. Its importance has been established during the formation of the early atrial 
region and regulating the expression of Shox2  and Tbx3 which are required for 
functional sinus node formation [87, 97]. As discussed earlier, expression of Tbx3 in 
SAN is crucial as it prevents atrialization of the SAN by repressing atrial myocardial 
genes (Cx40/Cx43/ANF) [95].  
Aside from Tbx3,  studies have demonstrated, animals lacking Shox2 function, 
develop severe hypoplasia of the SAN resulting in severe bradycardia and death [98]. 
In addition, Shox2 knockout revealed ectopic expression of Nkx2.5 and Nkx2.5 target 
genes (Cx40, Cx43, and ANF ) in developing SAN [98]. Cx40, Cx43 and ANF are 
non-pacemaker genes and inhibit SAN transcription. Moreover, the ability of Shox2 
binding directly to Nkx2.5 enhancer element represses Nkx2.5 and its target genes, 
reinforcing the SAN transcriptional program. In addition, Shox2 also prevents 
repression of Tbx3 and HCN4. On the contrary, in the working myocardium that 
lacks Shox2,  Nkx2.5 is activated which represses SAN specific genes thus 
preventing development of an ectopic pacemaker [99].   
The presence of the SAN in the right atrio-caval junction indicates 
morphological asymmetry and this is largely controlled by transcription factor Pitx2 
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[100]. In addition, Pitx2 also directly influences pacemaker function which has been 
established from studies that demonstrated its binding to Shox2 enhancer elements in 
order to mediate its transcriptional repression [101]. Another transcription factor, 
Tbx18, expressed in SAN precursor cells, is required for morphogenesis of the head 
domain of the SAN [91]. 
 
 
Figure 1-24: Development of Sinoatrial node 
A) diagram showing the difference in molecular pathways between atrial and 
sinoatrial nodal cell development, B) model of sinoatrial node and sinus horn 
formation in the right wall of the venous pole and C) a schematic diagram showing 




1.3.8 Molecular markers of the sinoatrial node 
Since the discovery of the SAN, several techniques have been implemented in 
order to identify its exact anatomical location and extension. Electrophysiology has 
been commonly used, both in vivo and vitro, to map the detailed properties of SAN 
cells and thus identify its location [68]. The technique has not only been extensively 
applied in basic but also in clinical research. Immunohistochemistry has also been 
used in identification of the SAN and to differentiate it from working 
cardiomyocytes [87]. In recent years, the genetic circuitry of the SAN has gained a 
lot of importance with respect to identification of the SAN [87]. Although the 
laboratory process of whole genome sequencing has undoubtedly increased the 
knowledge of ion channel genes, the molecular determinants controlling the 
pacemaking activity have been identified by large scale real-time PCR [102, 103] . A 
collection of SAN specific molecular markers associated with development and 
electrophysiological properties has been established. The molecular markers for the 
SAN are positive for HCN4, TBX3, Gjc1 (Cx45), Cacna1d (CaV1.3), Cacna1g 
(CaV3.1) and negative for Nppa (ANP), Scn5a (Nav1.5), Gja1 (Cx43) and Gja5 
(Cx40) [104]. 
1.3.8.1 Expression of neurofilament M  
Being detectable as early as embryonic day (E9.5), neurofilament M (NF-M) is 
considered to be an early marker of the conducting system [105]. But as it varies 
widely among species and with no evidence of its presence in human and rat, it 
certainly cannot be considered as a key marker to study morphological or functional 
properties of the SAN [105]. 
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1.3.8.2 Expression of Connexin isoforms 
Gap junctions are specialized channels connecting myocytes, permitting small 
molecules (< 1K Da) to pass between the cells and contribute to electrical signalling 
[106, 107]. Gap junctions are important for electrical coupling and propagation of 
APs throughout the heart [106]. Their presence has been extensively studied in the 
SAN of various species including rabbit, rat, mouse, bat, mole, dog, sheep, cow, 
monkey and human [79], and the distribution of gap junction channels varies 
between species [106]. The reason for these differences may be either due to 
variation in expression of connexin itself among species or technical problems in 
accurately accessing the connexin proteins in the heterogenous SAN [106].  
Microscopically gap junctions are composed of a group of hemichannels called 
connexons, attached to opposing cell membranes. Each connexon in turn comprises 
six transmembrane channels, connexin (Cx) [79, 108]. Interestingly, mRNA of 
several Cx (Cx30.2, Cx37, Cx40, Cx43, Cx45, and Cx46) has been detected in 
mammalian heart distributed in a non-uniform pattern in different regions of the 
heart [68, 79, 106]. Though all the isoforms have been detected in SAN, Cx45 and 
Cx30.2 is abundantly expressed in SAN relative to working myocardium[68] . 
Conversely, Cx43 is abundantly expressed in working myocardium relative to SAN 
[68].  The unitary conductance of Cx differs among the isoforms [106]. Cx45 which 
is most abundant in the center of the SAN, forms small conductance gap junctions, 
which explains poor electrical coupling and resulting slow conduction velocity of the 
APs in the center of the SAN [68, 107]. In contrast Cx43 forms large conductance 
gap junctions allowing fast conduction of APs [68, 107]. However, towards the 
periphery of the SAN, both Cx43 and Cx45 are present and this explains the 
61 
 
improvement in conduction velocity in this region of the SAN. Cx40 is poorly 
expressed in the SAN [68]. 
1.3.9 Ionic channels involved in the sinoatrial node action potential 
The ionic currents involved in SAN AP are shown in Fig. 1-25 and include: 1) 
rectifier K
+ 
current which decays outwards, 2) inward funny currents (If), 3) inward 
L-type Ca
2+
 current (ICa L), 4) inward T-type Ca
2+





 exchange current (INaCa) [68] 
 
Figure 1-25: Schematic diagram of a typical sinoatrial nodal cell and the ionic 
currents involved in pacemaking [68]. 
1.3.9.1 Potassium currents 
Activation of the outward delayed rectifier potassium current, IK, sets the 
repolarization phase of the SAN AP. It comprises the fast (IK,r) and slow (IK,s) 
components carried by ERG and KVLQT1 K
+
 channels, respectively. At the end of 
repolarization, slow potassium current decay occurs (Fig. 1-17); allowing other 
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inward currents to depolarize the myocyte, and this sets the initial part of pacemaker 
potential. In addition, a lack of Kir2.1 channel (encoded by Kcnj2 gene) is also 
responsible for the unstable resting membrane potential. This channel conducts the 
inward rectifier current, IK,1 , that is responsible for the stable resting membrane 
potential in working myocytes. 
1.3.9.2 Funny current 




 ions, and 
makes an important contribution to the pacemaker potential of the SAN. The 
channels responsible for conducting If are the hyperpolarized activated cyclic 
nucleotide gated (HCN) channels which are modulated by the autonomic nervous 
system [109]. Sympathetic stimulation accelerates pacemaker potential by activating 
β1 adrenoceptor which in turn produces cAMP that binds to the cytoplasmic cyclic 
nucleotide domain of HCN channel [109]. There is growing evidence that the HCN 
channel is not only crucial for impulse generation, but also propagation of impulses, 
coordination of sinoatrial activity and stabilizing cardiac rythmycity [110].  The 
HCN channels exhibit four isoforms: HCN1, HCN2, HCN3, HCN4 [111]; all of 
which are highly expressed in SAN relative to atrium, predominantly HCN1 and 
HCN4 [112]. Various studies have established the importance of If contributing to 
the generation of the pacemaker potential. Prolonged interval between the pacemaker 
potentials have been demonstrated in rabbits where If has been blocked by CsCl 
[113]. Similar results were obtained when If was blocked by ivibradine in isolated 
SAN preparations [113]. This heart rate lowering drug in human (given at a dose of 5 
mg twice daily) causes a decrease of heart rate (of around 9.5 beats/min) [113]. 
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Steiber et al demonstrated that HCN4 knockout resulted in severe bradycardia 
leading to death of the fetus [112]. 
1.3.9.3 Calcium currents 
The T-type Ca
2+
 current (ICa,T), carried by CaV 3.1 (encoded by Cacna1g gene) 
and CaV 3.2 (encoded by Cacna1h gene) calcium channel, is present in all the 
conducting tissues and is activated during the early phase of the pacemaker potential 
in SAN (around -55 mV). Expression of CaV 3.2 is higher during early 
embryogenesis while CaV 3.1 predominates during late embryogenesis and after birth 
[114]. SAN cycle length is reported to be prolonged in models where the Ca
2+ 
channel was blocked by Ni
2+ 
and heart rate is reduced in CaV 3.1 knockout mice. An 
additional role of I Ca,T in triggering Ca
2+ 
release from SR has been studied in 
pacemaker cells of cats, although their action is poorly understood in primary 
pacemaker cells [115].
 
 CaV 1.3 carries L-type Ca
2+
 current (ICa,L ), and 
 
is activated 
during the late stage of the pacemaker potential (-40 to -30 mV) and generates the 
upstroke of the AP [116]. In the working myocardium, this current is carried mainly 
by CaV 1.2 channel and has a less negative threshold potential (around -5mV) than 
CaV 1.3. So the upstoke is slower in SAN [116]. Though both types of channels are 
expressed in SAN, their relative abundance is species specific. For example, ICa,T is 
the predominant current in mice whereas in rabbit it is the ICa,L [106]. 
1.3.9.4 Sodium current 
The sodium (Na
+
) current (INa) is carried by Nav1.1 (encoded by Scn1a gene) 
and Nav1.5 (encoded by Scn5a gene) channels with Nav1.5 being the major 
contributor for fast upstroke of the AP in the working myocardium. Traditionally 
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believed to have no role in pacemaking activity, studies in recent years suggest that 
Na
+
 current may contribute to the electrical properties of the SAN. Though the 
pacemaker mechanism of Na
+
 current still remains unclear, studies conducted in 
SAN of adult rabbit identified the presence of Nav1.1 in the center while Nav1.5 is 
found towards the periphery (transitional myocyte) [117]. While bradycardia, 
prolonged SAN conduction time and conduction block has been observed in Nav1.5 
knockout mice, mutations of the encoding gene Scn5a in human resulted in familial 
sick sinus syndrome [68].  
1.3.10 Coupled clock theory 







, are key players in the generation of the SAN AP. These ion 
channels form the so called membrane clock (M clock). Localized Ca
2+  
release from 
the SR via ryanodine receptors during late diastolic depolarization is referred to as 
the Ca
2+
 clock. Studies have demonstrated interactions between these two clocks 
during cycles of the SAN AP [118]. In addition to experimental studies, various 
computer models have been proposed to understand the complex phenomenon of 
cardiac pacemaking. The most recent one defined as the coupled-clock theory is 
based on the combined intricate activity of two components: the intracellular calcium 





Figure 1-26: Schematic diagram showing the coupled clock system.
.
 
It shows the interactions between the key molecules of the two components: Ca2+ 
clock (red lettering) and the membrane clock (blue lettering) [119] 
1.3.10.1 Membrane clock  
The M clock based pacemaker cell model was first developed in 1960 [120]. 
The M clock model has predominated for several decades as the main mechanism 
responsible for AP generation in pacemaker cells. It is primarily composed of voltage 
dependent saroclemmal currents and hence, designated as the M clock, voltage clock 
or ion channel clock. The ensemble of ion channels and transporters on the surface 





[121]. According to the M clock theory the hyperpolarization activated current If, is 
the initiator of the spontaneous diastolic depolarization that drives the cell towards 
AP threshold [122]. However, the M clock model alone has proven to be insufficient 
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in understanding various experimental results such as a decrease in AP firing rate and 
termination of automacity of pacemaker cells when the Ca
2+
 cycle is inhibited [123]. 
This led to the emergence of a novel numerical model that involves interaction of the 
M clock, with intracellular signaling, defined as coupled-clock mechanism [124] 
1.3.10.2 Calcium clock 
The mechanism of Ca
2+
 release during excitation-contraction coupling in 
cardiac muscle was established by Fabiato in 1983. It is mainly dependent on 
calcium-induced calcium release (CICR) from the SR. This release of Ca
2+ 
is in turn 
triggered by the entry of calcium ions into the cell cytoplasm via ICa,L and ICa,T [125]. 
Another mode of Ca
2+
 release occurs within the SAN, during the final phase of the 
AP, which is known as local calcium release (LCR). During this phase there is a 
spontaneous release of Ca
2+
 from the SR via the ryanodine receptors which in turn 




 exchanger [118]. In 1989, Rubenstein first 
demonstrated LCR from pacemaker cells in the absence of any pathological 
condition [126]. These mechanisms of Ca
2+
 release constitute the Ca
2+
 clock. 
Although, several experiments have been carried out to study the cardiac pacemaker 
mechanism, its role in the generation of the AP remains poorly understood.  
Unlike the contractile cardiac muscle cells, the Ca
2+ 
clock in cardiac pacemaker 
cells is active in the basal state and contributes to diastolic depolarization. Two basic 
mechanisms of Ca
2+
 release occur in SAN cells during spontaneous AP firing: one is 
the AP induced Ca
2+
 transient via the CICR and the other is LCR from SR during 
diastolic depolarization. The LCRs are generated as rhythmic events at rates of 1-5 
Hz, via spontaneous activation of ryanodine receptors, and this rhythmic release is 
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driven by enhanced phosphorylation of Ca
2+
 cycling proteins and not by increased 
intracellular Ca
2+
  [127]. 
1.3.10.3 Interactions of the coupled clock system 
Interaction of the clocks occurs through the entire pacemaker cycle and this 
crosstalk operates on a beat to beat basis and determines both rate and rhythm of an 
AP [128]. Evidence from several studies concluded that the interaction between the 
two clocks is regulated by cyclic AMP (cAMP), subsarcolemmal Ca
2+
, protein kinase 
A (PKA) and CaMKII dependent protein phosphorylation [129, 130]. These 
modulations stabilize the coupled clock system, despite substantial transient cell Ca
2+ 
changes during each AP cycle, leading to generation of normal cardiac pacemaker 
cell automacity [131]. Importantly, the system‘s ability to function as a clock ensures 
Ca
2+
  balance and stability at the level of phosphorylation of the M and Ca
2+
 clock 
and as a result maintaining the same sequence, timing and magnitude of all events 
that recur in each cycle of the AP [119]. 
1.4 Sinus node dysfunction and Sick sinus syndrome 
Sinus node dysfunction (SND) is referred to as an abnormality in SAN AP 
generation and propagation and is characterized by a physiologically inappropriate 
atrial rate which is expressed as  sinus bradycardia, sinus pause or arrest, 
chronotropic incompetence, sinoatrial exit block and an alternating period of atrial 
bradycardia and tachyaarythmias (bradycardia-tahchycardia syndrome) [132]. When 
accompanied by symptoms such as dizziness, fatigue and syncope, SND is referred 
as sick sinus syndrome (SSS). 
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In healthy individuals the normal heart rate is 60-100 beats/min at rest. Sinus 
bradycardia is defined as a rate less than 60 beats/min whereas sinus tachycardia 
refers to a rate more than 100 beats/min in an average adult. Sinus pauses defined as 
temporary cessation of sinus node activity reflected on an electrocardiogram (ECG) 
as a disappearance of P waves from seconds to minutes. Short pauses are 
compensated by the lower pacemakers like the AVN but prolonged pauses result in 
dizziness and syncope. In SAN exit block, the SAN impulse is generated but its 
propagation through atrial muscles is impaired. The block ranges from mild to severe 
or complete heart block. The milder form is known as 1
st
 degree SA block, 
characterized by slow impulse conduction and a normal ECG. The 2
nd
 degree SA 
block type I also known as Wenckeback block is when slow conduction is followed 
by blocked P wave and interpreted as a decrease in P-R interval in ECG. In 2
nd
 
degree type II SA block, impulse conduction is blocked without prior slowing 
producing multiple appearance and disappearance of P-P intervals on the ECG. 
Lastly in 3
rd
 degree block, complete block of conduction occurs resulting in sinus 
arrest. 
1.4.1 Sinus node dysfunction and aging 
The function of the SAN is reduced with age in both humans and animals 
[133]. Studies have shown reduced heart rate and increase in SAN conduction time 
with increasing age. Hence, SND is age dependent and an exponential increase of its 
incidence with age has been established [134]. It is found to equally affect both 
genders and accounts for half of pacemaker implantations in people aged more than 
60 years in the United States. Degenerative fibrosis of the tissue with increasing age 
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is likely to be the most common cause of SND. However, studies demonstrating loss 
of INa from the periphery of the SAN resulting in slow AP upstroke in rabbit SAN 
and a decrease in KV 1.5 resulting in an increase in action potential duration (APD) 
in rabbit and cat SAN suggests that changes in ion channels and gap junctions may 
also contribute to SND development [132]. A decrease of Cx43 has also been 
observed in SAN of older guinea pig thus providing a probable explanation to 
increased sinus node conduction time and sinus node exit block with aging [135] 
1.4.2 Familial sick sinus syndrome 
Sick sinus syndrome can occur in families and is known as familial sick sinus 
syndrome. This occurs by mutations in ion channels. Mutations in SCN5a, HCN4 and 
Ankyrin B have been identified in humans and the same ion channel encoding genes 
when knocked out in a mouse model result in development of SND [132]. In addition 
knock out of Cav 1.3, Cav 3.1, HCN2a, Cx40 and Na
+ 
channel β2 subunit encoding 
gene also resulted in development of SND. Interestingly, SCN5a encoding voltage 
gated α subunit sodium channel Nav 1.5, is absent from the center of SAN. Hence, 
the dysfunction in the sinus node is hypothesized to be due to impairment of Nav 1.5 
located at the periphery of the SAN. Furthermore, Benson et al’s (2003) finding of 
compound heterozygous mutations in SCN5a, indicates that congenital SSS may be 
the result of recessive mutations of a cardiac Na
+
 channel gene [136].  
1.4.3 Sinus node dysfunction in heart failure and atrial fibrillation 
Reduced intrinsic heart rate is a salient feature of heart failure (HF) and 
underlying structural remodeling of the node, at the molecular level, partly underlies 
bradycardia in HF. In addition there is an increase in sinus node recovery time and 
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abnormal propagation of the AP from the sinus node. Zicha et al (2005) 
demonstrated a decrease in HCN2 and HCN4 mRNA and protein in SAN of a canine 
HF model [137]. Elctrophysiological remodeling has also been demonstrated in atrial 
fibrillation (AF). There is significant inflammatory damage to the SAN and nodal 
artery in chronic AF resulting in prolonged sinus node recovery time and a decrease 
in intrinsic heart rate. 
1.5 Diabetes and the sinoatrial node 
Diabetes can disrupt the conduction system of the heart. Various epidemio-
aetiological studies have been established that the incidence of bradyarrythmia, AV 
block, and Bundle branch block is significantly higher in DM patients compared to 
the general population [138]. Even after adjustment of confounding factors like CAD 
and CHF, incidence of AV block among diabetic patients is higher compared to the 
general population [139]. Changes in ion channel expression also gives rise to 
cardiac conduction dysfunction in diabetes [140, 141]. Hence, it is likely that 
diabetes can interfere with normal mechanical and electrical activity of the heart. 
Presently, information regarding the effects of diabetes on different cardiac 
regions is scanty and mostly centered on the ventricles, but given the propensity of 
diabetes to induce conduction defects, the impact of diabetes on the pacemaker 
conduction system needs to be clarified. Previous in vivo biotelemetry studies have 
demonstrated that HR is progressively and rapidly reduced after administration of 
STZ and that the reduction in HR can be partially normalized with insulin 
replacement [142]. Reductions in HR have also been reported in isolated perfused 
heart and superfused right atrial preparations [143]. In addition prolonged APD in 
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isolated prepration of SAN, RA and RV from STZ-induced diabetic rat have also 
been reported [143]. Another study also demonstrated prolonged SAN cycle length 
and conduction time in STZ-induced diabetic rat. Reduced heart rate has also been 
reported in Goto Kakizaki diabetic heart, a experimental model of T2DM [143, 144]. 
The long term effects of STZ-induced diabetes have also been reported which 
includes rapid reduction in HR, heart rate variability (HRV), physical activity and 
body temperature following treatment with STZ and reaching a low steady state 
within 1-2 weeks[145]. Recent work on AVN cells isolated from the STZ-induced 
diabetic rat demonstrated alterations in L-type calcium channel electrophysiology. 
These changes in ion channel activity may contribute to the abnormalities in cardiac 




Chapter 2: Hypothesis, Aims and Objectives 
2.1 Hypothesis 
We hypothesize that alterations of the genes encoding cardiac proteins and 
structural changes underlies abnormal electrical activity in the SAN and low heart 
rate in the STZ-induced diabetic rat.  
2.2 Aims and Objectives 
The aim of the study was to investigate the following:  
1. The effects of diabetes on action potential in the isolated perfused 
heart. 
2. The effects of diabetes on expression of cardiac genes (mRNA) in the 
SAN. 
3. The effects of diabetes on selected cardiac protein expression. 
4. The effects of diabetes on the ultrastructure of SAN. 
The experiments conducted in this study provide an insight into the effects 
of diabetes on structural and molecular aspects of the SAN which may be, 
one of the underlying causes of abnormal heart rate. 
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Chapter 3: Methodological principles 
3.1 Induction of diabetes mellitus  
Diabetes mellitus is one of the most common endocrine and animal models 
have contributed enormously to our understanding of this global metabolic disease. 
The use of animal models has allowed researchers to control in vivo genetic and 
environmental factors that influence the development of the disease, and ultimately 
find new treatments. Rodents are the most commonly used animal model. However, 
larger animals like rabbit, sheep and dog, with human like biological characteristics 
are also used [147]. Several methods have been used to induce DM in laboratory 
animal models including pancreatectomy, chemical induction and genetic breeding. 
The characteristic feature of T1DM is autoimmune destruction of pancreatic β cells, 
leading to lack of insulin production. The deficiency of insulin production in 
experimental animal models is achieved by a variety of mechanisms ranging from 
breeding animals that spontaneously develop autoimmune diabetes to chemical 
destruction of pancreatic β cells [148]. T2DM is characterized by insulin resistance 
and loss of β cell function. Therefore, T2DM is modeled with varying degrees of 
insulin resistance and β cell failure in both obese and non-obese animals [148]. The 
most commonly used rodent models of T1DM and T2DM are described in Table 3-1 
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Table 3-2: Animal model of T2DM. Adapted from [148] 
The most effective method is surgical excision of the pancreas [149]. However, 
precaution has to be taken to adequately remove at least 90-95% of the pancreas, 
otherwise insufficient removal of Langerhan islets may cause it to undergo 
hypertrophy and subsequent secretion of sufficient insulin to meet the metabolic need 
[149]. Another method which is widely used is chemical induction of diabetes. These 
chemicals, when administered in a single large dose or repeated low doses for several 
days, cause β cell destruction, leading to little or no insulin production and 
subsequently result in hyperglycemia and weight loss, representing a model for 
T1DM. Two of the most commonly used diabetogenic agents are STZ and alloxan 
(ALX). The dose required to induce diabetes depends on the animal species, route of 
administration (intravenous, intraperitoneal, or subcutaneous) and nutritional status 
[150]. Both the compounds are similar to glucose in structure, and hence compete 
with glucose in the cell [151]. Being relatively unstable, the solutions are ideally 
prepared just before use [151]. Their common mechanism involves destruction of β 
cells by reactive oxygen species and free radicals which in turn causes DNA 
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alkylation and reduction in ATP leading to cell necrosis  [147]. One of the 
disadvantages of ALX over STZ is that it has a narrow diabetogenic dose and even 
slight overdosing produces general toxicity [152].  
STZ a derivative of glucosamine, is a nitrosourea related antibiotic isolated 
from fermentations of Streptomyces achromogenes. Its chemical name is 2-deoxy-2-
(3-(methyl-3-nitrosoureido)-d-glucopyranose [147]. After i.p or i.v administration, 
STZ enters the pancreatic β cell via the GLUT2 transporter and inhibits DNA 
synthesis. Within the cell it reacts with the cytosine group and causes alkylation of 
the DNA ultimately causing cell death and inhibition of insulin production. 
Moreover free radical production due to STZ accelerates the mechanism of DNA 
damage and cell death. Hayashi et al (2006) reported that STZ induces dose 
dependent diabetes and different strains of the same species respond differently to a 
particular dose [153]. In a study conducted by Mahmoud et al (2009), it was 
demonstrated that Sprague-Dawley (SD) rats are more susceptible to i.p. injection of 
STZ given at a dose of 125 mg/kg, than nude rats [154]. The SD rats had higher 
blood glucose, required frequent insulin, suffered increased mortality compared to 
the nude rats [154]. STZ can be administered as a single high dose or as multiple low 
doses. The single high dose in rats ranges from 35 – 65 mg/kg body weight 
depending on the strain. For instance, diabetes is induced in Wistar rats within 3 days 
of STZ i.p. injection given at a dose of 60 mg/kg body weight. This high dose causes 
rapid destruction of β cells and hyperglycemia. Additionally, it also causes 
lymphopenia and an increase in T-regulatory cells [155]. DM can also be induced by 
multiple low doses of STZ. The low dose ranges from 20 to 40 mg/kg body weight, 
78 
 
depending on the species and strain. The low dose given over 5 days induces insulitis 
in mice and rats. Following administration, macrophages infiltrate the islet cells and 
produce cytokines that trigger the inflammatory pathway resulting in β cell 
destruction and consequently reduction in insulin secretion [148]. Induction of DM 
following STZ administration can be characterized by clinical and biochemical 
parameters. These include hyperglycemia, hypoinsulinemia, polyphagia, polydipsia, 
polyuria and weight loss [149]. These features are prominent within 3 days of STZ 
treatment and the biochemical characteristics remain stable indicating irreversible 
destruction of the β islet cells [149]. Furthermore, pancreatic biopsies from normal 
and diabetic rats confirm that STZ induces DM via β islet cell destruction Fig. 3-
1[149]. The STZ induced model being simple, inexpensive and easily available is 
widely used by researchers around the world. 
 
Figure 3-1: Pancreatic biopsies of A) normal rats B) STZ induced diabetic rats 
showing destruction of β islet cells [149] 
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3.2 Isolation of SAN tissue 
Isolation of conductive tissues of the heart for physiological and pathological 
studies has always been a challenge. However, with accurate understanding of 
various anatomical landmarks, located both on the external and internal surface of 
the heart, isolation of conductive tissues has been made easier for researchers [66]. 
Yet a dissection carried out even with high precision, carries the risk of 
contamination of the conductive tissues by the surrounding myocardial tissues. 
Hence, this preliminary step to study SAN is critical and poses a great challenge. 
Due to its extremely small size, location and vital function, biopsies of SAN have 
been limited to postmortem human hearts and rodents [75].  
The SAN is located at the junction between the SVC and right atrial appendage 
[156]. To be specific it lies immediately beneath the epicardium of the sulcus 
terminalis at the base of the SVC at its junction with the RA [157]. Mostly, the oval 
SAN is found at the antero-lateral surface of SVC, in some rare cases it may extend 
over the crest of the right atrial appendage where it appears to be in the form of a 
horseshoe in shape [157, 158]. A branch of the right coronary artery, SAN artery 
supplies the SAN in 55% of the hearts [158]. The SAN can be identified by tracing 
this branch up to its termination [158]. The location of the SAN and adjacent 




Figure 3-2: Topography of the sinoatrial node, right lateral view [157]. 
3.3 Action potential study 
3.3.1 Historical background 
Isolated perfused organ studies were introduced by Wild in 1846, a student of 
the German scientist, Carl Ludwig [159]. In the same year Ludwig invented the first 
device which could monitor the physiological process of the heart over time [159]. 
Ludwig and Wild working together, established the first model of an isolated heart 
preparation, by connecting the aorta of a killed animal with the carotid artery of a 
living animal [159]. That marked the evolution of the isolated perfused heart. In 
1866, another physiologist Elias Cyon along with Ludwig described their study on 
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isolated frog‘s heart [159]. Initially frogs were chosen because their heart consisted 
of a single ventricle devoid of any coronary circulation [159]. In their experiments, 
the aorta and vena cava were canulated and the heart filled with rabbit serum. The 
perfusate was circulated from the aorta to the vena cava through a glass tube [159]. 
One of the important conclusions derived from this experiment was that the function 
of the heart varies with change in temperature [159]. Subsequently several 
researchers modified the isolated frog heart preparation, which revealed various 
characteristics of cardiac muscle including the all or none law, absolute refractory 
period and cardiac automacity [159]. The use of mammalian heart was first 
introduced by H.N. Martin and the model constituted a mammalian heart-lung 
preparation [160]. In this model the systemic circulation was excluded and the circuit 
of blood flow was established between lung and heart only [160]. The bold step of 
excising the heart out of the mammalian body, perfusing it and keeping it beating 
was taken by Oscar Langendorff [161]. In 1897, he established the isolated perfused 
mammalian heart model. His choices of animals were cats, rabbits and dogs. In this 
model the isolated heart was perfused with defibrinated blood from the respective 
species, via a cannula inserted into the aorta [162]. A constant perfusion pressure was 
maintained by a manometer. Several discoveries were made using the isolated 
perfused mammalian heart preparation. Firstly, automacity of the isolated heart can 
be resumed and maintained for hours [162]. Secondly, ventricular blood plays no 
role in excitability [162]. He also demonstrated that vagal stimulation and muscarinic 
receptors have negative inotropic and chronotropic effect while atropine exerted a 
positive chronotropic effect on the heart [162]. He also established the relationship 
between cardiac contractility and temperature; high temperature causing tachycardia 
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and low temperature causing bradycardia and these finding were consistent with 
Ludwig‘s isolated frog heart study [162]. In 1967, Neely and Morgan, converted the 
Langendorff rat heart model into the working heart model [159].  
Of the various isolated organ models developed, the Langendorff isolated heart 
preparation is the one that is still in extensive use. The technique has been applied 
not only by physiologists, but also biochemists, morphologists and pharmacologists. 
Cardiovascular researchers have applied the method to study the effect of single gene 
alterations on heart physiology and the development of therapeutic means to protect 
cardiac injury. The general principle of the method is to perfuse the heart in a 
retrograde manner by cannulating the ascending aorta. The retrograde flow causes 
closure of the aortic valve thereby preventing flow of perfusion fluid to the left 
ventricle. This in turn results in the perfusate flowing to the coronary arteries through 
the ostia at the aortic root and finally draining into the right atrium via the coronary 
sinus. The perfusion pressure or flow rate is maintained throughout the experiment 
depending on requirements. For instance perfusion at constant pressure is preferred 
for studies of ischemia and perfusion and a constant flow rate is preferred to study 
coronary vascular resistance.  
3.3.2 Description of the method:  Langendorff isolated perfused heart 
The Langedorff isolated heart preparation is appropriate for any mammalian 
species. The most frequently studied heart model is that of rats. Nonetheless studies 
involving heart isolation from large animals and man have also been reported [163]. 
The working heart model is best exploited with the rat heart which is also easily 
handled and relatively inexpensive. A limitation posed by the rat heart model is its 
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short action potential duration [164]. However, incidence of ischemic ventricular 
arrhythmia is reported to be higher in the rat heart preparation, and hence it serves as 
the best model to study ischemia-induced arrhythmias [165].  
After killing the animal using a humane method, the animal is positioned in a 
supine position. The thorax is opened by a transperitoneal incision, and the heart is 
exposed. The heart is carefully excised and immediately placed into a beaker 
containing cold Krebs-Henseleit solution in order to rinse away blood and prevent 
any form of ischemic injury prior to perfusion. The heart is then mounted on the 
Langedorff apparatus by inserting a cannula into the aorta which is secured in place 
with a surgical clip. Care has to be taken not to insert the cannula too deep especially 
in the case of small hearts, as it may rupture the aortic valve leaflet and cause aortic 
regurgitation. The cannula and tubes connecting the heart to perfusate are filled and 
free of any air bubbles prior to cannulation. For optimal experimental results the time 
from excision of the heart to attachment to the perfusion apparatus should not exceed 
more than 30 secs [162]. Prolonged duration of cannulation may cause myocardial 
damage and stress signal activation [166]. Following initiation of perfusate flow, the 
heart turns pink due to elimination of blood from the capillaries and rhythmic 
contraction is generally restored within a few secs. According to Doring et al. 
(1990), re-establishment of complete cardiac contractile function can take up to 10 
mins [167]. The perfusion is carried out at physiological temperature and continuous 
gassing with a mixture containing 95% oxygen and 5% carbon dioxide (CO2). The 
5% CO2 helps to maintain adequate pH at physiological temperature.  
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The isolated perfused heart according to Langedorff can be applied in various 
studies especially cardiac physiology, pathology and pharmacology. The technique 
provides a methodology to isolate ventricular cardiomyocytes from the whole heart 
[166]. Furthermore, it is applied to study ischemic injuries and electrical properties 
of the heart [166]. APs can be measured using simple suction electrodes attached to 
different regions on its epicardial surface [168]. Last but not least, the model 
provides an excellent source of tissue for ultrastructural studies using electron 
microscopy and protein expression studies using Western blot analysis [166]. 
3.3.3 Extracellular potential measurements 
The membrane potential varies in different regions of the heart. The various 
currents flowing in the intracellular and the extracellular medium gives rise to 
potential difference across the membrane [169]. Extracellular recording of APs are 
called monophasic action potentials (MAPs) and they can be measured by placing an 
electrode on the surface of the heart [169]. Burdon et al (1882) presented the first 
MAP recording done on a frog‘s heart [170].  In 1934, Schuz introduced the suction 
electrode technique for MAP recording [171] which was further modified by 
Korsgren and Olsson, establishing the importance of MAP recording in studying 
human cardiac electrophysiology [172]. A limitation of the suction electrode 
technique is that it causes myocardial injury. An alternate method, and the first non-
traumatic method, which was later redefined as the contact electrode method was 
introduced by Jochim in 1935 [173]. The technique involved either gentle pressing of 




The extracellular potential difference is proportional to the current which in 
turn is proportional to the spatial gradient of the membrane potential that in turn is 
proportional to the time derivative of the potential [169]. This is obtained by making 
a seal between the non-polarizable electrode, also called the MAP electrode, and the 
epicardium [169]. The electrode causes a local depolarization of the tissue to a level 
estimated to -20 to -30mV, and a potential gradient is established between the 
depolarized cells and the adjacent normal cells [169]. Due to this potential gradient a 
potential difference results between MAP electrode (E1) and indifferent electrode 
(E2) [169]. The E2 is present a few mm proximal to the depolarizing tip electrode. 
This potential difference is then measured using a direct current (DC) coupled 
amplifier. The technique of MAP recording has proven to be very useful to study the 
action potential duration and its dispersion [169].  
3.4 Real time Reverse transcriptase – Polymerase chain reaction 
3.4.1 Background 
The introduction of polymerase chain reaction (PCR) by Kary Mullis in 1983 
brought about a revolution in medical and biological research [174]. Mullis along 
with Michael Smith was awarded the Noble prize in chemistry in 1993, for their 
work on PCR [175].  The basic principle of PCR involves exponential amplification 
of a single copy or a few copies of DNA, generating thousands to millions of copies 
of a particular DNA sequence. This indispensible molecular biology technique  has 
gained a lot of importance due to its application in DNA cloning, functional assay of 
genes, diagnosis of hereditary  and infectious disease, DNA fingerprinting and DNA 
paternity testing. According to the type of genetic study conducted, the PCR can be 
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extensively modified and these modifications are termed as variants. Some of them 
include multiplex PCR, nested PCR, asymmetric PCR, hot start PCR, quantitative 
PCR and reverse transcription PCR (RT-PCR). As my study involved the use of real 
time RT-PCR (qRT-PCR), a combination of quantitative/real time PCR (qPCR) and 
RT-PCR, its methodological principles are discussed in the following sections. 
RT-PCR is commonly used to detect RNA expression while the variant, qPCR 
is used to quantitatively measure the amplification of DNA using fluorescent probes. 
The combination of these two techniques, qRT-PCR, is currently one of the most 
sensitive techniques available for mRNA detection and quantification [176]. qRT-
PCR can detect mRNA accurately even if it is present in minute quantities in a 
sample, a feature which has led to replacement of the northern blot technique, that 
was extensively used earlier for detection and quantification of mRNA. The 
technique is also widely applied in DNA microarray results validation, analysis of 
small nuclear protein (SNP), measurement of bacterial, viral and fungal loads and to 
monitor prognostic effects of therapies used in hematological malignancies [177]. It 
consists of two steps: conversion of RNA to cDNA by an enzyme reverse 
transcriptase and amplification of the specific cDNA by PCR. These 2 steps of qRT-
PCR can be carried out either as a one step or a two-step reaction (Fig 3-3: a and b). 
In the one step reaction, the entire process from conversion of mRNA to cDNA to 
PCR amplification is carried in a single tube. The primer has to be sequence specific 
and RNA has to be of high quality for best results. The two-step reaction 
incorporates the use of separate tubes for the two individual steps: first the reverse 
transcription and then the PCR. This also requires high quality RNA but the primers 
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need not be sequence specific. The one-step approach is simple, rapid and causes 
minimal experimental variation due to fewer pipetting steps. It is the best choice for 
high throughput screening and in experiments requiring few assays [178]. But in 
cases of repeated assays from the same sample, the two-step approach is preferred as 
the starting RNA template degrades rapidly in the one step approach. However, 
frequent sample handling makes the two-step approach more susceptible to 
contamination [178].  
 




3.4.2 Reverse transcription 
Reverse transcription (RT) is the process of synthesizing DNA, using a single 
stranded RNA template (Fig. 3-4). The DNA formed is known as complementary 
DNA (cDNA). The process additionally requires an RNA dependent DNA 
polymerase called reverse transcriptase to catalyze the synthesis, a primer to initiate 
synthesis, deoxynuecleotide triphosphate (dNTPs) as a source of nucleotide, and 
ribonuclease (RNAse) inhibitor that prevents RNA degradation. The synthesis of 
cDNA occurs in 5‘ – 3‘ direction. The first strand of cDNA can then directly be used 
as a template for the PCR reaction. This combined method (qRT-PCR) facilitates 
detection of low abundance RNAs in a sample and production of cDNA facilitates 
the cloning of low copy genes. The first strand of cDNA can also be directly cloned 
without amplification using DNA polymerase I, DNA ligase and a helicase called 
RNAse H.  
 
Figure 3-4: Conversion of mRNA to cDNA by enzyme reverse transcriptase [179]. 
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The enzyme reverse transcriptases were discovered by Howard Tenim in 1960 
with his study on Rous sarcoma virus (RSV) where he demonstrated that this virus 
replicated by forming DNA [180].  However, it was David Baltimore who first 
isolated these groups of enzymes in 1970, from two RNA tumor viruses: Murine 
leukemia virus and RSV [181]. The RNA viruses that use reverse transcriptase are 
termed retroviruses. These retroviruses using the enzyme, reverse transcribe their 
RNA genomes into DNA, which is then incorporated into host DNA and replicates 
within it. The discovery of reverse transcriptase allowed researchers to understand 
the natural modes of transfer of genetic material [182] . Reverse transcription is the 
mechanism used by HIV virus to infect humans. The enzyme is also used to convert 
RNA to cDNA in reverse transcriptase PCR. Additionally, reverse transcriptase is 
used to create DNA libraries. Furthermore, it has been employed in insulin 
production. Large amounts of insulin can be produced by inserting insulin producing 
eukaryotic mRNA into the prokaryote‘s genome along with reverse transcriptase. 
The primers used in the RT reaction can be grouped into three categories: oligo 
(dT) primers, random (hexamer) primers, and gene specific primers [177]. Each has 
its own advantage and disadvantage. Oligo dT primers are used to develop full length  
copies of mRNA, but random primers are preferred in case of prokaryotic mRNA, 
mRNA without a poly A tail or mRNA >4Kb long [183]. The production of cDNA is 
high with random primers as the original target has multiple origins of transcription 
points [183]. However, the main disadvantage of random primers is that they have 
low melting temperatures and cannot be used with thermostable RT enzymes, 
without a low temperature incubation step [183]. Furthermore, the majority of cDNA 
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produced from total RNA will be ribosomal RNA (rRNA) which makes it the least 
preferred choice [177]. On the other hand oligo dT primers are more specific and do 
not prime the rRNA, but require very high quality RNA and cannot be used for 
priming RNA that is likely to be fragmented [177]. For qPCR of eukaryotic genes 
mixtures of oligo dT primer and random primers have been shown to give the best 
results [177]. The third choice of gene specific primer is used in experiments to study 
particular genes. Though the gene specific primers provide the most sensitive method 
of quantification, they are not the preferred choice for experiments with limited RNA 
as they require separate priming reactions for each target [184]. 
The dNTPs are neuleoside triphosphates containing deoxyribose sugar and 
include deoxyadenosine triphosphate (dATP),  deoxyguanosine 
triphosphate (dGTP), deoxycytidine triphosphate (dCTP), deoxythymidine 
triphosphate (dTTP) and deoxyuridine triphosphate (dUTP) [185]. These dNTPs are 
building blocks of DNA. The synthesis of DNA involves the formation of a 
phosphodiester bond between two adjacent dNTPS along with release of two 
phosphate groups [185]. The incoming dNTP is added to the 3‘ end of the newly 
synthesized DNA [185]. 
Generally, for a reverse transcription reaction to occur, 1-2 micrograms of high 
quality RNA is used. RNA purification from crude samples is a vital step as the yield 
of RNA, both quality and quantity, determines the choice of other factors required 
for the RT reaction. The basic steps are: i) Incubation of RNA with a primer, usually 
at high temperature that causes denaturing of RNA secondary structure, followed by 
immediate chilling on ice to allow the primer to bind to the RNA template; ii) 
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Addition of the remaining components of RT which include dNTPs, reverse 
transcriptase, RNAse inhibitor and RT buffer. Naked RNA is highly susceptible to 
degradation by endogenous RNAses that are present in all living cells. RNAse 
inhibitor inhibits the activity of endogenous or exogenous RNAses during the 
extraction procedure and iii) The mixture is allowed to incubate at 42 °C for 1 hour 
followed by heating the reaction at 70 °C to inactivate the enzyme. To perform the 
PCR reaction, RNAse is used in order to remove the template RNA from the 
reaction. 
3.4.3 Real time Polymearse chain reaction 
The classical methods to study gene expression which include northern blot, 
RNA protection assay and differential display have been replaced by the technique 
real time polymerase chain reaction (real time PCR).  The basic process involved is 
the same as the conventional PCR that is to amplify a single or a few copies of DNA. 
However, the real time PCR detects the amplification product as the reaction 
progresses in real time with product quantification after each cycle and not at its end 
like the conventional PCR. The real time PCR can be used for quantitative assays, 
semi-quantitative assays and qualitative assay of DNA molecules. Gene expression 
in a cell is regulated by gene transcripts comprising messenger RNA (mRNA), 
ribosomal RNA (rRNA) and transfer RNA (tRNA). It is the measure of mRNA 
transcript in a sample that reveals the amount of expressed gene in the cell. In order 
to detect and quantify the expressed gene from an RNA sample, a PCR technique is 
used that amplifies the DNA or complementary DNA (cDNA) which is reverse 
transcribed from mRNA by enzyme reverse transcriptase.  
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The basic components and reagents required for PCR are: i) a DNA or cDNA 
template which contains the target DNA sequence to perform amplification; ii) a pair 
of specific primers that are complementary to each of the sense and anti-sense 
strands of the DNA target; iii) a thermo-stable DNA polymerase (temperature 
optimum around 70 °C); iv) deoxynucleoside triphosphates (dNTPS); v) a buffer 
solution that stabilizes DNA polymerase; vi) bivalent cations; magnesium and 
manganese ions and monovalent cation; potassium ion and vii) a substance marked 
with a flurophore. The real time PCR detection system consists of a thermal cycler 
equipped with an optical detection module to measure the fluroscence signal. The 
thermal cycler is an automated device that amplifies specific DNA segments in vitro 
via a series of cyclical changes of temperature [186].  It consists of a thermal block 
with holes where tubes containing the reaction mixtures can be inserted [186]. The 
temperature changes are repeated 25 to 50 times and each cycle of change, as shown 
in Fig. 3-5.  consists of three stages [187]. The first stage is denaturation of the DNA 
template which occurs at a temperature of around 94 – 98 °C [187]. In the 
denaturation process hydrogen bonds are disrupted, yielding single stranded DNA. In 
the subsequent step the reaction temperature is lowered to 50 to 65 °C and this allows 
the primers to bind the single stranded DNA template [187]. The third stage, at a 




Figure 3-5: Diagram representing stages of PCR cycle [179]. 
The detection of PCR products can be obtained by two methods: nonspecific 
fluorescents dyes that bind to any double strand DNA and sequence specific 
fluorescent DNA probes. As the flurophore binds to the target sequence, fluorescence 
signals are generated which are measured during a short temperature phase lasting 
only a few secs in each cycle. This allows measurement of the rate of generation of 
amplified products at the end of each cycle and this is the reason the method is 
named real time PCR. Finally analysis of these data enables calculation of relative 
gene expression by computer software.  
There are four different fluorescent DNA probes for qRT-PCR detection which 
include SYBER Green, TaqMan, Molecular Beacons and Scorpions. Each having 
their own advantages and disadvantages, all of them detect the PCR products by 
generating fluorescence signals. The TaqMan probes are oligoneculeotides that 
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consist of a fluorophore attached to the 5‘end and a quencher to the 3‘end. These 
probes hybridize with the target sequence in the DNA template. When stimulated by 
an external light source (hv) (Fig. 3-6) or thermal cycler‘s light source the 
fluorophore emits fluorescence that is quenched by the quencher molecule which is 
in close proximity [188]. A commonly used fluorophore is fluorescence resonance 
energy transfer (FRET). As the PCR reaction progresses to the third stage, the 
5‘nuclease activity of the DNA polymearase cleaves the TaqMan hydrolysis probe 
resulting in separation of the detectable flurophore (R) from the quencher (Q) as 
shown in Fig. 3-6 [188]. The separation results in detection of a fluorescent signal 
which is directly proportional to the amount of product formed [189]. Although 
TaqMan probe produces efficient and accurate PCR results, its synthesis is time 
consuming, especially when separate probes have to be made for analysis of each 
mRNA target [189]. The Molecular Beacons and Scorpion probes also work on a 
similar principle as that of TaqMan, while the SYBER green probe emits the 





Figure 3-6: Principle of TaqMan probe [188]. 
The analysis of qRT-PCR can be further explained by a qRT-PCR 
amplification plot as shown in Fig. 3-7. In this plot the X-axis represents, the number 
of PCR cycles and Y axis represents the fluorescence from the amplification 
reaction. The fluorescence signal in the initial cycles (cycles 1-18) remains at the 
background level and are not detected by the instrument, even though the product 
accumulates exponentially [179]. This defines the baseline for the amplification plot. 
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As the amplified product accumulates, the fluorescence signal becomes detectable as 
it crosses a threshold level [176]. The cycle number at which this occurs is called the 
quantification cycle, or Cq. The amplification proceeds to the exponential phase 
followed by a non-exponential plateau phase [176]. During the exponential phase the 
amplification product approximately doubles in each cycle. However, as the reaction 
progresses, it slows down due to limitation of the reaction components that are 
consumed during PCR, and enters the plateau phase (cycles 28 – 40). 
 
Figure 3-7: Diagram representing the amplification plot of qRT-PCR, baseline 
subtracted fluorescence signal versus number of PCR cycles. 
http://www.bio-rad.com/en-ae/applications-technologies/what-real-time-pcr-qpcr 
The Cq value is measured in the exponential phase. One of the factors 
determining the Cq value is the amount of initial template present in the reaction. If a 
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large amount of template is present at the start of the reaction, few amplification 
cycles will be required to detect the fluorescence signal above background. Hence, 
the reaction will have early or low Cq. But if the amount of template is less at the 
start of the reaction, then comparatively more amplification cycles are required to 
detect the fluorescence signal above the background. Hence, the reaction will have 
high or late Cq. This relationship forms the basis of real time qPCR. The amount of 
target in an unknown sample can be quantified by measuring the Cq and using either 
an external standard curve or one or more co-amplified internal control mRNAs.  
The external curve is generated against initial target copy number using a series of 
dilutions of an external standard. The copy number is calculated from the linear 
regression of that standard curve. Quantifications using internal controls compare the 
Cq values of the target RNAs with those of internal reference genes and are expressed 
as ratios of the target specific signal to the internal reference [190]. The resulting 
relative expression of target mRNA allows comparison between samples [190]. The 
amplification efficiency of the target and internal control has to be similar as this 
would affect the accuracy of any calculated expression result [190]. Internal control 
genes are also often referred as to housekeeping genes or reference genes.  Their 
functions are related mostly to basic cellular survival and are expressed in all cells of 
the organism under normal and pathophysiological conditions. The most commonly 





Symbol Name Function 
ACTB Beta actin Cytoskeletal structural protein 
B2M Beta-2-microglobulin Beta-chain of major histocompatibility 
complex class I molecules 
GAPDH Glyceraldehyde-3-phosphate 
dehydrogenase 
Oxidoreductase in glycolysis and 
gluconeogenesis 
HMBS Hydrozymethyl-bilane sythase Heme synthesis, porphyrin metabolism 
HRTP1 Hypoxanthine phosphoribosyl- 
transferase 1 
Purine synthesis in salvage pathway 
RPL13A Ribosomal protein L13a Structural components of the large 60S 
ribosomal subunit 
SDHA Succinate dehydrogenase complex, 
subunit A 
Electron transporter in the TCA cycle and 
respiratory chain 
TBP TATA box binding protein General RNA polymerase II transcription 
factor 
UBC Ubiquitin C  Protein degradation 
YWHAZ Tyrosine3-monooxygease/  
tryptophan5-monooxygenase 
activation protein, zeta polypetide 
Signal transduction by binding to 
phosphorylated serine residues on a 
variety of signaling molecules 
Table 3-3: Commonly used housekeeping genes [190]. 
 The qRT-PCR assay demands careful consideration of several factors for 
optimal results. Optimal sample quality is the initial prerequisite to yield valid 
quantitative data [191]. Hence, all the steps involved in isolation of mRNA from the 
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crude sample which includes preparation and processing of samples and extraction of 
RNA, are all vital and need to be optimized in order to minimize contamination and 
enhance purity [191]. Secondly, primer selection is another critical step as it 
determines the sensitivity of the reaction [192]. Structure of the target mRNA must 
also be taken into account as the presence of extensive secondary structures may 
interfere with the primer binding site [192]. The Ct value depends on the real time 
instrument‘s threshold setting which in turn is determined by the background 
fluorescence which in turn varies with different probes, chemistries and assay 
protocols [177]. Hence, accurate and consistent results necessitate regular calibration 
of real time instruments [177]. Other parameters influencing the qRT-PCR assay 
includes analytical sensitivity, specificity, repeatability, reproducibility and inclusion 
of negative and positive controls in order to eliminate false positive or false negative 
results [193].  
3.5 Western blot 
The term Western blotting was first coined by W. Neal Brunette during a chat 
with Robert Nowinski , the founder of a biotechnology company, ContraFect [194]. 
Brunette‘s  manuscript describing the technique of Western blot was initailly rejected 
[194]. But as the unofficial preprints of the paper gained popularity among his peers 
and researchers worldwide, Analytical Biochemistry eventually agreed to publish the 
paper in 1981[195]. The drive to develop a method that could detect antigen specific 
antibodies, led to the development of a technique that allowed the production of a 
replica of electrophoretically separated proteins onto a nitrocellulose membrane and 
subsequent detection of the specific proteins by probing with antisera. While 
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Brunette widely employed the use of sodium dodecyl sulfate (SDS) polyacramide 
gels in Western blotting, another scientist, Harry Towbin, described the use of 
polyacramide-urea gels, thus contributing to further development of the most widely 
used technique for protein assays [196]. Western blotting is employed in various 
laboratories as a powerful tool to study the presence, relative abundance, relative 
molecular mass, post translational modification and specific interaction of proteins 
[196]. The technique involves an initial step of separation of protein by gel 
electrophoresis, followed by blotting the proteins on to a membrane and detection 
using specific antibodies. 
3.5.1 Protein purification and quantification 
Protein purification, constituting a series of steps, is vital for characterization of 
structure and function of the protein of interest. A sample collected is immediately 
frozen with liquid nitrogen in order to avoid protein degradation by protease or if 
lysed immediately then it has to be carried out at cold temperature. As the quality of 
protein lysate is integral to the effectiveness of Western blotting, the extraction of 
protein from a mixture of cells, tissues or whole organism has to be optimized using 
an appropriate lysis buffer [197]. The choice of an appropriate buffer system has to 
be calculated in order to stabilize the target proteins and protect them from various 
chemicals designed to separate protein from other cellular components [197]. The 
most commonly used buffer system includes sodium dihydrogen phosphate-disodium 
hydrogen phosphate, Tris-HCL and HEPES-NaOH [196]. As disruption of the cells 
or tissues causes release of phosphatase and protease that can attack the target 
proteins, protease and phosphatase inhibitor should be included in the lysis buffer 
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[196]. Furthermore, to improve the stability of target protein and to keep the protein 
in solution certain chemicals can be added including ligands, metal chelators, 
detergents, glycerol, glucose or sucrose and reducing agent [196]. Some of the 
commonly used general lysis buffers include radioimmunoprecipitation assay (RIPA) 
and Nonidet P-40 (NP-40) lysis buffer [196]. An appropriate buffer for a particular 
protein is the one that will efficiently isolate the protein while at the same time 
maintain its integrity. The protein buffer mixture is then subjected to 
homogenization, filtration and centrifugation to separate protein from other cellular 
components. After obtaining the protein mixture, the concentration of protein can be 
measured using a spectrophotometer.  
The spectrophotometer gives a quantitative measurement as a function of its 
transmitted wavelength [198]. It is employed to measure the amount of light that a 
sample absorbs using photometery [198]. The basic principle involves passing a 
beam of light through the sample, where the beam consist of a stream of photons, and 
measuring the intensity of light reaching the detector after being absorbed, reflected 
and transmitted by the sample [198]. Depending on the wavelength of the light 
source it can be classified as UV-visible spectrophotometery and IR 
spectrophotometery. The UV-visible spectrophotometer uses light over the 
ultraviolet range and visible range whereas the IR spectrophotometer uses light over 
the infra-red range of the electromagnetic radiation spectrum [198]. The device can 
also be classified as single beam or double beam. The double beam 
spectrophotometer compares the light intensity between two light paths, one 
containing the reference sample and the other the test sample whereas single beam 
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spectrophotometery measures the relative light intensity before and after a test 
sample is inserted [198]. The basic components of a spectrophotometer are illustrated 
in Fig. 3-8. The device consists of two parts: a spectrometer that produces the desired 
wavelength of light and a photometer that detects that amount of photons absorbed 
and sends a signal to the digital display. The data obtained can be utilized to derive 
two quantities: the transmittance (T) and the absorbance (A). The transmittance is the 
ratio of light passing through the sample (I) to the light passing through the blank (Io) 
and is expressed as a percentage (%T). The blank is a solution identical to the sample 
solution except that it does not contains the solute that absorbs light. The absorbance 
is the amount of light absorbed and is calculated using the equation A = - log10 T.  
 
Figure 3-8: Components of a spectrophotometer. 
http://chemwiki.ucdavis.edu/Physical_Chemistry/Kinetics/Reaction_Rates/Experime
ntal_Determination_of_Kinetcs/Spectrophotometry 
3.5.2 Gel electrophoresis 
Gel electrophoresis is a laboratory technique which is used to separate 
macromolecules (protein and nucleic acids) based on their size, molecular mass, 
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structure and charge. The most common type of gel electrophoresis for protein 
analysis employs SDS polyacramide gel electrophoresis (SDS-PAGE) [199]. The 
other commonly used gel is the agarose gel which is more suitable for separating 
DNA fragments of 50 – 20000 base pairs (bp) due to low resolving power of agarose 
and greater range of separation [200]. The polyacramide gel on the other hand has 
high resolving power and is used for separating small fragments of DNA (5 – 5000 
bp) and proteins (5-2000 kDa) [199]. With regard to casting the agarose gel sets 
thermally and is relatively easier to prepare and handle, while the polyacramide gel 
sets due to a chemical polymerization reaction [200]. Another difference between the 
two gels is the pore size which is uniform in case of polyacramide gels and non-
uniform in agarose gels [199, 200]. 
3.5.2.1 Sample preparation for SDS-PAGE electrophoresis 
The protein or nucleic acid extract obtained after a series of purification steps is 
processed further in order to make it suitable to run through the gel. A chemical 
denaturant is often added to the purified extract; SDS for proteins and urea for 
nucleic acids. While SDS being an anionic detergent denatures the secondary and 
tertiary structures of protein, urea on the other hand separates the two complementary 
strands of nucleic acid by breaking the hydrogen bonds. Reducing agents such as 
dithiothreitol (DTT) or 2 mercaptoethanol (beta-mercaptoethanol/BME) can be 
added to aid the denaturing process by breaking the disulfide linkage in the tertiary 
and quaternary structures of nucleic acids. Furthermore, heating the mixture near to 
the boiling point for a brief period accelerates denaturation. Lastly, as proteins and 
nucleic acid are mostly colorless a tracking dye can be added to the solution to 
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impart color during their progress in gel electrophoresis. Some of the commonly used 
tracking dyes include bromophenol blue, xylene cyanol and Orange G. 
3.5.2.2 Polyacramide gel casting and electrophoresis 
A common method for separating protein by electrophoresis uses polyacramide 
gel as a supporting medium and SDS to denature proteins and provide overall 
negative charge to the proteins [201]. This method is commonly abbreviated as SDS-
PAGE. An illustration of the SDS-PAGE apparatus is shown in Fig. 3-9. The method 
consists of casting the SDS polyacramide gel followed by electrophoresis of the 
sample protein to be analyzed [201]. The constituent of polyacramide gel includes 
acrylamide, bisacrylamide, SDS or urea, a buffer with adjusted pH, ammonium 
persulfate and tetraethylmethylenediamine (TEMED) [201]. Ammonium persulfate 
is a source of free radical and TEMED is a stabilizer; both together initiate 
polymerization between acrylamide molecules with bisacrylamide acting as a cross-
linker [199]. The amount of total acrylamide and cross-linker used governs the size 
of pore formation in the gel [202]. Hence, the acrylamide concentration of the gel 
determines the resolving power of the supporting gel [199, 202]. Lower percentage 
gels facilitate resolving of high molecular weight molecules and higher percentage of 
gel is required to resolve low molecular weight molecules. The gel is polymerized 
between two glass plates (Fig. 3-9.) and is cast in two layers. The lower layer is 
called the separating or resolving gel where the proteins separate according to their 
molecular mass [199]. The upper layer is called the stacking gel which includes 
several wells for loading the sample protein to be analyzed [199]. Usually resolving 
gels are prepared in 6%, 8%, 10%, 12% and 15% while stacking gels are prepared in 
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5% of acrylamide. Once the sample wells are loaded with sample proteins or nucleic 
acids and ladder (molecular weight size marker) and a running buffer added to the 
electrophorator, voltage applied allows the negatively charged proteins or nucleic 
acids to migrate, through the gel towards the positive electrode, at different speeds 
depending on their molecular weight [199]. Smaller molecules migrate faster 
whereas large molecules move slower producing different bands as the proteins or 
nucleic acids separates. Voltage also influences migration: higher voltage causes 
rapid migration and inadequate separation of proteins while low voltage causes 
slower migration and is more accurate [199]. The major role of buffer in the gel and 
electrophoresis is to stabilize the pH, though it also facilitates electrophoretic 
mobility of intrinsic charged ions. Depending on the denaturating properties, the gels 
can be classified as denaturating and native gel. Denaturating gels cause the analytes 
to unfold into a linear structure and thus the mobility of the molecule is solely 
dependent on its molecular mass. On the other hand the native gels allow the analytes 
to run in their native state and hence, the molecules separated not only differ in their 




Figure 3-9: Illustration representing SDS-PAGE system.  
https://ww2.chemistry.gatech.edu/~lw26/bCourse_Information/4581/techniques/gel_
elect/page_protein.html 
3.5.2.3 Transfer of proteins to membrane, blot development and analysis 
After the completion of electrophoresis, the gel can be processed in either of 
the following ways: i) the gel can be stained which allows direct visualization of the 
separated protein as distinct bands. Some of the commonly used stains include 
Coomassie Brilliant Blue R-250 for proteins, ethidium bromide for nucleic acids and 
silver stain for both. By using a marker molecule in parallel with the sample, the 
approximate molecular size of an unknown biomolecule can be estimated and ii) the 
107 
 
proteins on the gel can be transferred onto a membrane sheet and analyzed, a process 
known as Western blotting. 
Western blotting is a powerful technique to detect and characterize a wide 
range of proteins. It involves transfer of the proteins separated on SDS-PAGE to a 
membrane sheet followed by immunodetection of the proteins with specific 
antibodies.[201]. The blot produced on the membrane is the exact replica of the 
protein blots on the gel [203]. Efficient protein blotting depends on certain factors 
which include, efficiency of the polyacramide gel to elute the protein, molecular 
mass of protein to be transferred and the efficiency of the membrane to bind with the 
protein [196].  For example, transfer of proteins from gels consisting of low 
percentages of acrylamide and cross-linker, is easier and faster than those consisting 
of higher percentage of acrylamide and cross-linker. Some additional steps like 
disruption of gel matrix and partial digestion of proteins by proteolytic enzymes prior 
to transfer has been documented to enhance the efficacy of protein blotting, 
especially the high molecular weight protein that blots poorly [204].  The type of 
membrane used also affects protein transfer. The membranes that have been shown 
to successfully bind to the proteins include nitrocellulose, polyvinylidene difluoride 
(PVDF) and activated paper or activated nylon. Nitrocellulose membrane is 
commonly used, but suffers the drawback of being fragile and brittle when dry. 
Additionally, the proteins do not bind covalently to the membrane. In contrast, the 
PVDF membranes though more expensive, offer high protein binding capacity, 
physical strength and chemical stability. The physical strength of activated nylon is 
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also high, but its ability to bind with small amounts of protein makes it unsuitable for 
most applications. 
Several modifications are employed to transfer the protein from SDS-PAGE to 
nitrocellulose or PVDF membranes. The most commonly used method is 
electroblotting. The method uses electric current in order to elute proteins out of the 
gel and bind to the nitrocellulose or PVDF membrane [205]. This method of 
electroelution of proteins offers the advantage of rapid and complete transfer of 
proteins, over other methods which include diffusion blotting and vacuum blotting. 
Electroblotting can be achieved in 2 ways; wet transfer blotting which requires 
complete immersion of the gel-membrane sandwich in a buffer (Fig. 3-10) and semi-
dry transfer blotting in which the gel-membrane sandwich is placed between 





Figure.3-10: Schematic diagram representing the assembly of a wet type 
electroblotting. 
It shows arrangements of gel, transfer membrane, filter paper and direction of protein 
transfer towards the anode. https://www.thermofisher.com/ae/en/home/life-
science/protein-biology/protein-biology-learning-center/protein-biology-resource-
library/pierce-protein-methods/western-blot-transfer-methods.html 
To obtain a good quality protein transfer several modifications have been made 
to the basic electroblotting procedure which include pressure double blotting, electro 
double blotting, slice blotting, tissue printing, grid immunoblotting, native 
electrophoresis Western blot analysis, multiple antigen blot assay, multiple tissue 
Western blot, dot immunoblotting assay, high efficiency blotting of high molecular 
weight proteins and Western blot with KODAK BIOMAX Multi-Blot kit [196]. 
Electroblotting is carried out at constant current and voltage and like electrophoresis, 
low molecular weight proteins are transferred faster than high molecular weight 
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protein. Transfers have to be carried out in a cold environment (around 4 °C) to 
compensate for the heat that is produced [196].  
Once the transfer of protein is complete the next step involves blocking the 
membrane prior to probing for proteins. As the membrane has the capability of 
binding to proteins, antibodies have to be prevented from binding to the membrane. 
This is achieved by washing the membrane with 3-5% of bovine serum albumin 
(BSA) or 5% non-fat dry milk mixed in Tris buffered saline. The protein present in 
this solution binds to the membrane in all areas where the target proteins have not 
attached and thus enabling the antibodies to bind only to the target proteins. Finally, 
in order to detect the target proteins the membranes are incubated with respective 
primary and secondary antibodies. The antibodies could be either monoclonal or 
polyclonal. The polyclonal antibodies containing many antibody molecules not only 
bind the target proteins but also those proteins unrelated to proteins of interest. 
Hence,  results produced by polyclonal antibodies are relatively less specific and 
sensitive to that produced by monoclonal antibodies that bind only to proteins of 
interest  [203]. However, a major disadvantage with using monoclonal antibodies is 
that target proteins could be missed if their antigen binding site is damaged during 
electrophoresis or denaturation [203]. Detection of proteins can be achieved by 
several methods. Some of the common methods of detection include enzyme-linked 
reagents, radioactive detection, chemiluminescent detection, detection with gold and 
fluorescent detection [196].  
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3.6 Transmission Electron microscopy 
The word microscope is of Greek origin where mikros means ‗small‘ and 
skopeo means ‗to look at‘. The simple microscope invented by Antony Van 
Leeuwenhoek was one of the earliest instruments of magnification. It consisted of a 
simple convex lens with a magnification of 400X and an adjustable holder for the 
object to be studied [206]. Addition of a second lens to this instrument led to the 
development of a compound microscope which increased the magnification several 
fold. This simple lens microscope offered a tool for scientists and researchers to 
study minute structures until the identification of electric and magnetic field use in 
the microscope. The first transmission electron microscope (TEM) was built by Ernst 
Ruska and Max Knoll, in 1931 and this brought a revolution to the ultrastructural 
world [207].  
Broadly microscopes can be classified as optical, electron or charged particle 
and scanning probe. Optical microscopes are simple microscopes that use visible 
light and transparent lenses to magnify objects as small as one micrometer (µm). The 
electron microscope makes use of charged particles like electrons and ions and can 
magnify objects as small as one tenth of a nanometer. The scanning probe 
microscope makes use of a very sharp probe or needle that can interact with the 
sample and create the image of objects as small as ten billionth of a meter or 0.1 
nanometer. The basic principles of TEM are discussed in the following paragraph. 
3.6.1 Sample preparation: fixation, embedding, sectioning and staining 
The preparation of the sample poses a major challenge to a successful electron 
microscopic (EM) study. The steps of processing the sample for EM are time 
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consuming and demand experience but at the same time is a critical step to produce 
an efficient image for both qualitative and quantitative analysis of the ultrastructure.  
Fixation is the first step to sample preparation for EM. Adequate fixation is 
essential to arrest the metabolic processes and retain the tissue or cell in their original 
state [208]. As the metabolic process is halted, crosslink between molecules occurs 
which arrests their activity thus enabling the cells and organelles to be preserved for 
a prolonged period [208]. Fixation also stabilizes the sample for further processing 
[208]. Inadequate or delayed fixation results in autolytic changes within seconds or 
minutes thus hampering the objective of the experiment [208]. Autolysis refers to 
self-destruction of a cell through the action of its own enzymes. An ideal fixative 
should contain isotonic fluid in order to maintain the cells and organelles in their 
physiological state and fix them as quickly as possible. As fixation should occur at 
cellular level, the method used to fix the sample is also important. Perfusion fixation 
is preferred over immersion fixation due to slow penetration of the fixative during 
immersion fixation. Also as the fixative penetrates, it reacts differently with cellular 
components, the fixative may inadequately fix the center of the sample. Live cells or 
tissues should be kept completely immersed in fixative as even a slight exposure to 
dry environment might destroy them. The most commonly used fixative for TEM 
work are aldehydes and osmium tetroxide. Among aldehydes, glutaraldehyde is 
extensively used for TEM due its characteristic of excellent fine structure 
preservation. However, it does not react with most lipids, hence spares the cell 
membrane partially, causing cellular components to leak out during processing. But 
this drawback is overcome by the use of osmium tetroxide which fixes tissue by 
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crosslinking lipids. In addition to stabilizing the membranous structure, it also 
enhances the contrast by adding electron dense particles to the section. The fixed 
sample is then dehydrated by subjecting it to increasing concentrations of ethanol. 
The series of dehydration causes replacement of water in the tissue by a medium that 
solidifies and thus makes sectioning of the sample easier. The residual ethanol in the 
tissue is then removed by passing the sample through a transition fluid such as 
propylene oxide. Also called clearing agents the transition fluid has the capability to 
mix with both ethanol and embedding resin. 
In order to attain good quality images of the ultrastructure, TEM sample 
sections have to be thin (around 80 nm to 100 nm), to permit penetration of at least 
50% of the electron beam through the sample [209]. This is achieved by embedding 
the samples in epoxy resin [209]. In addition epoxy resins harden uniformly and are 
very stable with the electron beam. Thin sections are cut from these resin blocks by 
using an ultra-microtome. Initially a semi thin section (1µm) is obtained with a glass 
knife using the ultra-microtome, stained with Toluidine blue and observed under the 
light microscope [209]. This helps to decide the orientation, identify any lesions and 
select the appropriate area for ultrathin sectioning. Ultrathin sections are cut by a 
diamond knife in a microtome and mounted on a grid which is basically a circular 
metallic mesh of 3 mm that supports the section [209]. The grids containing the 
sections are further processed by positive staining with heavy metals to increase 
tissue contrast. The most commonly used stains for TEM are uranyl acetate and lead 
citrate [209]. Lead citrate reacts with atmospheric carbon dioxide and forms 
precipitate which is retained by tissue sections if inappropriately washed with water 
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[209]. Hence, care must be taken during staining with lead citrate. Finally the grid 
containing the stained sample specimen is loaded in the TEM via a specimen holder. 
3.6.2 Parts and operation of the transmission electron microscope 
The TEM system can be divided into 3 parts (Fig. 3-11): i) the illumination 
system which controls the movements of electrons from electrogun to the specimen 
allowing the generation of a broad or focused beam; ii) the objective lens and stage 
and iii) the imaging system which includes intermediate and projector lenses [210]. 
The electrogun is the source of emmision of the electron stream that passes through a 
vacuum column which contains the elements of the TEM. A vacuum system is 
necessary to increase the mean free path of electrons as well as to reduce collision 
frequency of the electron particles with gas atoms [210]. Additionally the passage of 
electrons is assisted by annular apertures made of metallic plates. These apertures 
permit only central electron flow in TEM and subsequently decreases the beam 
intensity and filters out high angle scattered electrons that are unwanted for sensitive 
samples [210]. There are two types of apertures; fixed like that of the condenser lens 
aperture and moveable which can be adjusted according to the needs of the 
experiment. All the lenses used in TEM are electron lenses that operate 
electromagnetically [211]. These lenses are usually made of alloys of iron, cobalt or 
nickel, chosen for their magnetic properties [211]. The electromagnetic properties of 
the lenses help the incoming parallel rays to converge at a constant focal length 
[211]. The transmitted beam passes through first and second condenser lenses, 
condenser aperture, sample, objective lense and aperture, first and second 
intermediate lenses and projector lens. Finally, the electron beam  is projected on the 
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imaging device to form the image on the screen [211]. Fig 3-11 illustrates the 
pathways followed by the electron beams after emission from the electron gun in 
order to produce the ultramicroscopic image.  
 




Chapter 4: Methodologies 
4.1 Action potential 
4.1.1 Langendorf apparatus set up 
Hearts from both control and STZ rats were rapidly removed from the 
sacrificed animals and mounted on the Langendorff apparatus (Fig. 4-1: A and B). 
Hearts were continuously perfused retrogradely with normal Tyrode solution at a 
flow of 8ml/g heart/min. The normal Tyrode contained 1.8 mM CaCl2 and was 
maintained at physiological temperature (36-37 
o
C). Action potentials were recorded 
in spontaneously beating hearts on the epicardial surface of the left ventricle with an 
extracellular suction electrode. Signals from the electrode were collected at 400 Hz, 
amplified (AD Instruments, ML136 Bioamp) and conveyed via a Powerlab (AD 
Instruments, PL410) for display on a PC monitor. Heart rate and the duration of the 
AP from peak to 50% and 70% repolarization were analyzed with AD Instruments 






Figure 4-1:  Langendorff set up for action potential study.  
1- Reservior containing perfusate, 2 – three way valve for flow adjustment, 3 – 




4.2 Expression of mRNA 
Expression of genes encoding a range of cardiac muscle proteins was assessed 
using Real time RT-PCR according to previously described techniques. 
4.2.1 Sample collection 
After sacrifice, hearts were removed rapidly from the rats and placed in a dish 
containing:  NaCl 140 mM; KCL 5.4 mM; MgCl2 1 mM; HEPES 5 mM; CaCl2 1.8 
mM and adjusted to pH 7.4 with NaOH. Intact SAN preprations were dissected from 
hearts as previously described [212].  Firstly around 2 cm of apex was cut in order to 
expose right and left ventricles. A careful incision was carried out in order to open 
the RV, right atrioventricular orifice, anterior border of RA and SVC. The opened 
flaps were then pinned in order to expose the SAN (Fig. 4-2). The SAN artery was 
identified and approximately 1 x 1 mm biopsy, were taken from center of SAN. 
Additionally samples from right atrial free wall were also collected. The biopsies 
were placed immediately in RNA later (AM7021, Life Technologies, Carlsbad, CA, 
USA) and kept overnight at -4 °C to allow through penetration of tissue. Tissue 




Figure 4-2: Sinoatrial node prepration. 
A) Dissection of rat sinoatrial node B) The SAN region is outlined by a yellow 
dotted line. RA, right atrium; CT, crista terminalis; PM, pectinate muscles. 
4.2.2 RNA extraction 
Isolation of total RNA from the tissue was performed using the SV Total RNA 
Isolation System (Promega, Madison, USA) according to the manufacturer‘s 
instructions. Samples of control-SAN (1x1 mm), RA (1x1 mm) and STZ-SAN (1x1 
mm), RA (1x1 mm) were taken out of RNA later, tap dried on an absorbent tissue 
and transferred to homogenizing tubes containing ceramic (zirconium oxide) beads. 
After adding 400 µl of trizol in the tube the samples were homogenized using the 
Preceylls 24 (Berlin Technology, USA) at 6500 rpm for 2 runs of 20 seconds each 
with a 15 second gap. Next the homogenate mixture was transferred to eppendorf 
tubes, to which 80 µl of chloroform was added and centrifuged. This causes phase 
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separation where protein is extracted to the organic phase, DNA resolves at the 
interface and RNA remains in the aqueous phase. The supernatant containing RNA 
was then mixed with 200 µl of 95% ethanol in a fresh eppendorf tube, transferred 
into a spin column and centrifuged for 1 minute at 12000 rpm at 25 °C. Next the 
elute in the collection tube was discarded and the column was washed with wash 
buffer (600 µl of RNA wash solution; centrifuged for 1 minute, 12000 rpm, 25 °C). 
Next 50 µl of DNase Incubation mix (containing 40 µl yellow core buffer, 5 µl 
0.09M MnCl2 and 5 µl DNAse I enzyme) was applied to the membrane of each 
column and the samples were incubated for 15 minutes at 25 °C. In order to stop 
digestion, DNase stop solution was added and centrifuged (1 minute, 12000 rpm, 25 
°C). Next, the samples were washed twice with 600 µl and 250 µl of wash buffer, 
respectively. Then the columns were transferred to 1.5 ml elution tubes to which 100 
µl of nuclease free water was added. After incubation for 2 minutes on ice, the RNA 
was eluted by centrifugation (1 minute, 12000 rpm). The concentration and purity of 
the RNA samples was determined by measuring the absorbance at 260 nm and the 
ratio of absorbance at 260 nm and 280 nm (ND-1000, NanoDrop). Samples were 
aliqouted and stored at -80 °C pending further processing. 
4.2.3 Reverse transcription to cDNA 
A two-step RT-PCR procedure was used to generate cDNA. Total RNA (500 
ng) was converted into cDNA in a 25 μl PCR reaction with 10 x RT Buffer 2.0 μl, 25 
x dNTP Mix (100 mM) 0.8 μl, 10 x RT Random Primers 2.0 μl, MultiScribe™ 
Reverse Transcriptase 1.0 μl, RNase inhibitor 1.0 μl, and Nuclease-free H2O (High 
Capacity cDNA Reverse Transcription Kit (4374966, Applied Biosystems, USA). 
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Reverse transcription was carried out using the following parameter values: 25 °C for 
10 min, 37 °C for 120 min, and 85 °C for 5 min on the Veriti thermal cycler (Applied 
Biosystems, USA). 
4.2.4 Real time reverse transcription polymerase chain reaction 
Gene Expression Assays were performed using custom TaqMan Low Density 
Arrays (Format 32, 4346799, Applied Biosystems, USA). The TaqMan assays are 
pre-loaded in each reaction well of the array in triplicate for each RNA sample. The 
target genes and associated proteins for the real time RT-PCR analyses are shown in 
Table 4-1. Several endogenous controls were incorporated into the plate. 18s was 
considered the most appropriate as expression was not significantly different 
between STZ-SAN, STZ-RA, CON-SAN and CON-RA and it has been widely used 
as a reference gene [213, 214]. 100 ng of cDNA (RNA-equivalent) was loaded 
together with 2 × TaqMan Gene Expression Master Mix (No AmpErase UNG, 
Applied Biosystems, USA) for a total of 100 µL per port. Two SAN samples were 
combined and two RA samples were combined for each real-time RT-PCR assay. 
Real-time RT-PCR was performed in a Fast ABI Prism 7900HT Sequence Detection 
System (Applied Biosystems, USA). The PCR thermal cycling parameters were run 
in standard mode as follows: 50 °C for 2 min, 94.5 °C for 10 min, followed by 40 
cycles of 97 °C for 30 sec and 59.7 for 1 min. Results were initially analyzed using 
ABI Prism 7900HT SDS, v2.4. All remaining calculations and statistical analysis 
were performed by the SDS RQ Manager 1.1.4 software using the 2−ΔΔCt method 




Genes Proteins  Protein descriptions 
Cardiac muscle and associated regulatory proteins 
Myh6 MHC-α Myosin Heavy Chain, Cardiac Muscle Alpha 
Isoform 
Myl1 MLC1 Myosin light chain 3, skeletal muscle isoform 
Myl2 MLC-2 Myosin regulatory light chain 2, 
ventricular/cardiac muscle isoform 
Tnnc1 TN-C Troponin C Type 1 
Intercellular proteins 
Gja1 Cx43 Connexin43 
Gja5 Cx40 Connexin40 
Gjc1  Cx45 Connexin45 
Gjd3  Cx31.9 Connexin31.9 
Cell membrane transport 




Atp1a2 Na/K ATPase,α2 ATPase, Na+/K+ Transporting, Alpha 2 
Polypeptide 
Atp1a3 Na/K ATPase,α3 ATPase, Na+/K+ Transporting, Alpha 3 
Polypeptide 
Atp1b1 Na/K ATPase,β1 ATPase, Na+/K+ Transporting, Beta 1 
Polypeptide 
Atp2b1 Na/K ATPase,β2 ATPase, Ca++ Transporting, Plasma Membrane 
1  
Slc8a1 NCX1 Solute Carrier Family 8 (Sodium/Calcium 
Exchanger), Member 1 
Trpc1 TRPC1 Transient receptor potential channel 1 
Trpc3 TRPC3 Transient receptor potential channel 3 
Trpc6 TRPC6 Transient receptor potential channel 6 
Intercellular Ca
2+
 transport and Ca
2+
 regulation 
Atp2a2 SERCA2 Sarcoplasmic/Endoplasmic Reticulum Calcium 
ATPase 2 
Calm1 Calm1 Calmodulin1 
Calm3 Calm3 Calmodulin3 
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Casq2 Casq2 Calsequestrin 2 
Itpr1 IP3R1 Inositol 1,4,5-Trisphosphate Receptor, Type 1  
Itpr2 IP3R2 Inositol 1,4,5-Trisphosphate Receptor, Type 2 
Itpr3 IP3R3 Inositol 1,4,5-Trisphosphate Receptor, Type 3  
Pln PLB Phospholamban  
Ryr2/ RYR2 RYR2 Ryanodine Receptor 2 
Ryr3/ RYR3 RYR3 Ryanodine Receptor 3 
Hyperpolarization-activated cyclic nucleotide-gated channels 
Hcn1 HCN1 Hyperpolarization-activated cyclic nucleotide-
gated channels 1 
Hcn2 HCN2 Hyperpolarization-activated cyclic nucleotide-
gated channels 2 
Hcn3 HCN3 Hyperpolarization-activated cyclic nucleotide-
gated channels 3 
Hcn4 HCN4 Hyperpolarization-activated cyclic nucleotide-




Cacna1c Cav1.2 Calcium Channel, Voltage-Dependent, L Type, 
Alpha 1C Subunit  
Cacna1d Cav1.3 Calcium Channel, Voltage-Dependent, L Type, 
Alpha 1D Subunit  
Cacna1g Cav3.1 Calcium Channel, Voltage-Dependent, T Type, 
Alpha 1G Subunit 
Cacna1h Cav3.2 Calcium Channel, Voltage-Dependent, T Type, 
Alpha 1H Subunit 
Cacna2d1 Cavα2δ1 Calcium Channel, Voltage-Dependent, Alpha 
2/Delta Subunit 1 
Cacna2d2 Cavα2δ2 Calcium Channel, Voltage-Dependent, Alpha 
2/Delta Subunit 2 
Cacna2d3 Cavα2δ3 Calcium Channel, Voltage-Dependent, Alpha 
2/Delta Subunit 3 
Cacnb1 Cavβ1 Calcium Channel, Voltage-Dependent, Beta 1 
Subunit 
Cacnb2 Cavβ2 Calcium Channel, Voltage-Dependent, Beta 2 
Subunit 




Cacng4 Cavγ4 Calcium Channel, Voltage-Dependent, Gamma 
Subunit 4 
Cacng7 Cavγ7 Calcium Channel, Voltage-Dependent, Gamma 
Subunit 7 
Sodium channels 
Scn1a Nav1.1 Sodium Channel, Voltage Gated, Type I Alpha 
Subunit 
Scn1b Navβ1 Sodium Channel, Voltage Gated, Type I Beta 
Subunit 
Scn2b Navβ2 Sodium Channel, Voltage Gated, Type II Beta 
Subunit  
Scn3a Nav1.3 Sodium Channel, Voltage Gated, Type III Alpha 
Subunit 
Scn3b Navβ3 Sodium Channel, Voltage Gated, Type III Beta 
Subunit  
Scn4a Nav1.4 Sodium Channel, Voltage Gated, Type IV Alpha 
Subunit 




Scn7a Nav2.1 Sodium Channel, Voltage Gated, Type VII Alpha 
Subunit 
Potassium channels 
Kcna2 Kv1.2 Potassium Channel, Voltage Gated Shaker 
Related Subfamily A, Member 2 
Kcna3 Kv1.3 Potassium Channel, Voltage Gated Shaker 
Related Subfamily A, Member 3 
Kcna4 Kv1.4 Potassium Channel, Voltage Gated Shaker 
Related Subfamily A, Member 4 
Kcna5 Kv1.5 Potassium Channel, Voltage Gated Shaker 
Related Subfamily A, Member 5 
Kcna6 Kv1.6 Potassium Channel, Voltage Gated Shaker 
Related Subfamily A, Member 6 
Kcnb1 Kv2.1 Potassium Channel, Voltage Gated Shab Related 
Subfamily B, Member 1  
Kcnd1 Kv4.1 Potassium Channel, Voltage Gated Shal Related 
Subfamily D, Member 1 
Kcnd2 Kv4.2 Potassium Channel, Voltage Gated Shal Related 
Subfamily D, Member 2 
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Kcnd3 Kv4.3 Potassium Channel, Voltage Gated Shal Related 
Subfamily D, Member 3 
Kcne4 MIRP3 Minimum Potassium Ion Channel-Related 
Peptide 3  
Kcnh2 ERG-1 Ether-A-Go-Go-Related Protein 1 
Kcnip2 KChIP2 Kv Channel Interacting Protein 2 
Kcnj11 Kir6.2 Potassium Channel, Inwardly Rectifying 
Subfamily J, Member 11 
Kcnj12 Kir2.2 Potassium Channel, Inwardly Rectifying 
Subfamily J, Member 12  
Kcnj14 Kir2.4 Potassium Channel, Inwardly Rectifying 
Subfamily J, Member 14 
Kcnj2 Kir2.1 Potassium Channel, Inwardly Rectifying 
Subfamily J, Member 2 
Kcnj3 Kir3.1 Potassium Channel, Inwardly Rectifying 
Subfamily J, Member 3 
Kcnj5 Kir3.4 Potassium Channel, Inwardly Rectifying 
Subfamily J, Member 5 
Kcnj8 Kir6.1 Potassium Channel, Inwardly Rectifying 
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Subfamily J, Member 8 
Kcnk1 TWIK1 Potassium Channel, Two Pore Domain Subfamily 
K, Member 1  
Kcnk2 TREK1 Potassium Channel, Two Pore Domain Subfamily 
K, Member 2 
Kcnk3 K2P3.1 Potassium Channel, Two Pore Domain Subfamily 
K, Member 3 
Kcnk5 K2P5.1 Potassium Channel, Two Pore Domain Subfamily 
K, Member 5 
Kcnk6 TWIK2 Potassium Channel, Two Pore Domain Subfamily 
K, Member 6 
Kcnn1 SK1 Potassium Channel, Calcium Activated 
Intermediate/Small Conductance Subfamily N 
Alpha, Member 1 
Kcnn2 SK2 Potassium Channel, Calcium Activated 
Intermediate/Small Conductance Subfamily N 
Alpha, Member 2 
Kcnn3 SK3 Potassium Channel, Calcium Activated 
Intermediate/Small Conductance Subfamily N 
Alpha, Member 3 
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Kcnq1 Kv7.1 Potassium Channel, Voltage Gated KQT-Like 
Subfamily Q, Member 1 
Miscellaneous proteins 
Abcc8 SUR1 ATP-binding cassette transporter sub-family C 
member 8 
Abcc9 SUR2 ATP-binding cassette, sub-family C member 9 
Nppa ANP Atrial natriuretic peptide 
Nppb BNP Brain natriuretic peptide 
Pias3 KChAP Protein Inhibitor of activated STAT, 3 
Table 4-1: Target genes and proteins 
4.3 Western blot 
4.3.1 Tissue preparation 
Tissue samples of SAN (1x1mm) were collected from the heart of both the 
control and STZ rats and frozen immediately in liquid nitrogen and stored at -80° C 
till further processing. For processing the SAN samples were initially thawed, 
washed with ice cold  0.9% normal saline and homogenized in isotonic 100 mM 
potassium phosphate buffer (pH 7.4) containing 1 mM ethylene diamine tetra acetic 
acid (EDTA), a metal chelator and 0.1 mM phenymethylsulfonyl fluoride (PMSF), a 
protease inhibitor. The homogenization was carried using the Preceylls 24 (Berlin 
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Technology, USA) bead homogenizer at 6500 rpm for 3 runs of 20 seconds each 
with a 15 second gap. The mixture/superanatant was collected, alliquoted and stored 
at -80°C. The entire procedure was conducted on ice in order to avoid proteolysis of 
protein. The protein content of samples was measured using Bradford assay and 
quantified using spectrophotometry. 
4.3.2 Preparation of sodium dodecyl-sulphate polyacramide gel electrophoresis 
(SDS-PAGE) 
4.3.2.1 Gel preparation 
The materials required for preparation of SDS-polyacramide gel were: vertical 
clamp stand, gel casting cassette/plates, casting stand, separator, comb and buffer 
tank. After arranging the apparatus, two different layers of acrylamide gel were 
prepared: separating gel (12% and 7.5%) and stacking gel. The 10 ml 12% separating 
gel was prepared using 3.35 ml of distilled water, 2.5 ml of 1.5 M Tris HCL, 100 µl 
of 10% SDS, 4 ml of 30% acrylamide/bis, 50 µl of 10% ammonium persulfate 
(APS), 5 µl of TEMED and 7.5% separating gel was prepared using the same 
reagents except 4.85 ml of distilled water and 2.5 ml of 30% acrylamide/bis 
respectively. The prepared gel was then immediately loaded between the gel casting 
plates. A thin layer of distilled water of about 2 ml was applied on top of the gel in 
order to prevent oxidation. This is the layer which allows protein to migrate different 
distances depending on their size and molecular weight. After the gel polymerized 
the water was removed and the stacking gel containing 6.1 ml of distilled water, 2.5 
ml of 0.5 M Tris-HCL, 100 µl of 10% SDS, 1.3 ml of 30% acrylamide/bis, 50 µl of 
APS and 10 µl TEMED was loaded on top of the separating gel. A comb was 
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inserted into the stacking gel so as to form wells where sample proteins could be 
loaded. After the gel had set, the comb was removed and the formed wells were 
rinsed with distilled water making the SDS polyacramide gel ready for loading the 
protein samples. 
4.3.2.2 Protein loading and electrophoresis 
Protein equivalent to 10 µg in 50 µl from SAN of control and STZ were mixed 
with a 50 µl sample buffer (containing 4.0 ml of distilled water, 0.5 M Tris- HCL, 
0.8 ml of glycerol, 1.6 ml of 10% SDS, 0.4 ml of 2-b-mercaptoethanol and 0.2 ml of 
0.05% bromophenol blue) to give a final volume of 100 µl. These resulting sample 
protein mixtures were then heated for 10 minutes in a water bath at 95 °C. After a 
brief spin of 5 seconds, about 30 µl of sample protein mixtures along with 5 µl of pre 
stained protein molecular weight marker were loaded onto the wells of prepared 12% 
or 7.5%  SDS gel and electrophoresed at 100 V in running buffer (25 mM Tris base, 
192 mM glycine and 0.1% SDS, pH 8.3).  
4.3.3 Protein expression 
4.3.3.1 Electrophoretic transfer of proteins from SDS polyacramide gel to 
nitrocellulose membrane and blocking 
The apparatus required for protein transfer are: nitrocellulose membrane, filter 
paper, pads, support grid and buffer tank. The gel containing separated protein was 
carefully removed from the cassette plate and washed with Towbin system buffer 
(transfer buffer) solution for 20 mins at room temperature. The filter paper, pads and 
nitrocellulose membrane were also kept immersed in transfer buffer solution for 30 
mins. The transfer stack was then arranged in sandwich pattern and the proteins were 
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then electrically transferred to nitrocellulose membrane at 80 V in a tank containing 
transfer buffer for 2 hours at 4 °C. A successful protein transfer was indicated by the 
complete transfer of pre stained molecular weight marker on the nitrocellulose 
membrane. Non-specific binding sites were then blocked by incubating the 
membrane overnight in 5% fat free milk or BSA at 4 °C. 
4.3.3.2 Antibody probing 
The following day the membranes were allowed to thaw at room temperature 
for 1 hour and then washed twice with Tris-buffered saline (TBS) containing 0.05% 
Tween 20 (TBST) for 10 mins each. Next the membranes were probed with primary 
antibodies (diluted in TBST) with the proteins (listed in Table 4-2) for 2 hours at 
room temperature. After that the membranes were washed several times with TBST 
and TBS buffers and then incubated with secondary antibody for 1-2 hours at room 
temperature. Finally the membranes were washed again several times with TBST and 
TBS buffers before developing the blots. 
mRNA Protein/primary antibody Molecular weight of 
the protein (kDa) 
Gjc1 Connexin 45 45 
Ryr3  RYR3 565 
Cacna1g Cav3.1 252 
Kcnd2 Kv 4.2 80 
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Nppa ANP 16 
Nppb  BNP 15 
Table 4-2: List of primary antibodies with their molecular weight. 
4.3.3.3 Blot development and protein detection 
The blot was developed using Thermo Scientific Pierce ECL 2 Western blotting 
substrate. Each membrane was incubated with developing solution for 5 minutes. 
The developing solution was prepared by mixing substrate A and substrate B in 40:1 
ratio. The developed blots were then removed and dried using absorbent tissues to 
remove excess liquid. These blots were then placed on a Typhoon Imager (Typhoon 
FLA 9500) with the protein side facing up and scanned using 473 nm excitation and 
LPB (510) emission filter in fluroscence mode to visualize the protein bands. The 
protein bands were then quantified using ImageQuant TL 7.0 software. To check for 
equal loading of protein in each blot, beta (β) actin was used as control. Each of the 
blots were incubated with stripping buffer containing 62.5 mM Tris-HCL, pH 6.7, 10 
mM β mercaptoethanol and 2% SDS, for 1 hour at 56 °C. The stripping buffer 
removes the primary and secondary antibodies from the blot. The blot was then 
blocked overnight with BSA at 4 °C and incubated with β-actin (internal control 
primary antibody). The density of each band was then normalized to the internal 
control. The intensity of the bands were calculated and expressed as a relative 
intensity compared to control sedentary proteins, which was arbitrarily taken as 
100%. The analyses were representative data of 3 independent experiments. 
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4.4 Transmission electron microscopy 
4.4.1 Sample processing 
Fresh biopsies of SAN taken from heart of control and STZ rats were 
immediately placed in eppendorf tubes containing Karnovsky fixative (2.5% 
paraformaldehyde, 25% EM grade glutaraldehyde. 0.1 M sodium phosphate buffer, 
pH 7.2) and kept overnight at -4 °C. The subsequent steps were carried out on a Rota 
mixer. The samples were transferred to glass vials and washed with 0.1 M phosphate 
buffer 3 times for 15 minutes each. Next the samples were treated with 1 ml of 
buffered 1% osmium tetraoxide (staining agent) and left for 1 hour at room 
temperature in the dark environment. This step helps to provide contrast to the 
image. Following this, samples were subjected to graded ethanol dehydration: 15 
mins each, once in 30%, 50%, 70%, 80%, 90%, 95% ethanol and twice in absolute 
ethanol and propylene oxide. Resin, the embedding compound, was prepared in a 
plastic beaker as follows: 23 g Agar 100 epoxy resin, 13 g Dodecenylsuccinic 
anhydride, 14 g Methylnadic anhydride and 1.1 Tri Dimethylaminomethyl phenol. 
Tissues were then treated with agar resin-propylene oxide mixture in the ratio 1:1, 
2:1 and 3:1 each for 1 hour. Next samples were dipped in pure resin and left 
overnight at 4°C.  
4.4.2 Sample embedding 
Samples dipped in resin were removed from the fridge and thawed for 1 hour at 
room temperature. Tissues were then embedded in fresh resin using flat molds that 
were labeled (Fig. 4-3). Next the molds were placed in a desiccator for 3-4 hours to 
remove any extra air bubbles and proper infiltration. After that the embedded 
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samples in the molds were kept in an oven set at 64 °C for 24 hours for 
polymerization. Ultrathin sections (90 – 100 nm) were cut with a Diatone knife 
(Agar Scientific, Essex, England) and mounted on 3.0 mm 200 mesh copper grids. 
The sections were stained with saturated uranyl acetate for 1 hour and lead citrate 
solution for 30 minutes. Ultrathin sections were scanned and photographed using a 
Phillips CM10 electron microscope (Eindhoven, The Netherlands) 
 
Figure 4-3: Embedment of samples in resin molds.  
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Chapter 5: Results 
5.1 General characteristics of the animals 
All the experiments were performed 10 – 12 weeks after STZ injection. DM 
was confirmed by measuring the non-fasting blood glucose level in blood sample 
taken from tail vein. The general characteristics of the STZ-induced diabetic and age 
matched Control group obtained immediately before experiments is shown in Table 
5-1. The body and heart weight of STZ rats were significantly (P<0.01) reduced 
compared to Controls. There was a significant (P<0.01) increase in the heart to body 
weight ratio in STZ rats compared to Controls. The non-fasting blood glucose was 
also significantly (P<0.01) elevated (5 fold) in STZ rats compared to Controls. 
 Control Streptozotocin 
Body weight (g) 322.50±22.98 207.00±51.99** 
Heart weight (g) 1.15±0.12 0.85±0.13** 
Heart weight / Body weight 
ratio 
3.59±0.45 4.19±0.48** 
Blood glucose (mg/dl) 96.92±15.03 514.33±54.60** 
Table 5-1: General characteristics of streptozotocin-induced diabetic rats and age 
matched controls.  
Data were analyzed using Independent samples T-test. Data are mean ± SEM, n = 12 
animals, **P < 0.01. 
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5.2 Streptozotocin-induced diabetes results 
5.2.1 Effect of Streptozotocin-induced diabetes on ventricular action potential  
The effect of STZ-induced diabetes on the AP of the isolated heart was 
investigated in STZ rats and compared to Controls. The data including heart rate and 
AP duration are shown in Figures 5-1a-d. The heart rate was significantly (P < 0.05) 
reduced in STZ rat hearts (203.2 ± 7.138, n = 12) compared to Control rat hearts 
(239.04 ± 10.631, n = 12) (Fig. 5-1a). There was no significant (P < 0.05) difference 
in time to peak (TTP) AP in STZ rats compared to Control rats (Fig. 5-1b). Action 
potential duration at 50% (APD 50) from peak AP was significantly (P < 0.05) 
prolonged in STZ rats (19.34 ± 1.671, n = 12) compared to Control rats (12.37 ± 
2.411 n = 12) (Fig. 5-1c). Action potential duration at 70% (APD 70) from peak AP 
was also significantly (P < 0.05) prolonged in STZ rats (36.47 ± 2.649, n = 12) 




Figure 5-1: Effects of STZ-induced diabetes on: A) Heart rate, B) Time to peak, C) 
Action potential duration at 50% (APD 50) from peak action potential and D) Action 
potential duration at 70% (APD 70) from peak action potential 70%.  
Data were analyzed using Independent samples T-test. Data are mean ± SEM, n=12 
hearts, *P < 0.05. 
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5.2.2 Effect of Streptozotocin-induced diabetes on mRNA expression encoding 
various cardiac proteins in sinoatrial node 
The expression of genes encoding various cardiac proteins was assessed in 
SAN of Control and STZ rats (CON-SAN and STZ-SAN) and RA of Control and 
STZ rats (CON-RA and STZ-RA) using real time RT-PCR assay as described in 
section 4.2. The levels of mRNA reflecting the expression of genes encoding cardiac 
proteins are shown in Figure 5-2 to 5-10 
5.2.2.1 Expression of genes encoding cardiac muscle protein 
Expression of mRNA for cardiac muscle proteins are shown in Figure 5-2. 
Expression of Myl1 (encoding MLC1 protein) was significantly (P < 0.05) 
upregulated in STZ-SAN compared to CON-SAN and downregulated in STZ-RA 
compared to CON-RA. Expression of Tnnc1 (encoding TN-C protein) was 
significantly (P < 0.05) downregulated in STZ-RA compared to CON-RA. There 
were no significant (P < 0.05) changes in Mhy6 (encoding MHCα protein) and Myl2 





Figure 5-2: – Expression of genes encoding various cardiac muscle proteins.  
Data were analyzed using One way ANOVA and Bonferoni tests. Data are mean ± 
SEM, n=4-10 samples from STZ and control rat each containing SANs from 2 hearts. 
The numbers above the bars indicate significance at P < 0.05. 
5.2.2.2 Expression of genes encoding intercellular proteins. 
Expressions of mRNA for intercellular proteins are shown in Figure 5-3. 
Expression of Gjc1 (encoding Cx45 protein) was significantly (P < 0.05) upregulated 
in STZ-SAN compared to CON-SAN. There were no significant (P < 0.05) changes 
in expression of Gja1 (encoding Cx43 protein), Gja5 (encoding Cx40 protein) and 




Figure 5-3: Expression of genes encoding various intercellular proteins.  
Data were analyzed using One way ANOVA and Bonferoni tests. Data are mean ± 
SEM, n=6-10 samples from STZ and control rat each containing SANs from 2 hearts. 
The numbers above the bars indicate significance at P < 0.05. 
5.2.2.3 Expression of genes encoding cell membrane transport proteins. 
Expressions of mRNA for cell membrane transport are shown in Figure 5-4. 
Expression of Atp2b1 (encoding Na/K ATPase β2 protein), Slc8a1 (encoding NCX1 
protein), Trpc1 (encoding TRPC1 protein), and Trpc6 (encoding TRPC6 protein) 
were significantly (P < 0.05) upregulated in STZ-SAN compared to CON-SAN. 
Expression of Trpc6 was also significantly (P < 0.05) upregulated in STZ-RA 
compared to CON-RA. There were no significant changes in expression of Atp1a1 
(encoding Na/K ATPase α1 protein), Atp1a2 (encoding Na/K ATPase α2 protein), 
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Atp1a3 (encoding Na/K ATPase α3 protein), Atp1b1 (encoding Na/K ATPase β1 
protein) and Trpc3 (encoding TRPC3 protein). 
 
Figure 5-4: Expression of genes encoding various membrane transport proteins. 
Data were analyzed using One way ANOVA and Bonferoni tests. Data are mean ± 
SEM, n=6-10 samples from STZ and control rat each containing SANs from 2 hearts. 
The numbers above the bars indicate significance at P < 0.05. 
5.2.2.4 Expression of genes encoding intercellular Ca
2+
 transport and regulatory 
proteins 
Expression of mRNA for intracellular Ca
2+
 transport and regulatory proteins are 
shown in Figure 5-5. Expression of Casq2 (encoding Casq2 protein) and Itpr1-3 
(encoding IP3R 1-3 protein) were significantly (P < 0.05) upregulated in STZ-SAN 
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compared to CON-SAN. Expression of Itpr1 was also significantly (P < 0.05) 
upregulated in STZ-RA compared to CON-RA. There were no significant (P < 0.05) 
changes in Atp2a2 (encoding SERCA2 protein), Calm1 (encoding Calm1 protein), 
Calm3 (encoding Calm3 protein), Pln (encoding PLB protein) and Ryr2 (encoding 
RYR2 protein). 
 




Data were analyzed using One way ANOVA and Bonferoni tests. Data are mean ± 
SEM, n=6-10 samples from STZ and control rat each containing SANs from 2 hearts. 
The numbers above the bars indicate significance at P < 0.05. 
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5.2.2.5 Expression of genes encoding hyperpolarization-activated cyclic 
nucleotide-gated channel proteins 
Expressions of mRNA for HCN proteins are shown in Figure 5-6. Expression 
of Hcn1 and Hcn4 were significantly (P < 0.05) downregulated in STZ-RA 
compared to CON-RA. Hcn4 was also significantly (P < 0.05) upregulated in CON-
RA compared to CON-SAN and modestly upregulated in STZ-SAN compared to 
CON-SAN however, the difference was not significant (P < 0.05). There were no 
significant (P < 0.05) changes in expression of Hcn2 and Hcn3. 
 
Figure 5-6: Expressions of genes encoding various hyperpolarization-activated 
cyclic-nucleotide gated channels. 
Data were analyzed using One way ANOVA and Bonferoni tests. Data are mean ± 
SEM, n=5-10 samples from STZ and control rat each containing SANs from 2 hearts. 
The numbers above the bars indicate significance at P < 0.05. 
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5.2.2.6 Expression of genes encoding calcium channel proteins 
Expressions of mRNA for calcium channel proteins are shown in Figure 5-7. 
Expression of Cacna1g (encoding Cav3.1 protein), Cacna1h (encoding Cav3.2 
protein), Cacna2d2 (encoding Cavα2δ2 protein) and Cacnb3 (encoding Cavβ3 
protein) were significantly upregulated (P < 0.05) whilst Cacng4 (encoding Cavγ4 
protein) was significantly (P < 0.05) downregulated in STZ-SAN compared to CON-
SAN. Expression of Cacna2d2 and Cacnb3 were also significantly (P < 0.05)  
upregulated in STZ-RA compared to CON-RA. There were no significant (P < 0.05) 
changes in Cacna1c (encoding Cav1.2 protein), Cacna1d (encoding Cav1.3 protein), 
Cacna2d1 (encoding Cavα2δ1 protein), Cacna2d3 (encoding Cavα2δ3 protein), 
Cacnb1 (encoding Cavβ1 protein), Cacnb2 (encoding Cavβ2 protein) and Cacng7 








Figure 5-7: Expression of genes encoding various calcium channel proteins.  
Data were analyzed using One way ANOVA and Bonferoni tests. Data are mean ± 
SEM, n=5-10 samples from STZ and control rat each containing SANs from 2 hearts. 
The numbers above the bars indicate significance at P < 0.05. 
5.2.2.7 Expression of genes encoding sodium channel proteins 
Expressions of mRNA for sodium channel proteins are shown in Figure 5-8. 
Expression of Scn7a (encoding Nav2.1 protein) was significantly (P < 0.05) 
upregulated in STZ-SAN compared to CON-SAN. Expression of Scn5a (encoding 
Nav1.5 protein) was significantly (P < 0.05) downregulated in STZ-RA compared to 
CON-RA. Scn2b (encoding Navβ2 protein) was significantly (P < 0.05) 
downregulated in CON-SAN compared to CON-RA. There were no significant (P < 
0.05) changes in expression of Scn1a (encoding Nav1.1 protein), Scn1b (encoding 
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Navβ1 protein), Scn3a (encoding Nav1.3 protein), Scn3b (encoding Navβ3 protein) 
and Scn4a (encoding Nav1.4 protein). 
 
Figure 5-8: Expression of genes encoding various sodium channel proteins.  
Data were analyzed using One way ANOVA and Bonferoni tests. Data are mean ± 
SEM, n=8-10 samples from STZ and control rat each containing SANs from 2 hearts. 
The numbers above the bars indicate significance at P < 0.05. 
5.2.2.8 Expression of genes encoding potassium channel proteins 
Expression of mRNA for potassium channel proteins are shown in Figures 5-9 
a and b. Expression of Kcna2 (encoding Kv1.2 protein) and Kcnd2 (encoding Kv4.2 
protein) were significantly (P < 0.05) downregulated whilst Kcnj2 (encoding Kir2.1 
protein), Kcnj5 (encoding Kir3.4 protein), Kcnk3 (encoding K2P3.1 protein)  and 
Kcnk6 (encoding TWIK2 protein) were significantly (P < 0.05) upregulated in STZ-
SAN compared to CON-SAN. Expression of Kcnk3 (encoding K2P3.1 protein), 
Kcnn3 (encoding SK3 protein), Kcnd1 (encoding Kv4.1 protein) were also 
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significantly (P < 0.05) upregulated and Kcna2, Kcnd2, Kcnd3 (encoding Kv4.3 
protein), Kcnj12 (encoding Kir2.2 protein) were significantly (P < 0.05) 
downregulated in STZ-RA compared to CON-RA. There were no significant (P < 
0.05) changes in mRNA expression encoding Kv1.3, Kv1.4, Kv1.5, Kv1.6, Kv2.1, 
MIRP3, ERG-1, KChIP2, Kir6.2, Kir2.4, Kir3.1, Kir6.1, TWIK1, TREK1, K2P5.1, 






Figure 5-9 A and B: Expression of genes encoding various potassium channel 
proteins 
Data were analyzed using One way ANOVA and Bonferoni tests. Data are mean ± 
SEM, n=6-10 samples from STZ and control rat each containing SANs from 2 hearts. 
The numbers above the bars indicate significance at P < 0.05. 
5.2.2.9 Expression of genes encoding miscellaneous cardiac proteins 
Expressions of mRNA for miscellaneous cardiac proteins are shown in Figure 
5-10. Expression of Abcc9 (encoding SUR2 protein), Nppa (encoding ANP protein), 
Nppb (encoding BNP protein) and Pias3 (encoding KChaP protein) were 
significantly upregulated in STZ-SAN compared to CON-SAN. Nppa and Nppb were 
also significantly expressed more in STZ-SAN compared to STZ-RA. There was no 





Figure 5-10: Expression of genes encoding miscellaneous cardiac proteins.  
Data were analyzed using One way ANOVA and Bonferoni tests. Data are mean ± 
SEM, n=8-10 samples from STZ and control rat each containing SANs from 2 hearts. 
The numbers above the bars indicate significance at P < 0.05. 
5.2.3 Effect of Streptozotocin-induced diabetes on expression of cardiac proteins 
in sinoatrial node 
Western blot techniques were used to compare expression of selected proteins 
in STZ-SAN and CON-SAN and the results are shown in Figure 5-11: A and B. 
Expression of Cav3.1 and RYR3 were significantly (P<0.05) increased and ANP was 




Figure 5-11: A) Western blots comparing expression of various proteins from STZ-
SAN and CON-SAN. 
The blots shown are representative of 3 individual samples from STZ and control rats 
each containing SANs from 3 hearts. 
































Figure 5-11: B) The Protein/actin ratio for the different proteins.  
Data were analyzed using Independent samples T-test. Data are mean ± SEM, n=3 
samples from STZ and control rat each containing SANs from 3 hearts. * P < 0.05, 
** P < 0.01 
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5.2.4 Effect of Streptozotocin-induced diabetes on ultrastructure of sinoatrial 
node 
The ultrastructural morphology of SAN in Control and STZ rats was assessed 
using TEM as described in section 4.4. Light microscopy of SAN is shown in Figure 
5-12. At a magnification of X100 semithin sections showed a reduction in cell size in 
STZ-SAN compared to CON-SAN. In addition there was also an increase in 
connective tissue mass in STZ-SAN compared to CON-SAN. SAN from STZ rats 
appeared to be granular in nature compared to Control rats. 
 
Figure 5-12: Shows light micrographs of semithin sections of sinoatrial node in (a) 
Control and (b) STZ rats.  
Note that SAN cells (thick arrows) are smaller in the STZ-SAN compared to CON-
SAN. Thick arrow = SAN cells, Thin arrow = connective tissue cells, NA= Nodal 
artery. Magnification: X100 
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Electron micrographs of SAN in Control and STZ rat are shown in Figure 5-13. 
Mitochondria were less numerous and irregular in STZ-SAN compared to CON-
SAN. Moreover, the STZ-SAN contained degenerating cytoplasmic organelles.  
 
Figure 5-13: Shows transmission electron micrographs of sinoatrial nodal cells in (a) 
Control and (b) STZ rats.  
Note that SA nodal cells of normal rats (a) contain more mitochondria (m) compared 
to those of diabetic rats (b).  Moreover, the SA nodal cells of diabetic rat contain 
degenerating cytoplasmic organelles (thick arrow). Thin arrow = cytoplasmic 
inclusions. Scale bar = 500 nm 
The quantitative results of mitochondria and cytoplasmic granules are shown in 
Figure 5-14. The number of mitochondria and cytoplasmic granules were modestly 




Figure 5-14: shows the average number of mitochondria and cytoplasmic granules 
per section of SA nodal cell in control and STZ rat.  




Chapter 6: Discussion 
This study investigated effects of DM on the SAN. The major finding is that 
diabetes results in widespread remodeling (at the mRNA level) of ion channels and 
related proteins. 
6.1 Diabetes mellitus induction in rats 
DM is an endocrine disorder and its complications involve different organ 
systems in the body. Thus choosing the right animal model depends primarily on 
what aspect of disease is being investigated. Cardiovascular complications are a 
leading cause of diabetes related morbidity and mortality [52]. Among the different 
experimental methods used to produce diabetic animal models, the chemically 
induced STZ model has several advantages including cost-effectiveness and ease of 
inducing DM regardless of the genetic background [216, 217]. STZ induced DM is a 
widely used model and resembles DM in human in various ways. It exhibits 
hyperglycemia, reduced body weight, polyphagia, polydipsia as well as 
complications such as retinopathy, cataract, cardiomyopathy, neuropathy and 
nephropathy [218, 219]. 
The effects of DM on the cardiovascular system have been studied in STZ rats 
both in vivo (whole animal) and in vitro (isolated heart). The defects in vivo include a 
decrease in HR [220], altered time course of cardiac contractility and relaxation, 
decrease in myocardial blood flow reserve [221], mean arterial blood pressure and 
left ventricular function and increases in stroke volume and cardiac output due to 
diabetes induced structural changes [222] [223] . The effects of DM in vitro include 
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both structural and functional effects. The structural defects include reduced weight 
of heart, atria, right and left ventricles [224], decreased thickness and increased 
internal diameter of left ventricle [218], loss of contractile proteins, myocytolysis 
[225], decreased myocardial capillary size [221], increase in the number of 
sarcolemmal Ca
2+
 channels, increased lipid deposition, and increased collagen 
content in left ventricular tissues [220]. Functional defects include reduced HR, 
diastolic stiffness [218], impaired relaxation and contraction, decreased ATPase 
activity of cardiac contractile proteins, increased ventricular sensitivity to Ca
2+ 
, 
reduced depolarization of resting membrane potential [218], depressed atrial activity, 
enhanced right RV activity, prolonged AP duration in SAN, RA and RV, elevated 
Fe
+
 levels in RV, elevated Na
+
 levels in the atria and RV, lower Ca
2+
 levels in the 
atria, RV and LV, increased Cu
2+
 levels in the atria and decreased Cu
2+
 levels in the 
LV [224]. 
Several methods of STZ dosing have been described in the literature depending 
on the severity and type of DM required for the specific experimental protocol [152, 
226] [227]. In our study, DM was induced in adult male Wistar rats by a single i.p 
injection with STZ (60 mg/kg body weight) dissolved in citrate buffer. However, the  
i.v route of administration would have been preferable as the i.p. route involves an 
additional absorption step of STZ to the bloodstream before its effect can take place, 
thus decreasing the bioavailability compared to the i.v route of administration [228]. 
DM induced by 60 mg/kg STZ can be characterized as T1DM, T2DM or unspecified 
DM. Like T1DM, hypoinsulinaemia results due to rapid destruction of β cells after a 
single STZ injection (60 mg/kg), but the cells are destroyed due toxic effects rather 
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than an autoimmune response which is the major etiology in T1DM [44, 149]. An 
autoimmune response can be induced by multiple injections [229]. Some studies 
have also reported that the damaged pancreatic β cells can spontaneously regenerate 
with time after STZ injection in rats and mice [230, 231]. In addition STZ rat models 
produced by a single 60 mg/kg injection do not exhibit DKA and rather show 
significant glycemic improvement by oral anti-diabetic drugs, a characteristic that 
resembles T2DM [232, 233]. Hence, the STZ rat model produced by a single 60 
mg/kg injection cannot be strictly described as T1DM or T2DM, but rather an 
unspecified model of hyperglycemia. 
The characteristics of DM take some time to develop in STZ-induced diabetic 
rats. Reduction in body weight of STZ-induced diabetic rats becomes significantly 
lower than the age matched Controls 2 weeks after STZ injection [142]. Diabetic 
cardiovascular complications begin 5-7 days after STZ injection and continue to 
worsen with time [142]. The earliest symptom is reduced HR which occurs 5-7 days 
after STZ treatment followed by reduced mean arterial pressure after 14 days and 
eventually reduced variability of HR after 30-45 days [234]. Experiments were 
carried out 10 -12 weeks after STZ-injection. As hyperglycemia is known to be the 
key element of DM, BGL was measured 3-5 days after STZ injection. So as to ensure 
that the injected rats were still diabetogenic and regeneration of β cells had not 
occurred glucose levels were also measured just before experiments. Injected rats 
that exhibited recovery from DM, indicated by normoglycemia, were excluded from 
the experiment. Only rats with BGL 200 mg/dl and above were included in the 
diabetic group. Control rats were injected with an equivalent volume of citrate buffer 
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only and their BGL ranged from 75-130 mg/dl. The other differences between STZ 
and Control rats included reduced body weight, reduced HR and increased heart 
weight to body weight ratio. These results have been shown repeatedly in previous 
studies using this model [143] [235] [236]. 
6.2 Effect of STZ-induced diabetes on action potential of isolated heart 
HR in spontaneously beating isolated perfused heart was significantly reduced 
in STZ-induced diabetic rats compared to Controls in ventricles. The time to peak 
during APD was not significantly altered in STZ rat heart compared to control. The 
repolarization at APD 50% and APD 70% were also prolonged in diabetic rat heart 
compared to controls.  
HR was significantly reduced in isolated perfused diabetic rat heart compared 
to Controls. Previous in vivo biotelemetry experiments have also demonstrated 
reduced HR in STZ rats [142, 145, 237]. Reduction in spontaneous beating rate in 
superfused STZ-SAN preparations has also been reported suggesting that intrinsic 
defects, and in particular SAN defects may partly underlie the reduced HR in STZ 
rats [142] . 
The duration of ventricular AP repolarization was prolonged at 50% and 70% 
from peak of AP in STZ rat heart compared to Controls. Prolongation of SAN AP in 
isolated perfused heart with no significant change in time to peak and prolongation in 
duration of AP repolarization in SAN at 50% and 70% from peak of AP have been 
demonstrated in STZ rat heart [143] [238]. Recent ion channel gene expression 
studies have shown that many different ion channels are expressed in mammalian 
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SAN [102]. Several of these ion channels contribute to the process of SAN 
repolarization in rat including the inward rectifying K
+
 current (IKi), the transient 
outward current (Ito) and the delayed rectifier K
+
 currents which include the rapidly 
activating current (IKr) and perhaps a smaller contribution from the slowly activating 
current (IKs) [239] [240]. Studies have also demonstrated prolonged pacemaker cycle 
length and sinoatrial conduction time in isolated SAN preparations in STZ rats 
compared to controls [238].  
6.3 Effect of STZ-induced diabetes on mRNA expression 
An early step in elucidating the mechanisms that underlie low HR in the STZ 
rat heart is to study the profile of genes associated with proteins that are involved in 
the generation and propagation of the SAN AP. 
In this study, the protein encoding genes that were significantly altered in STZ-SAN 
compared to CON-SAN include: Myl1(2 fold increase), Gja7 (2-fold increase), 
Atp2b1 (2 fold increase), Slc8a1 (2.5-fold increase), Trpc1 (2.5-fold increase), Trpc6 
(4-fold increase), Casq2 (2.5 fold increase), Itpr1-3 (2-3 fold increase), Cacna1g (2-
fold increase), Cacna1h (2 fold increase), Cacna2d2 (2 fold increase), Cacnb3 (3-
fold increase), Cacng4 (7-fold decrease), Scn7a (2 fold increase), Kcna2 (2 fold 
decrease), Kcnd2 (2 fold decrease), Kcnj2 (2 fold increase), Kcnj5 (3-fold increase), 
Kcnk3 (3 fold increase), Kcnk6 (2 fold increase), Abcc9 (2 fold increase), Nppa (5-
fold increase), Nppb (7-fold increase) and Pias3 (4 fold increase).  
Among the cardiac muscle and regulatory protein encoding genes, Myl1 
(MLC1) was upregulated in STZ-SAN compared to CON-SAN. It is also interesting 
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to note that within the Control group Myl1 was upregulated in RA compared to SAN 
while in the STZ group Myl1 is downregulated in RA compared to SAN. Myl1 
encodes myosin alkali light chain, a component of myosin which is a hexameric 
ATPase cellular motor protein and is predominantly expressed in fast skeletal 
muscles. A recent study has shown that Myl1 is highly expressed in working 
cardiomyocytes, which are concerned primarily with muscle contraction [241]. The 
functional difference of MLC1 protein between cells of working myocardium and 
conductive tissue cells remains to be studied. 
The gap junction protein encoding gene, Gjc1 (Cx45) was significantly 
upregulated in STZ-SAN compared to CON-SAN. Cx45 protein was also moderately 
upregulated in STZ-SAN compared to CON-SAN.  Connexin proteins, pore forming 
subunits of gap junctions, play an important role in ensuring efficient cell-to-cell 
communication and the maintenance of cardiac rhythmicity [242]. At least five 
connexins (Cx30.2, Cx37, Cx40, Cx43 and Cx45) are prominently expressed in the 
heart and each shows regional and cell type specific expression [243]. Gjc1 (Cx45) is 
expressed in the SAN and previous studies have demonstrated upregulation of genes 
encoding connexin proteins, and in particular Cx45, in STZ-SAN [135, 244]. It is 
known that APD and SAN conduction and pacemaker cycle length may be prolonged 
in diabetic heart and this may be associated with remodeling of connexin proteins. 
Among the cell membrane transport protein encoding genes Trpc1 (TRPC1) 
and Trpc6 (TRPC6) were upregulated in STZ-SAN compared to CON-SAN. The 
transient receptor potential (TRP) channels are a large family of non-selective and 
non-voltage gated ion channels that are widely expressed in human tissue including 
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the heart and vasculature [245] [246]. TRPC1 and TRPC6 are mechano-sensitive, 
non-selective cation channels that are expressed in mouse ventricular muscle [247]. 
In the cardiovascular system the TRPC family has been found to play a role in 
vascular and cardiac disease [248]. Upregulation of TRPC channels is involved in the 
development of cardiac hypertrophy and heart failure [245, 249, 250]. TRPC6 is 
induced in heart hypertrophy and inhibition of TRPC6 has been shown to suppress 
agonist-induced hypertrophic responses [251] [252]. Whilst the physiological role of 
the TRP channels in the SAN is unclear, upregulation of Trpc1 and  Trpc6 in STZ-




through non-selective TRP 
channels might have implications for the generation of the pacemaker potential or 
AP in diabetic SAN cells [249] [253] . Other genes that were upregulated in this 





exchanger (NCX1) protein and helps in regulation of Ca
2+
 concentration during 
contraction and relaxation of cardiac myocytes. The NCX1 is one of the essential 
regulators of Ca
2+
 homeostasis in cardiomyocytes and thus an important modulator 
of cardiac contractile function [254]. In SAN cells, NCX1 is the dominant Ca
2+
 
efflux mechanism [254]. Recent studies have demonstrated that NCX1 is a critical 
target for the proper function of cardiac pacemaking and the absence of NCX-
mediated depolarization in combination with impaired Ca
2+
  efflux results in 
intermittent bursts of pacemaker activity, reminiscent of human sinus node 
dysfunction and "tachy-brady" syndrome [255] [256]. The plasma membrane 
calcium transporting ATPase 1, encoded by Atp2b1, also plays a critical role in 
maintaining intracellular Ca
2+
 homeostasis. However, the role of Atp2b1 in 
generation of SAN autorythmicity is not understood. Yet, upregulation of Slc8a1 and 
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Atp2b1, are both involved in maintaining Ca
2+
 homeostasis and may play a role in 
the generation of the SAN AP. 
Regarding Ca
2+
 signalling and Ca
2+
 regulatory proteins, the inositol 1,4,5 
triphosphate receptor proteins (IP3R1-3) encoding genes (Itpr1-3) were upregulated 
in STZ-SAN compared to CON-SAN. IP3R is a membrane glycoprotein complex 
acting as a SR Ca
2+
 release channel activated by inositol triphosphate (IP3). 
Compared to the ryanodine receptor, the expression level of IP3Rs is much lower in 
cardiac SR membranes. However, several studies have suggested that Ca
2+
 release 
from IP3Rs modulates excitation-contraction coupling in both atrial and ventricular 
myocytes [257]. Recent studies also suggest that arrythmogenic activity in atria may 
be associated with increased IP3Rs expression [258]. In addition, a substantial 
increase in IP3 generation in atrial tissue from valvular heart disease patients, in the 
atria of mice with dialated cardiomyopathy and in heart failure have been recently 
reported [259] [260]. Studies have also demonstrated that functional IP3R2s are 
expressed in mouse SAN and serve as an additional Ca
2+
 - dependent mechanism 
modulating cardiac pacemaker activity and other Ca
2+
 - dependent processes [261]. 
These results suggest that the increase in expression of Itprs in STZ-SAN may have a 
significant effect on pacemaker electrical activity. The expression of Casq2, 
encoding calsequestrin, was also upregulated in STZ-SAN compared to CON-SAN. 
Calsequestrin, located in the cisterna of SR, is a Ca
2+ 
binding protein that helps to 
store high amount of Ca
2+
 ions after a muscle contraction. Studies have demonstrated 
that loss of Casq2 causes abnormal SR Ca
2+
  release and selective interstitial fibrosis 
in the atrial pacemaker complex, which disrupts SAN pacemaking, enhances latent 
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pacemaker activity, creates conduction abnormalities and increases the susceptibility 
to AF [262]. Thus Casq2 upregulation in STZ-SAN could contribute to a 
compensatory mechanism for the bradycardic effect of DM in STZ rats. 
Ryr3 (RYR3) was moderately upregulated in STZ-SAN compared to CON-
SAN. RYR3 protein was also increased in STZ-SAN compared to CON-SAN. 
Various studies have provided evidence that sub-sarcolemmal diastolic Ca
2+
 release 
from the SR may contribute to the generation of electrical activity in SAN cells [263] 
[264]. Upregulation of the SR Ca
2+
 release channel (ryandodine receptor) would be 
expected to facilitate increased release of Ca
2+
 from the SR and hence, influence 
spontaneous electrical activity in the SAN cell. 
Ca
2+
 influx via T-type and L-type Ca
2+
  channels contribute to the 
depolarization phase of SAN AP. Cacna1g encoding the alpha 1G subunit T-type 
channel (Cav3.1) was upregulated in STZ-SAN compared to CON-SAN . In the heart 
T-type Ca
2+
 channels are found in SAN and conduction cells [265]. Cav3.1 protein 
was also increased in STZ-SAN compared to CON-SAN. Previous studies have 
reported upregulation of Cacna1g in ventricle from the Goto-Kakizaki rat, an 
experimental model of T2DM, and the Zucker diabetic fatty rat [266, 267]. In mice 
disruption of the gene encoding Cav3.1 channels abolishes T-type Ca
2+
 current in 
isolated cells from the SAN and atrioventricular node without affecting L-type Ca
2+
 
current. Inactivation of Cacna1g slowed the heart rate in vivo and prolonged the 
SAN recovery time and slowed pacemaker activity of individual SAN cells through a 
reduction of the slope of the diastolic depolarization [268]. The Cacna1h encoding 
alpha 1H subunit T-type channel (Cav3.2) was also upregulated in CON-SAN 
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compared to CON-RA. Compared to Cav3.1 which is prominently expressed in SAN, 
most dense in central regions, Cav3.2 is diffusely present at moderate levels 
throughout the SAN [269]. Upregulation of Cacna1g and Cacna1h might be 
expected to increase T-type Ca
2+
 current and hence, the slope of the pacemaker 
potential and HR in STZ rat.   
Cacnb3 was upregulated in STZ-SAN compared to CON-SAN. Cacnb3 
encodes expression of the voltage dependent Ca
2+
 channel beta 3 subunit (Cavβ3). 
Previous studies have demonstrated that overexpression of the beta subunits (1-4) in 
adult cultured heart cells increased whole-cell L-type Ca
2+
 current density 
[270]. Cacna2d2 that encodes voltage dependent Ca
2+
 channel alpha 2 delta 2 
subunit (Cavα2δ2) was also upregulated in STZ-SAN compared to CON-SAN. It has 
been reported that Cavα2δ2 increases the T-type current amplitude related to Cav3.1 
by 176% [271].  In the SAN L-type Ca
2+
 current contributes to the pacemaker 
potential and generates the upstroke of the AP therefore upregulation of  Cacnb3 and 
Cacna2d2 might be expected to increase L-type Ca
2+
 current, the slope of the 
pacemaker potential and hence, HR.  
Cacng4 was downregulated (7-fold) in STZ-SAN compared to CON-SAN 
however, expression of Cacng4 was not altered in STZ-RA compared to CON-RA. 
The protein encoded by Cacng4 is one of the gamma subunits of the L-type Ca
2+
 
channel (Cavγ4). The cardiac voltage-gated L-type Ca
2+
 channel is the Ca
2+
 channel 
that is required for excitation-contraction coupling and that also contributes to the 
plateau phase of the cardiac AP and pacemaker activity in nodal cells [272] [273]. It 
has been reported that the gamma subunits expressed in heart (gamma 4, 6, 7 and 8) 
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form macromolecular complexes with Cav1.2 and can differentially modulate its 
function [272].  Downregulation of Cacng4 might have implications for the 
modulation and hence, function of the L-type Ca
2+
 channel and L-type Ca
2+
 current 
which in turn are important for generation of the pacemaker potential and the 
upstroke of the SAN AP. 
Among the voltage gated Na
+
 channel, the expression of Scn7a encoding the 
protein Nav2.1 was upregulated in STZ-SAN compared to CON-SAN.  Cardiac 
sodium channels are expressed in the peripheral region of the SAN and their precise 
role in pacemaking is not fully understood [117]. Hence, upregulation of Scn7a may 
be attributed to atrial contamination of STZ-SAN. 
Among the voltage-gated K
+
 channel, Shal-related family member Kcna2 
(Kv1.2) and Kcnd2 (Kv4.2) were downregulated in STZ-SAN compared to CON-
SAN. Kv4.2 plays a vital role in mouse ventricular repolarization and has been 
reported to be minimally expressed in pacemaker cells compared to working 
cardiomyocytes [274]. In addition, Kv4.2 is also responsible for producing a 
transient outward current (Ito) with rapid inactivation in ventricular and atrial 
myocytes of several species, including ferret [269]. The inwardly rectifying K
+ 
channel subunits encoded by Kcnj2 (Kir2.1), Kcnj5 (Kir3.4) and Kcnk6 (TWIK2) and 
outwardly rectifying K
+ 
channel encoded by Kcnk3 (K2P3.1) were upregulated in 
STZ-SAN compared to CON-SAN. In spite of the classical concept that pacemaker 
cells express low inward rectifier current (IKI), significant expression of  Kir2.1 has 
also been reported in mouse SAN [102] [275]. As the K
+
  current (IK) is the primary 
current responsible for repolarization in nodal cells, the change in pattern of 
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expression of mRNA encoding K
+
 channel proteins may contribute to the generation 
of AP in SAN. 
Nppa (ANP) and Nppb (BNP) were upregulated in STZ-SAN compared to 
CON-SAN however, neither Nppa or Nppb were altered in STZ-RA compared to 
CON-RA. Natriuretic peptides are a family of related peptides that include atrial 
natriuretic peptide (ANP) and B-type natriuretic peptide (BNP) that are secreted from 
the cardiac atria and ventricles [276]. ANP and BNP decrease blood pressure and 
BNP acts locally to reduce ventricular fibrosis and they are both involved in the 
pathogenic mechanisms leading to major cardiovascular diseases, including heart 
failure, coronary heart diseases, hypertension and left ventricular hypertrophy [276] 
[277]. Previous studies have demonstrated the expression of ANP, albeit at low 
levels, in the SAN node [83]. ANP plays a key role in cardiac electrophysiology, 
modulating the autonomic nervous system and regulating the function of various 
cardiac ion channels which includes ICa,L and If channels [278] [279]. Previous 
studies have demonstrated increases in ANP and BNP in blood plasma and atrial 
tissues and varying effects of ANP and BNP on the amplitude and kinetics of 
shortening and [Ca
2+
] in ventricular myocytes from STZ-induced diabetic rat  [280] 
[281]. BNP has been shown to increase HR and electrical conduction velocity in 
isolated hearts and in the SAN and also increase spontaneous AP frequency in 
isolated SAN myocytes [282] [279]. Upregulation of Nppa and Nppb in the SAN and 
increases in ANP and BNP may be associated with mechanisms that compensate for 
low HR seen in the STZ-induced diabetic rat [280] [281]. 
168 
 
6.4 Effect of STZ-induced diabetes on protein expression 
Some of the selected proteins were analyzed to verify that the changes in 
mRNA translate and produce similar changes in the respective proteins. 
Interestingly, expression of Cx45, Ryr3 and Cav3.1 were increased and in STZ-SAN 
compared to CON-SAN and these results were consistent with the mRNA data. 
Expression of Kv4.2 protein was decreased in STZ-SAN compared to CON-SAN, 
again consistent with gene data. However, expression of ANP and BNP proteins 
were decreased while mRNA for the proteins were increased in STZ-SAN compared 
to CON-SAN. We have previously reported that ANP and BNP levels in plasma and 
atria are increased in STZ rats compared to controls  [280] [281]. Since, ANP and 
BNP are secretory proteins increased mRNA expression might not necessarily result 
in increased localization of ANP or BNP protein in SAN tissues. 
6.5 Effect of STZ-induced diabetes on the structure of the sinoatrial node 
The effects of STZ-induced diabetes on the ultrastructure of SAN were 
investigated. The ultrastructure was generally preserved in both groups. The 
mitochondria are important determinants of myocyte function and survival. 
Approximately 40% of working cardiomyocyte volume and 15% of pacemaker cell 
volume is occupied by mitochondria [283]. The mitochondria are essential for 
supplying all types of cardiomyocytes with ATP to sustain their function. 
Mitochondria are the major source of ROS due to continuously generated 
superoxide, a by-product of electron transport [284]. There is strong evidence that 
ROS from mitochondria activate other pathological pathways, such as protein kinase 
C, aldose reductase, and advanced glycation end products, all of which induce 
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diabetic complications [285] [286]. Because mitochondria appear to be the source of 
most ROS, it is not unexpected that mitochondria have been shown to be a primary 
target of damage in diabetes [287] [288]. Impairment of mitochondrial function and 
energy metabolism in diabetic heart has been reported in numerous clinical and 
experimental studies [289]. Additionally, a morphological study on diabetic heart 
showed a significant increase in mitochondrial area and number along with severe 
damage to mitochondria [290]. Results from the present study showed a decreasing 
trend in mitochondrial numbers in STZ-SAN compared to CON-SAN. Though the 
number of mitochondria was not significantly altered, the biochemical activities 
might change. A previous study has reported that mitochondrial function in chronic 
diabetic rats and in particular ATP and phosphocreatinine levels were altered [289]. 
It is most likely that the reduction in mitochondria will compromise cardiac ATP 
generation, ultimately leading to impairment of SAN AP generation. 
6.6 Limitations of study 
There were some limitations in this study as follows: 
 The SAN is a heterogeneous structure, with respect to both anatomy 
and physiology. Heterogeneity also applies to various nodal cell 
types within the same structure. The SAN region is composed of a 
central area of dense nodal cells, and a peripheral / paranodal area 
which includes both transitional cells as well as cells showing atrial 
phenotype. Hence, our technique to isolate SAN cannot take into 
account the fine structure and crucial location of the SAN, 
suggesting that contamination of the SAN with atrial myocytes may 
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mask some differences between the SAN and the working 
myocardium.  
 Due to a shortage of time, the ultrastructure study of the SAN with 
EM was done with a small number of samples.  
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Chapter 7: Conclusions and Future Directions 
7.1 Conclusions 
Collectively, this study has demonstrated a reduction in HR in STZ-induced 
DM rats, differences in the profile of mRNA encoding a variety of proteins that are 
associated with the generation, conduction and regulation of electrical signals in the 
SAN. It has also demonstrated structural changes. Hence the reduction of HR in the 
STZ-induced diabetic rat may be attributed to prolongation of APD in the SAN, 
which in turn may be caused by altered expression and/or function of ion channels. 
The direct action of STZ may also make a contribution to heart rhythm disturbances. 
Data from this study will provide a basis for a substantial range of experiments to 
investigate whether these changes in mRNA translate into changes in 
electrophysiological function. 
7.2 Future directions 
Data generated in this study has provided a platform for several future studies. 
These might include the following: 
 Although technically difficult it might be interesting to repeat the 
mRNA and protein studies in individual SAN. This would ensure zero 
contamination of the SAN cells with atrial cells. 
 Expression of SAN transcription factors and regulatory gene such as 
Shox2, Tbx3, Tbx5 and Nkx2.5 that might be responsible for alterations in 
mRNA expression could be investigated. 
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 The functions of the ion channels responsible for SAN APs can be 
investigated by whole cell (SAN cells) patch clamp experiments in order to 
verify if the changes at molecular level have electrophysiological effects.  
 Localization and distribution of  proteins associated with calcium 
clock like Ryanodiane receptor protein and inositol triphosphate receptor 
can be assessed among different nodal cells using immunohistochemistry .  
 The distribution and localization of ANP and BNP receptor proteins 
can be investigated using immunohistochemitry. 
The diabetic SAN can be investigated in depth using histochemistry, 
immunohistochemistry and transmission electron microscopy, and results 
on distribution of different types of SAN cells, elastic and connective 
tissue fibres , mitochondria, sarcoplasmic reticulum and mast cells can be 
obtained. The size and number of cells and its organelle like mitochondria, 
sarcomere, sarcoplasmic reticulum, myofibrils and desmosomes can be 
investigated using electron microscope. 
 Intracellular flux of major ions responsible for SAN AP can also be 
quantified using confocal microscopy. 
 The sample size for the experiments of SAN ultrastructure study 
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